{"d94167cbc4f6cfa22018f2fe0ea1bb2c28ae8081": [["Notwithstanding the foregoing, different protein concentrations may have protective effects and may affect the inactivation efficiency, due to which, it is well-advised to prolong the heating time or increase the temperature to completely inactivate viruses [12] [13] [14] [15] .", [["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 258, 277], ["different protein concentrations", "TREATMENT", 31, 63], ["the inactivation efficiency", "PROBLEM", 107, 134], ["the temperature", "PROBLEM", 209, 224], ["completely inactivate viruses", "PROBLEM", 228, 257]]], ["However, because viral RNA would easily be degraded by ribonucleases, which affects the detection result of rRT-PCR of virus.", [["ribonucleases", "GENE_OR_GENE_PRODUCT", 55, 68], ["viral RNA", "RNA", 17, 26], ["ribonucleases", "PROTEIN", 55, 68], ["rRT", "PROTEIN", 108, 111], ["viral RNA", "PROBLEM", 17, 26], ["rRT-PCR of virus", "PROBLEM", 108, 124]]]], "ddc223077af6b924c77f3d22b1ac80feedee184a": [["Severe community-acquired pneumonia (SCAP) is usually defined as CAP admitted to an intensive care unit (ICU).", [["community-acquired pneumonia", "DISEASE", 7, 35], ["SCAP", "DISEASE", 37, 41], ["CAP", "DISEASE", 65, 68], ["Severe community-acquired pneumonia", "PROBLEM", 0, 35], ["pneumonia", "OBSERVATION", 26, 35]]], ["The mortality associated with SCAP is still very high, particularly in patients needing mechanical ventilation (30%) [1] .", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["SCAP", "PROBLEM", 30, 34], ["mechanical ventilation", "TREATMENT", 88, 110], ["SCAP", "OBSERVATION", 30, 34], ["very", "OBSERVATION_MODIFIER", 44, 48], ["high", "OBSERVATION", 49, 53]]], ["Indeed, these patients represent an important target population for future research.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["In this ICM research document we focus on three major aspects of SCAP: (1) Influenza pneumonia; (2) adjunctive antiinflammatory treatments; and (3) medium and long-term outcomes.Influenza pneumonia: cutting-edge epidemiology in future pandemicsTo determine the timing and spread of influenza, health agencies in Spain and abroad have used a sentinel surveillance system.", [["pneumonia", "DISEASE", 85, 94], ["Influenza pneumonia", "DISEASE", 178, 197], ["influenza", "DISEASE", 282, 291], ["Influenza", "SPECIES", 178, 187], ["Influenza pneumonia", "PROBLEM", 75, 94], ["adjunctive antiinflammatory treatments", "TREATMENT", 100, 138], ["Influenza pneumonia", "PROBLEM", 178, 197], ["pandemics", "PROBLEM", 235, 244], ["influenza", "PROBLEM", 282, 291], ["pneumonia", "OBSERVATION", 85, 94], ["pneumonia", "OBSERVATION", 188, 197]]], ["Using high-quality data, it has been possible to establish the composition of a seasonal influenza vaccine, to track changes in circulating influenza viruses and to design an alert system for potential pandemic viruses.", [["influenza", "DISEASE", 89, 98], ["influenza viruses", "DISEASE", 140, 157], ["a seasonal influenza vaccine", "TREATMENT", 78, 106], ["circulating influenza viruses", "PROBLEM", 128, 157], ["potential pandemic viruses", "PROBLEM", 192, 218], ["influenza viruses", "OBSERVATION", 140, 157]]], ["However, mechanisms for detecting triggers of severe influenza are still lacking.", [["influenza", "DISEASE", 53, 62], ["severe influenza", "PROBLEM", 46, 62], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["influenza", "OBSERVATION", 53, 62]]], ["For this reason, the World Health Organization (WHO) introduced a sentinel surveillance system for hospitalized patients who met the definition of syndromic Severe Acute Respiratory Infection (SARI) [2] .", [["Acute Respiratory Infection", "DISEASE", 164, 191], ["SARI", "DISEASE", 193, 197], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["syndromic Severe Acute Respiratory Infection", "PROBLEM", 147, 191], ["Severe", "OBSERVATION_MODIFIER", 157, 163], ["Acute", "OBSERVATION_MODIFIER", 164, 169], ["Respiratory", "ANATOMY", 170, 181], ["Infection", "OBSERVATION", 182, 191]]], ["In the ICU setting the information is scarce; the Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI), launched by the European Society of Intensive Care Medicine (ESICM), reported that SARI is very common in the ICU and is associated with high morbidity and mortality rates [3] .Influenza pneumonia: cutting-edge epidemiology in future pandemicsIn recent years the information provided on pandemic preparedness has been extremely useful, although it has mainly been based on trends in the community and Primary Care settings [4] .", [["Acute Respiratory Infection", "DISEASE", 88, 115], ["SARI", "DISEASE", 214, 218], ["Influenza pneumonia", "DISEASE", 308, 327], ["Influenza", "SPECIES", 308, 317], ["Global Study", "TEST", 65, 77], ["Severe Acute Respiratory Infection", "PROBLEM", 81, 115], ["high morbidity", "PROBLEM", 268, 282], ["Influenza pneumonia", "PROBLEM", 308, 327], ["pandemics", "PROBLEM", 365, 374], ["Severe", "OBSERVATION_MODIFIER", 81, 87], ["Acute", "OBSERVATION_MODIFIER", 88, 93], ["Respiratory", "ANATOMY", 94, 105], ["Infection", "OBSERVATION", 106, 115], ["pneumonia", "OBSERVATION", 318, 327]]], ["The aim is to describe not only attack rates but also their severity; we believe that the implementation of the four \"S\"s concept for outbreaks (Seasonality, Sentinel critical care, Severity and geopolitical hospital Settings) would improve the detection of pandemics and would also help to determine strategies, triage, and priorities for optimizing patient care during hospital admission [5] .Influenza pneumonia: cutting-edge epidemiology in future pandemicsParticularly notable is the increase in the number of patients with influenza who are admitted to hospitals with bacterial co-infections.", [["Influenza pneumonia", "DISEASE", 395, 414], ["influenza", "DISEASE", 529, 538], ["bacterial co-infections", "DISEASE", 574, 597], ["patient", "ORGANISM", 351, 358], ["patients", "ORGANISM", 515, 523], ["patient", "SPECIES", 351, 358], ["Influenza", "SPECIES", 395, 404], ["patients", "SPECIES", 515, 523], ["outbreaks", "PROBLEM", 134, 143], ["pandemics", "PROBLEM", 258, 267], ["Influenza pneumonia", "PROBLEM", 395, 414], ["pandemics", "PROBLEM", 452, 461], ["influenza", "PROBLEM", 529, 538], ["bacterial co-infections", "PROBLEM", 574, 597], ["pneumonia", "OBSERVATION", 405, 414], ["increase", "OBSERVATION_MODIFIER", 489, 497], ["influenza", "OBSERVATION", 529, 538], ["bacterial co-infections", "OBSERVATION", 574, 597]]], ["One might expect the high mortality associated with influenza to be due to the severity of the virus, but little is known about co-pathogenic mechanisms.", [["influenza", "DISEASE", 52, 61], ["the high mortality", "PROBLEM", 17, 35], ["influenza", "PROBLEM", 52, 61], ["the virus", "PROBLEM", 91, 100], ["virus", "OBSERVATION", 95, 100]]], ["In a large multicenter study our group recently found that co-infection was an independent risk factor for ICU, 28-day, and hospital mortality [6] .", [["co-infection", "DISEASE", 59, 71], ["co-infection", "PROBLEM", 59, 71], ["large", "OBSERVATION_MODIFIER", 5, 10], ["co-infection", "OBSERVATION", 59, 71]]], ["Biomarkers, used on a \"one value-one intervention\" basis, have the potential to rule out bacterial co-infections, but more complex models of analysis can be envisaged which include combinations or panels of biomarkers with biological plausibility and decision-tree analyses that will help to determine a wider range of clinical variables such as treatment failure, patient's risk stratification and composite outcomes for clinical cure in randomized clinical trials [7] .", [["patient", "ORGANISM", 365, 372], ["patient", "SPECIES", 365, 372], ["Biomarkers", "TEST", 0, 10], ["bacterial co-infections", "PROBLEM", 89, 112], ["biomarkers", "TEST", 207, 217], ["treatment failure", "PROBLEM", 346, 363], ["clinical cure", "TREATMENT", 422, 435], ["co-infections", "OBSERVATION", 99, 112]]], ["Future research in SCAP should focus on all these aspects.Influenza pneumonia: cutting-edge epidemiology in future pandemicsCoadjuvant treatments: will we be able to reduce acute mortality in SCAP?Influenza pneumonia: cutting-edge epidemiology in future pandemicsSCAP-related mortality is still very high, particularly in patients with increased inflammatory response despite rapid, adequate antibiotic treatment.Influenza pneumonia: cutting-edge epidemiology in future pandemics*Correspondence: atorres@ub.edu 1 Pulmonology Department, Respiratory Institute, Hospital Clinic of Barcelona, Ciberes, IDIBAPS, Barcelona, Spain Full author information is available at the end of the article 1.", [["Influenza pneumonia", "DISEASE", 58, 77], ["Influenza pneumonia", "DISEASE", 197, 216], ["pandemicsSCAP", "DISEASE", 254, 267], ["Influenza pneumonia", "DISEASE", 413, 432], ["patients", "ORGANISM", 322, 330], ["Influenza", "SPECIES", 58, 67], ["Influenza", "SPECIES", 197, 206], ["patients", "SPECIES", 322, 330], ["Influenza", "SPECIES", 413, 422], ["Future research in SCAP", "PROBLEM", 0, 23], ["Influenza pneumonia", "PROBLEM", 58, 77], ["pandemics", "PROBLEM", 115, 124], ["Coadjuvant treatments", "TREATMENT", 124, 145], ["acute mortality in SCAP", "PROBLEM", 173, 196], ["Influenza pneumonia", "PROBLEM", 197, 216], ["increased inflammatory response", "PROBLEM", 336, 367], ["adequate antibiotic treatment", "TREATMENT", 383, 412], ["Influenza pneumonia", "PROBLEM", 413, 432], ["SCAP", "OBSERVATION_MODIFIER", 19, 23], ["pneumonia", "OBSERVATION", 68, 77], ["SCAP", "ANATOMY", 192, 196], ["pneumonia", "OBSERVATION", 207, 216], ["edge", "OBSERVATION_MODIFIER", 226, 230], ["high", "OBSERVATION", 300, 304], ["increased", "OBSERVATION_MODIFIER", 336, 345], ["inflammatory", "OBSERVATION", 346, 358], ["pneumonia", "OBSERVATION", 423, 432]]], ["Studies of corticosteroids in these populations suggest that their use reduces treatment failure [8] , the development of ARDS, and mortality rates [9] .", [["corticosteroids", "CHEMICAL", 11, 26], ["ARDS", "DISEASE", 122, 126], ["corticosteroids", "CHEMICAL", 11, 26], ["corticosteroids", "TREATMENT", 11, 26], ["treatment failure", "PROBLEM", 79, 96], ["ARDS", "PROBLEM", 122, 126], ["mortality rates", "TEST", 132, 147], ["ARDS", "OBSERVATION", 122, 126]]], ["Due to their potential side effects, however, corticosteroids may not be cost-effective These publications suggest that they are beneficial in patients with high systemic inflammatory response, but as they may increase mortality [10] in hospitalized patients with influenza in the presence of rhinovirus, adenovirus, RSV and metapneumovirus, their true value remains to be established.", [["influenza", "DISEASE", 264, 273], ["RSV and metapneumovirus", "DISEASE", 317, 340], ["corticosteroids", "CHEMICAL", 46, 61], ["corticosteroids", "SIMPLE_CHEMICAL", 46, 61], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 250, 258], ["rhinovirus", "ORGANISM", 293, 303], ["adenovirus", "ORGANISM", 305, 315], ["RSV", "ORGANISM", 317, 320], ["metapneumovirus", "ORGANISM", 325, 340], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 250, 258], ["RSV", "SPECIES", 317, 320], ["adenovirus", "SPECIES", 305, 315], ["RSV", "SPECIES", 317, 320], ["corticosteroids", "TREATMENT", 46, 61], ["high systemic inflammatory response", "PROBLEM", 157, 192], ["influenza", "PROBLEM", 264, 273], ["rhinovirus", "PROBLEM", 293, 303], ["adenovirus", "PROBLEM", 305, 315], ["RSV", "PROBLEM", 317, 320], ["metapneumovirus", "PROBLEM", 325, 340], ["inflammatory", "OBSERVATION", 171, 183], ["rhinovirus", "OBSERVATION", 293, 303], ["metapneumovirus", "OBSERVATION", 325, 340]]], ["Only new RCTs or individual metaanalyses will be able to do determine their real benefit.", [["new RCTs or individual metaanalyses", "PROBLEM", 5, 40], ["new", "OBSERVATION_MODIFIER", 5, 8], ["RCTs", "OBSERVATION", 9, 13]]], ["Macrolides are antibiotics with potent immunomodulatory effects.", [["Macrolides", "CHEMICAL", 0, 10], ["Macrolides", "CHEMICAL", 0, 10], ["Macrolides", "SIMPLE_CHEMICAL", 0, 10], ["Macrolides", "TREATMENT", 0, 10], ["antibiotics", "TREATMENT", 15, 26], ["potent immunomodulatory effects", "TREATMENT", 32, 63]]], ["Retrospective analyses in SCAP have demonstrated that their inclusion in therapeutic regimes seems to reduce mortality [11] .", [["Retrospective analyses in SCAP", "TEST", 0, 30], ["therapeutic regimes", "TREATMENT", 73, 92]]], ["However, many doubts and questions regarding the use of macrolides need to be resolved in the coming years: for instance, are they more effective than quinolones when combined with beta-lactams?", [["macrolides", "CHEMICAL", 56, 66], ["quinolones", "CHEMICAL", 151, 161], ["beta-lactams", "CHEMICAL", 181, 193], ["macrolides", "CHEMICAL", 56, 66], ["quinolones", "CHEMICAL", 151, 161], ["beta-lactams", "CHEMICAL", 181, 193], ["macrolides", "SIMPLE_CHEMICAL", 56, 66], ["quinolones", "SIMPLE_CHEMICAL", 151, 161], ["beta-lactams", "SIMPLE_CHEMICAL", 181, 193], ["macrolides", "TREATMENT", 56, 66], ["quinolones", "TREATMENT", 151, 161], ["beta-lactams", "PROBLEM", 181, 193]]], ["And which particular SCAP target population will benefit most from macrolide treatment? 3.", [["macrolide", "CHEMICAL", 67, 76], ["macrolide", "CHEMICAL", 67, 76], ["macrolide", "SIMPLE_CHEMICAL", 67, 76], ["macrolide treatment", "TREATMENT", 67, 86]]], ["Immunoglobulins (Ig) have been administered in sepsis and in septic shock, but their use is controversial.", [["sepsis", "DISEASE", 47, 53], ["septic shock", "DISEASE", 61, 73], ["Immunoglobulins", "GENE_OR_GENE_PRODUCT", 0, 15], ["Ig", "GENE_OR_GENE_PRODUCT", 17, 19], ["Immunoglobulins", "PROTEIN", 0, 15], ["Ig", "PROTEIN", 17, 19], ["Immunoglobulins (Ig", "TREATMENT", 0, 19], ["sepsis", "PROBLEM", 47, 53], ["septic shock", "PROBLEM", 61, 73], ["sepsis", "OBSERVATION", 47, 53], ["septic shock", "OBSERVATION", 61, 73]]], ["Survival Sepsis Campaign guidelines [12] do not recommended Ig administration.", [["Sepsis", "DISEASE", 9, 15], ["Ig", "GENE_OR_GENE_PRODUCT", 60, 62], ["Ig", "PROTEIN", 60, 62], ["Ig administration", "TREATMENT", 60, 77]]], ["The Cigma study [13] is a phase II study comparing 15% enriched IgM in patients with SCAP needing mechanical ventilation, with a primary end-point of ventilator-free days.Influenza pneumonia: cutting-edge epidemiology in future pandemicsThe provisional results suggest a significant reduction in mortality in certain subgroups of patients.Influenza pneumonia: cutting-edge epidemiology in future pandemicsThere is now a clear need for a large phase III trial in target populations with CAP: i.e., patients who are mechanically ventilated, and those with high levels of systemic inflammation or low levels of IgM.Medium and long-term prognosis in pneumoniaAfter an episode of CAP, patients of all ages present an increased risk of long-term adverse events and mortality compared to the general population [14] .", [["Influenza pneumonia", "DISEASE", 171, 190], ["Influenza pneumonia", "DISEASE", 339, 358], ["CAP", "DISEASE", 486, 489], ["inflammation", "DISEASE", 578, 590], ["CAP", "DISEASE", 675, 678], ["IgM", "GENE_OR_GENE_PRODUCT", 64, 67], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 330, 338], ["patients", "ORGANISM", 497, 505], ["patients", "ORGANISM", 680, 688], ["IgM", "PROTEIN", 64, 67], ["patients", "SPECIES", 71, 79], ["Influenza", "SPECIES", 171, 180], ["patients", "SPECIES", 330, 338], ["Influenza", "SPECIES", 339, 348], ["patients", "SPECIES", 497, 505], ["patients", "SPECIES", 680, 688], ["The Cigma study", "TEST", 0, 15], ["a phase II study", "TEST", 24, 40], ["SCAP", "TREATMENT", 85, 89], ["mechanical ventilation", "TREATMENT", 98, 120], ["Influenza pneumonia", "PROBLEM", 171, 190], ["pandemics", "PROBLEM", 228, 237], ["a significant reduction in mortality", "PROBLEM", 269, 305], ["Influenza pneumonia", "PROBLEM", 339, 358], ["pandemics", "PROBLEM", 396, 405], ["a large phase III trial", "TREATMENT", 435, 458], ["mechanically ventilated", "PROBLEM", 514, 537], ["systemic inflammation", "PROBLEM", 569, 590], ["low levels of IgM.", "PROBLEM", 594, 612], ["Medium and long-term prognosis", "PROBLEM", 612, 642], ["CAP", "PROBLEM", 675, 678], ["long-term adverse events", "PROBLEM", 730, 754], ["mechanical ventilation", "OBSERVATION", 98, 120], ["pneumonia", "OBSERVATION", 181, 190], ["significant", "OBSERVATION_MODIFIER", 271, 282], ["reduction", "OBSERVATION_MODIFIER", 283, 292], ["pneumonia", "OBSERVATION", 349, 358], ["clear", "OBSERVATION", 420, 425], ["mechanically", "OBSERVATION_MODIFIER", 514, 526], ["ventilated", "OBSERVATION", 527, 537], ["systemic", "OBSERVATION_MODIFIER", 569, 577], ["inflammation", "OBSERVATION", 578, 590], ["long-term prognosis", "OBSERVATION_MODIFIER", 623, 642], ["CAP", "OBSERVATION_MODIFIER", 675, 678], ["increased", "OBSERVATION_MODIFIER", 712, 721], ["long-term", "OBSERVATION_MODIFIER", 730, 739]]], ["Short-term prognosis usually comprises the period up until 30 days and follow-up periods of 1 year of more have been reported in the literature as long-term [15] .", [["Short-term prognosis", "PROBLEM", 0, 20]]], ["In fact, the risk may even persist until 10 years after the episode, as has been described after sepsis; indeed, CAP is one of the main causes of sepsis.", [["sepsis", "DISEASE", 97, 103], ["CAP", "DISEASE", 113, 116], ["sepsis", "DISEASE", 146, 152], ["sepsis", "PROBLEM", 97, 103], ["sepsis", "PROBLEM", 146, 152], ["sepsis", "OBSERVATION", 97, 103], ["sepsis", "OBSERVATION", 146, 152]]], ["The most widely recognized causes of mortality related to medium and long-term prognosis include cardiovascular diseases, new lung infections and cancer.", [["cardiovascular", "ANATOMY", 97, 111], ["lung", "ANATOMY", 126, 130], ["cancer", "ANATOMY", 146, 152], ["cardiovascular diseases", "DISEASE", 97, 120], ["lung infections", "DISEASE", 126, 141], ["cancer", "DISEASE", 146, 152], ["cardiovascular", "ANATOMICAL_SYSTEM", 97, 111], ["lung", "ORGAN", 126, 130], ["cancer", "CANCER", 146, 152], ["medium and long-term prognosis", "PROBLEM", 58, 88], ["cardiovascular diseases", "PROBLEM", 97, 120], ["new lung infections", "PROBLEM", 122, 141], ["cancer", "PROBLEM", 146, 152], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["mortality", "OBSERVATION", 37, 46], ["cardiovascular", "ANATOMY", 97, 111], ["diseases", "OBSERVATION", 112, 120], ["new", "OBSERVATION_MODIFIER", 122, 125], ["lung", "ANATOMY", 126, 130], ["infections", "OBSERVATION", 131, 141], ["cancer", "OBSERVATION", 146, 152]]], ["The potential mechanisms involved are: the direct adverse effect of microorganisms, the inflammatory host response, platelet activation and alterations of the endothelium or disruption of atheroma plaque.", [["platelet", "ANATOMY", 116, 124], ["endothelium", "ANATOMY", 159, 170], ["atheroma plaque", "ANATOMY", 188, 203], ["atheroma plaque", "DISEASE", 188, 203], ["platelet", "CELL", 116, 124], ["endothelium", "TISSUE", 159, 170], ["atheroma plaque", "PATHOLOGICAL_FORMATION", 188, 203], ["the direct adverse effect of microorganisms", "PROBLEM", 39, 82], ["the inflammatory host response", "PROBLEM", 84, 114], ["platelet activation", "PROBLEM", 116, 135], ["the endothelium", "PROBLEM", 155, 170], ["atheroma plaque", "PROBLEM", 188, 203], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100], ["platelet activation", "OBSERVATION", 116, 135], ["endothelium", "ANATOMY", 159, 170], ["atheroma", "OBSERVATION_MODIFIER", 188, 196], ["plaque", "OBSERVATION", 197, 203]]], ["The study of biomarkers to monitor cardiovascular risk (both during the episode and at discharge) is becoming crucial for diagnosis, although several questions remain unanswered: for example, the identification of the best biomarker and/or panel of biomarkers, the precise factors triggered in each patient, its duration after the acute episode, and the associated risk factors [16] .", [["cardiovascular", "ANATOMY", 35, 49], ["cardiovascular", "ANATOMICAL_SYSTEM", 35, 49], ["patient", "ORGANISM", 299, 306], ["patient", "SPECIES", 299, 306], ["The study of biomarkers", "TEST", 0, 23], ["cardiovascular risk", "PROBLEM", 35, 54], ["biomarkers", "TEST", 249, 259], ["the acute episode", "PROBLEM", 327, 344], ["the associated risk factors", "PROBLEM", 350, 377], ["acute", "OBSERVATION_MODIFIER", 331, 336]]], ["All are important questions for designing interventional strategies and personalized treatments in order to curb poor prognosis.", [["interventional strategies", "TREATMENT", 42, 67], ["personalized treatments", "TREATMENT", 72, 95]]], ["Currently, although proadrenomedullin (proADM) and other cardiovascular biomarkers have shown high prognostic power for community-acquired pneumonia (CAP) outcomes, their application in the clinical setting has been slow.", [["cardiovascular", "ANATOMY", 57, 71], ["pneumonia", "DISEASE", 139, 148], ["CAP", "DISEASE", 150, 153], ["proadrenomedullin", "GENE_OR_GENE_PRODUCT", 20, 37], ["proADM", "GENE_OR_GENE_PRODUCT", 39, 45], ["other cardiovascular biomarkers", "TEST", 51, 82], ["community-acquired pneumonia (CAP) outcomes", "PROBLEM", 120, 163], ["pneumonia", "OBSERVATION", 139, 148], ["slow", "OBSERVATION_MODIFIER", 216, 220]]], ["MicroRNA (miRNA) analysis has emerged as a useful tool for sepsis diagnosis and for prognosis. miRNAs are small non-coding RNAs which can act as master regulators of gene expression; they are able to modulate almost all biological processes and are essential for maintaining cellular homeostasis.", [["cellular", "ANATOMY", 275, 283], ["sepsis", "DISEASE", 59, 65], ["cellular", "CELL", 275, 283], ["miRNAs", "RNA", 95, 101], ["small non-coding RNAs", "RNA", 106, 127], ["MicroRNA (miRNA) analysis", "TEST", 0, 25], ["sepsis diagnosis", "PROBLEM", 59, 75], ["prognosis", "PROBLEM", 84, 93], ["small non-coding RNAs", "PROBLEM", 106, 127], ["small", "OBSERVATION_MODIFIER", 106, 111], ["non-coding RNAs", "OBSERVATION", 112, 127], ["cellular homeostasis", "OBSERVATION", 275, 295]]], ["Dysregulation of miRNA expression has been associated with aberrant gene expression and may lead to pathologic conditions [17] .", [["Dysregulation of miRNA expression", "PROBLEM", 0, 33], ["aberrant gene expression", "PROBLEM", 59, 83], ["pathologic conditions", "PROBLEM", 100, 121], ["miRNA expression", "OBSERVATION", 17, 33]]], ["Studies investigating immune responses and inflammatory responses from the perspective of the potential inhibition of translation or transcription of miRNA will be very welcome.ConclusionsIn conclusion, our main recommendation for SCAP research is that it should focus on reducing its short-and long-term mortality.", [["Studies", "TEST", 0, 7], ["immune responses", "PROBLEM", 22, 38], ["inflammatory responses", "PROBLEM", 43, 65], ["transcription of miRNA", "TREATMENT", 133, 155], ["SCAP research", "TEST", 231, 244], ["inflammatory", "OBSERVATION_MODIFIER", 43, 55], ["long-term", "OBSERVATION_MODIFIER", 295, 304]]], ["The next steps can be summarized as follows:Conclusions\u2022 To investigate the epidemiology (risk and prognosis factors and etiology) of the four \"S\"s-Seasonality, Sentinel critical care, Severity and geopolitical Settings-in SCAP. \u2022 To establish which patients with SCAP would benefit from coadjuvant anti-inflammatory or immunomodulatory treatment in order to reduce short-term mortality. \u2022 To investigate biomarkers and phenotypes of SCAP patients with a higher risk of dying during hospital admission (short-term) and after hospital discharge.", [["patients", "ORGANISM", 250, 258], ["patients", "ORGANISM", 439, 447], ["patients", "SPECIES", 250, 258], ["patients", "SPECIES", 439, 447], ["geopolitical Settings", "TREATMENT", 198, 219], ["SCAP", "PROBLEM", 264, 268], ["coadjuvant anti-inflammatory", "TREATMENT", 288, 316], ["immunomodulatory treatment", "TREATMENT", 320, 346], ["short-term mortality", "PROBLEM", 366, 386], ["biomarkers", "TEST", 405, 415]]]], "b670d2abb62ed3eb4d75e7cd7582b03a898a5f12": [["IntroductionAs the first cases of pneumonia of unknown origin were officially reported in China on 8 December 2019, this disease has rapidly spread to many other regions within China and abroad [1] .", [["pneumonia", "DISEASE", 34, 43], ["pneumonia", "PROBLEM", 34, 43], ["this disease", "PROBLEM", 116, 128], ["pneumonia", "OBSERVATION", 34, 43]]], ["As of 13 April 2020, over 1 200 000 confirmed COVID-19 patients have been documented worldwide.IntroductionThere are many similarities, indicated by the published literatures, between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS as well as MERS, such as that they are all mainly transmitted through respiratory droplets, and their most common symptom is fever [1] [2] [3] .", [["respiratory droplets", "ANATOMY", 324, 344], ["acute respiratory syndrome coronavirus", "DISEASE", 191, 229], ["SARS", "DISEASE", 249, 253], ["fever", "DISEASE", 379, 384], ["patients", "ORGANISM", 55, 63], ["SARS-CoV-2", "ORGANISM", 233, 243], ["patients", "SPECIES", 55, 63], ["severe acute respiratory syndrome coronavirus", "SPECIES", 184, 229], ["SARS-CoV-2", "SPECIES", 233, 243], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 184, 229], ["SARS", "PROBLEM", 249, 253], ["fever", "PROBLEM", 379, 384], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["respiratory syndrome", "OBSERVATION", 197, 217]]], ["Yet the SARS-CoV-2 was also found with R0 [4] .", [["SARS", "DISEASE", 8, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["the SARS", "TEST", 4, 12], ["CoV", "TEST", 13, 16]]], ["It has more clinical symptoms of dyspnoea while headaches and diarrhoea are rare [5] .", [["dyspnoea", "DISEASE", 33, 41], ["headaches", "DISEASE", 48, 57], ["diarrhoea", "DISEASE", 62, 71], ["dyspnoea", "PROBLEM", 33, 41], ["headaches", "PROBLEM", 48, 57], ["diarrhoea", "PROBLEM", 62, 71]]], ["As to radiological features, COVID-19 usually has abnormalities on chest computed tomography (CT), of which the most typical one is ground-glass opacity, and the lesions are generally multiple and located in the posterior or peripheral lung [6] .", [["lesions", "ANATOMY", 162, 169], ["posterior", "ANATOMY", 212, 221], ["peripheral lung", "ANATOMY", 225, 240], ["lesions", "CANCER", 162, 169], ["posterior", "ORGAN", 212, 221], ["lung", "ORGAN", 236, 240], ["COVID-19", "DNA", 29, 37], ["radiological features", "TEST", 6, 27], ["COVID", "TEST", 29, 34], ["abnormalities", "PROBLEM", 50, 63], ["chest computed tomography", "TEST", 67, 92], ["CT", "TEST", 94, 96], ["ground-glass opacity", "PROBLEM", 132, 152], ["the lesions", "PROBLEM", 158, 169], ["chest", "ANATOMY", 67, 72], ["most typical", "OBSERVATION_MODIFIER", 112, 124], ["ground", "OBSERVATION_MODIFIER", 132, 138], ["glass opacity", "OBSERVATION", 139, 152], ["lesions", "OBSERVATION", 162, 169], ["generally", "OBSERVATION_MODIFIER", 174, 183], ["multiple", "OBSERVATION_MODIFIER", 184, 192], ["posterior", "ANATOMY_MODIFIER", 212, 221], ["peripheral", "ANATOMY_MODIFIER", 225, 235], ["lung", "ANATOMY", 236, 240]]], ["Patients infected with SARS-CoV-2 normally develop symptoms in 2\u22127 days after infection with a rapid disease progress.", [["SARS", "DISEASE", 23, 27], ["infection", "DISEASE", 78, 87], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 23, 33], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["symptoms", "PROBLEM", 51, 59], ["infection", "PROBLEM", 78, 87], ["a rapid disease progress", "PROBLEM", 93, 117], ["infected", "OBSERVATION", 9, 17]]], ["They usually die of acute respiratory distress syndrome (ARDS) and multiple organ failure caused by cytokine storm [5] .IntroductionDespite many reports on SARS-CoV-2, few studies focused on disease progress and it is still unclear how clinical, radiological characteristics and laboratory indicators and their dynamic changes as disease progressed are related to prognosis.", [["respiratory", "ANATOMY", 26, 37], ["organ", "ANATOMY", 76, 81], ["acute respiratory distress syndrome", "DISEASE", 20, 55], ["ARDS", "DISEASE", 57, 61], ["organ failure", "DISEASE", 76, 89], ["organ", "ORGAN", 76, 81], ["SARS-CoV-2", "ORGANISM", 156, 166], ["cytokine", "PROTEIN", 100, 108], ["SARS-CoV", "SPECIES", 156, 164], ["acute respiratory distress syndrome", "PROBLEM", 20, 55], ["ARDS", "PROBLEM", 57, 61], ["multiple organ failure", "PROBLEM", 67, 89], ["cytokine storm", "PROBLEM", 100, 114], ["few studies", "TEST", 168, 179], ["laboratory indicators", "TEST", 279, 300], ["disease", "PROBLEM", 330, 337], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory distress", "OBSERVATION", 26, 46], ["ARDS", "OBSERVATION", 57, 61], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["organ", "ANATOMY", 76, 81], ["failure", "OBSERVATION", 82, 89], ["cytokine storm", "OBSERVATION", 100, 114]]], ["In this study, we comprehensively collected the clinical, radiological characteristics and laboratory information of 101 confirmed COVID-19 patients in Renmin Hospital of Wuhan University and aimed to explore the association between prognosis and the variation trend of those indicators.MethodsThe study was approved by the Ethics Committee of the Wuhan University Renmin Hospital (ethics number: V1.0), and written informed consent was waived.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["this study", "TEST", 3, 13], ["laboratory information", "TEST", 91, 113]]], ["A retrospective study was performed on 101 laboratory-confirmed patients with SARS-CoV-2, who were randomly selected from all the confirmed patients from 2 January 2020 to 28 January 2020, at Wuhan University Renmin Hospital, one of the first hospitals designated by the Chinese government to treat COVID-19, using isolation and airborne precautions (fit-tested N95 masks) for aerosol-generating immediately.", [["SARS", "DISEASE", 78, 82], ["COVID", "DISEASE", 299, 304], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 140, 148], ["A retrospective study", "TEST", 0, 21], ["COVID", "TEST", 299, 304], ["isolation", "TREATMENT", 315, 324], ["airborne precautions", "TREATMENT", 329, 349]]], ["The laboratory-confirmed patients were defined as positive results from any one of the following specimens: respiratory secretions obtained from bronchial alveolar lavage, tracheal aspirate, nasopharyngeal or oropharyngeal swabs.", [["specimens", "ANATOMY", 97, 106], ["respiratory secretions", "ANATOMY", 108, 130], ["bronchial alveolar lavage", "ANATOMY", 145, 170], ["tracheal aspirate", "ANATOMY", 172, 189], ["nasopharyngeal", "ANATOMY", 191, 205], ["oropharyngeal swabs", "ANATOMY", 209, 228], ["patients", "ORGANISM", 25, 33], ["bronchial alveolar lavage", "MULTI-TISSUE_STRUCTURE", 145, 170], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 172, 189], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 191, 205], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 209, 228], ["patients", "SPECIES", 25, 33], ["respiratory secretions", "PROBLEM", 108, 130], ["bronchial alveolar lavage", "TEST", 145, 170], ["tracheal aspirate", "TEST", 172, 189], ["nasopharyngeal or oropharyngeal swabs", "PROBLEM", 191, 228], ["respiratory", "ANATOMY", 108, 119], ["secretions", "OBSERVATION", 120, 130], ["bronchial", "ANATOMY", 145, 154], ["alveolar lavage", "OBSERVATION", 155, 170], ["tracheal", "ANATOMY", 172, 180], ["aspirate", "OBSERVATION", 181, 189], ["nasopharyngeal", "ANATOMY", 191, 205], ["oropharyngeal swabs", "ANATOMY", 209, 228]]], ["Clinical, imaging and laboratory data were collected and privacy masking was performed in data analysis.", [["imaging", "TEST", 10, 17], ["laboratory data", "TEST", 22, 37], ["privacy masking", "TEST", 57, 72], ["data analysis", "TEST", 90, 103]]], ["The follow-up endpoint was on 8 February 2020.Data collectionThe demographic and epidemiological characteristics, laboratory findings as well as clinical diagnosis and treatment outcomes were extracted from electronic medical records.", [["Data collection", "TEST", 46, 61], ["laboratory findings", "TEST", 114, 133]]], ["Several standardised data collection forms were designed first and relevant data were then correspondingly extracted by two experienced doctors and a third senior doctor would perform the final review to ensure data quality.", [["Several standardised data collection", "TEST", 0, 36]]], ["Laboratory indicators of blood routine test, blood coagulation and their medical reference ranges were collected.", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["blood routine test", "TEST", 25, 43], ["blood coagulation", "TEST", 45, 62]]], ["The presence of SARS-CoV-2 in respiratory specimens was detected by real-time RT-PCR methods, issued by the Chinese CDC [7] .", [["respiratory specimens", "ANATOMY", 30, 51], ["SARS", "DISEASE", 16, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["respiratory specimens", "CANCER", 30, 51], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["respiratory specimens", "TEST", 30, 51], ["SARS", "OBSERVATION", 16, 20]]], ["All the thin-layer images were collected in the format of Digital Imaging and Communications in Medicine (DICOM).", [["Digital Imaging", "TEST", 58, 73]]], ["Then the imaging signs and their features were extracted using a double-blind method, by which two intermediate radiologists in respiratory medicine (with more than 5 years' experience) would read and report the images independently and their results would finally be reviewed and confirmed by a senior doctor (engaged in imaging diagnosis for more than 15 years).", [["the imaging signs", "TEST", 5, 22], ["a double-blind method", "TREATMENT", 63, 84], ["the images", "TEST", 208, 218], ["imaging diagnosis", "TEST", 322, 339]]], ["Radiological findings such as lesions, lesion size (the longest diameter of the lesion) and radiological patterns were extracted.", [["lesions", "ANATOMY", 30, 37], ["lesion", "ANATOMY", 39, 45], ["lesion", "ANATOMY", 80, 86], ["lesions", "PATHOLOGICAL_FORMATION", 30, 37], ["Radiological findings", "TEST", 0, 21], ["lesions", "PROBLEM", 30, 37], ["lesion size", "PROBLEM", 39, 50], ["lesions", "OBSERVATION", 30, 37], ["lesion", "OBSERVATION", 39, 45], ["size", "OBSERVATION_MODIFIER", 46, 50], ["longest", "OBSERVATION_MODIFIER", 56, 63], ["diameter", "OBSERVATION_MODIFIER", 64, 72], ["lesion", "OBSERVATION", 80, 86], ["radiological patterns", "OBSERVATION", 92, 113]]], ["In addition, to evaluate the lesion size accurately, a diagnosis system for novel coronavirus pneumonia based on artificial intelligence (AI), was employed to analyse CT images using CT value to measure volume ratio of pneumonia automatically, which had been used at this hospital in early January [8] [9] [10] [11] .Clinical stagingThe guidelines on COVID-19 treatment issued by the National Health Commission of the People's Republic of China have classified patients into four types, including uncomplicated illness, mild, severe and critical pneumonia [12] .", [["lesion", "ANATOMY", 29, 35], ["coronavirus pneumonia", "DISEASE", 82, 103], ["pneumonia", "DISEASE", 219, 228], ["COVID-19", "CHEMICAL", 351, 359], ["illness", "DISEASE", 511, 518], ["pneumonia", "DISEASE", 546, 555], ["coronavirus", "ORGANISM", 82, 93], ["patients", "ORGANISM", 461, 469], ["patients", "SPECIES", 461, 469], ["the lesion size", "PROBLEM", 25, 40], ["a diagnosis system", "TEST", 53, 71], ["novel coronavirus pneumonia", "PROBLEM", 76, 103], ["CT images", "TEST", 167, 176], ["CT value", "TEST", 183, 191], ["pneumonia", "PROBLEM", 219, 228], ["Clinical staging", "TEST", 317, 333], ["COVID", "TREATMENT", 351, 356], ["uncomplicated illness", "PROBLEM", 497, 518], ["mild, severe and critical pneumonia", "PROBLEM", 520, 555], ["lesion", "OBSERVATION", 29, 35], ["size", "OBSERVATION_MODIFIER", 36, 40], ["coronavirus", "OBSERVATION_MODIFIER", 82, 93], ["pneumonia", "OBSERVATION", 94, 103], ["pneumonia", "OBSERVATION", 219, 228], ["mild", "OBSERVATION_MODIFIER", 520, 524], ["severe", "OBSERVATION_MODIFIER", 526, 532], ["critical", "OBSERVATION_MODIFIER", 537, 545], ["pneumonia", "OBSERVATION", 546, 555]]], ["Patients with uncomplicated illness have mild clinical symptoms but no signs of pneumonia on chest images, while mild pneumonia has fever and respiratory symptoms as well as pneumonitis signs on radiographs.", [["chest", "ANATOMY", 93, 98], ["respiratory", "ANATOMY", 142, 153], ["pneumonia", "DISEASE", 80, 89], ["pneumonia", "DISEASE", 118, 127], ["fever", "DISEASE", 132, 137], ["respiratory symptoms", "DISEASE", 142, 162], ["pneumonitis", "DISEASE", 174, 185], ["Patients", "ORGANISM", 0, 8], ["chest", "ORGAN", 93, 98], ["Patients", "SPECIES", 0, 8], ["uncomplicated illness", "PROBLEM", 14, 35], ["mild clinical symptoms", "PROBLEM", 41, 63], ["pneumonia", "PROBLEM", 80, 89], ["chest images", "TEST", 93, 105], ["mild pneumonia", "PROBLEM", 113, 127], ["fever", "PROBLEM", 132, 137], ["respiratory symptoms", "PROBLEM", 142, 162], ["pneumonitis signs", "PROBLEM", 174, 191], ["radiographs", "TEST", 195, 206], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["no signs of", "UNCERTAINTY", 68, 79], ["pneumonia", "OBSERVATION", 80, 89], ["chest", "ANATOMY", 93, 98], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["pneumonia", "OBSERVATION", 118, 127], ["fever", "OBSERVATION_MODIFIER", 132, 137], ["pneumonitis", "OBSERVATION", 174, 185]]], ["Severe patients have at least one of the following: (1) respiratory distress, respiratory rate (RR)\u2a7e30 breaths/min; (2) finger oxygen satur-ation\u2a7d93% in a state of rest; (3) partial pressure of oxygen (PaO 2 )/fraction of inspired oxygen (FiO 2 ) \u2a7d300 mmHg.", [["respiratory", "ANATOMY", 56, 67], ["respiratory", "ANATOMY", 78, 89], ["finger", "ANATOMY", 120, 126], ["respiratory distress", "DISEASE", 56, 76], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "CHEMICAL", 231, 237], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 194, 200], ["PaO 2 )", "CHEMICAL", 202, 209], ["oxygen", "CHEMICAL", 231, 237], ["FiO 2", "CHEMICAL", 239, 244], ["patients", "ORGANISM", 7, 15], ["finger", "ORGANISM_SUBDIVISION", 120, 126], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["oxygen", "SIMPLE_CHEMICAL", 231, 237], ["patients", "SPECIES", 7, 15], ["respiratory distress", "PROBLEM", 56, 76], ["respiratory rate", "TEST", 78, 94], ["RR", "TEST", 96, 98], ["finger oxygen satur", "TEST", 120, 139], ["partial pressure of oxygen (PaO", "TREATMENT", 174, 205], ["inspired oxygen (FiO", "TREATMENT", 222, 242], ["respiratory", "ANATOMY", 56, 67], ["distress", "OBSERVATION", 68, 76], ["pressure", "OBSERVATION_MODIFIER", 182, 190]]], ["Critical pneumonia has one of respiratory failure with mechanical ventilation required, shock, other organs failure required ICU monitoring.", [["respiratory", "ANATOMY", 30, 41], ["organs", "ANATOMY", 101, 107], ["pneumonia", "DISEASE", 9, 18], ["respiratory failure", "DISEASE", 30, 49], ["shock", "DISEASE", 88, 93], ["organs", "ORGAN", 101, 107], ["Critical pneumonia", "PROBLEM", 0, 18], ["respiratory failure", "PROBLEM", 30, 49], ["mechanical ventilation", "TREATMENT", 55, 77], ["shock", "PROBLEM", 88, 93], ["other organs failure", "PROBLEM", 95, 115], ["ICU monitoring", "TEST", 125, 139], ["pneumonia", "OBSERVATION", 9, 18], ["respiratory failure", "OBSERVATION", 30, 49], ["mechanical ventilation", "OBSERVATION", 55, 77], ["shock", "OBSERVATION", 88, 93], ["organs", "ANATOMY", 101, 107], ["failure", "OBSERVATION", 108, 115]]], ["It should be noted that each patient may have multiple clinical stages as the disease progressed.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["multiple clinical stages", "PROBLEM", 46, 70], ["the disease", "PROBLEM", 74, 85], ["disease", "OBSERVATION", 78, 85]]], ["We recorded all the clinical classifications for every selected patient and the time at which the classification began or change of classification occurred.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71]]], ["The time (\u00b12 days) was then used to match their latest imaging and laboratory information for each clinical stage of the patients.Statistical analysisClinical characteristics were described via means and standard deviations (for normally distributed variables) or interquartile range (Median(IQR)) (for not normally distributed variables) or frequency and percentages (for categorical variables), and their differences were then correspondingly compared by t test, Mann\u2212Whitney U test (or Kruskal\u2212Wallis H test), Chi-square test (or Fisher's exact probability), respectively.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["their latest imaging", "TEST", 42, 62], ["Statistical analysisClinical characteristics", "PROBLEM", 130, 174], ["Whitney U test", "TEST", 470, 484], ["Kruskal\u2212Wallis H test", "TEST", 489, 510], ["Chi-square test", "TEST", 513, 528]]], ["Cochran \u2212Armitage trend test was further used to check whether an upward or downward trend exists in ordinary variables.", [["Armitage trend test", "TEST", 9, 28], ["an upward or downward trend", "PROBLEM", 63, 90]]], ["A P-value <0.05 was considered statistically significant.", [["A P-value", "TEST", 0, 9]]], ["All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, 2017) while graphs were plotted by R-3.6.0.Demographic and clinical characteristics of study participantsThe median age of the 101 patients was 51.0 years (IQR 37.0-61.0), and 53 (52%) were female.", [["patients", "ORGANISM", 199, 207], ["participants", "SPECIES", 161, 173], ["patients", "SPECIES", 199, 207], ["All analyses", "TEST", 0, 12], ["SAS", "TEST", 34, 37], ["NC", "TREATMENT", 64, 66], ["graphs", "TEST", 80, 86], ["IQR", "TEST", 224, 227]]], ["Among them, 34 (34%) were medical staff and 47 (47%) had suspected nosocomial infections.", [["nosocomial infections", "DISEASE", 67, 88], ["nosocomial infections", "PROBLEM", 67, 88], ["nosocomial infections", "OBSERVATION", 67, 88]]], ["More than half of the patients (51%) had coexisting disorders, which mainly were hypertension (20%), cardiovascular or cerebrovascular disease (14%), diabetes (13%) and malignant tumours (12%).", [["cardiovascular", "ANATOMY", 101, 115], ["cerebrovascular", "ANATOMY", 119, 134], ["malignant tumours", "ANATOMY", 169, 186], ["hypertension", "DISEASE", 81, 93], ["cardiovascular or cerebrovascular disease", "DISEASE", 101, 142], ["diabetes", "DISEASE", 150, 158], ["malignant tumours", "DISEASE", 169, 186], ["patients", "ORGANISM", 22, 30], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 119, 134], ["malignant tumours", "CANCER", 169, 186], ["patients", "SPECIES", 22, 30], ["coexisting disorders", "PROBLEM", 41, 61], ["hypertension", "PROBLEM", 81, 93], ["cardiovascular or cerebrovascular disease", "PROBLEM", 101, 142], ["diabetes", "PROBLEM", 150, 158], ["malignant tumours", "PROBLEM", 169, 186], ["hypertension", "OBSERVATION", 81, 93], ["cerebrovascular", "ANATOMY", 119, 134], ["disease", "OBSERVATION", 135, 142], ["malignant", "OBSERVATION_MODIFIER", 169, 178], ["tumours", "OBSERVATION", 179, 186]]], ["None of the 101 patients had a history of exposure to the Wuhan Huanan seafood market.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["The common symptoms include fever (68%), cough (50%), fatigue (23%), myalgia (16%) and dyspnoea (14%).", [["fever", "DISEASE", 28, 33], ["cough", "DISEASE", 41, 46], ["fatigue", "DISEASE", 54, 61], ["myalgia", "DISEASE", 69, 76], ["dyspnoea", "DISEASE", 87, 95], ["The common symptoms", "PROBLEM", 0, 19], ["fever", "PROBLEM", 28, 33], ["cough", "PROBLEM", 41, 46], ["fatigue", "PROBLEM", 54, 61], ["myalgia", "PROBLEM", 69, 76], ["dyspnoea", "PROBLEM", 87, 95], ["fever", "OBSERVATION", 28, 33], ["myalgia", "ANATOMY", 69, 76]]], ["Mechanical ventilation, primarily nasal cannula/ oxygen mask (20 patients, 20%), was used in 26 patients (26%).", [["nasal", "ANATOMY", 34, 39], ["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 49, 55], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 34, 47], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 96, 104], ["Mechanical ventilation", "TREATMENT", 0, 22], ["primarily nasal cannula/ oxygen mask", "TREATMENT", 24, 60], ["ventilation", "OBSERVATION", 11, 22], ["nasal cannula", "OBSERVATION", 34, 47]]], ["Almost all the patients (98%) were treated with antibiotics.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["antibiotics", "TREATMENT", 48, 59]]], ["While interferon, antiviral, gamma globulin and thymosin therapy were initiated in 40 (40%), 85 (84%), 65 (64%) and 10 (10%) patients, respectively.", [["gamma globulin", "CHEMICAL", 29, 43], ["interferon", "GENE_OR_GENE_PRODUCT", 6, 16], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 29, 43], ["thymosin", "GENE_OR_GENE_PRODUCT", 48, 56], ["patients", "ORGANISM", 125, 133], ["interferon", "PROTEIN", 6, 16], ["gamma globulin", "PROTEIN", 29, 43], ["thymosin", "PROTEIN", 48, 56], ["patients", "SPECIES", 125, 133], ["interferon", "TREATMENT", 6, 16], ["antiviral", "TREATMENT", 18, 27], ["gamma globulin", "TREATMENT", 29, 43], ["thymosin therapy", "TREATMENT", 48, 64]]], ["The median time from the initial symptom, hospital admission to the laboratory-confirmed diagnosis were 7.0 days (IQR: 5.0-13.0) and 4.0 days (IQR: 2.0-7.0).", [["IQR", "TEST", 114, 117], ["IQR", "TEST", 143, 146]]], ["Overall, the person-times of uncomplicated illness, mild, severe and critical pneumonia was there were 1, 88, 55 and 14 during course of illness, respectively.", [["illness", "DISEASE", 43, 50], ["pneumonia", "DISEASE", 78, 87], ["illness", "DISEASE", 137, 144], ["person", "SPECIES", 13, 19], ["uncomplicated illness", "PROBLEM", 29, 50], ["mild, severe and critical pneumonia", "PROBLEM", 52, 87], ["illness", "PROBLEM", 137, 144], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["critical", "OBSERVATION_MODIFIER", 69, 77], ["pneumonia", "OBSERVATION", 78, 87]]], ["As of 8 February 2020, more than one-third (37, 37%) were cured and discharged, one half (53, 52%) remained hospitalised, respectively, while 11 (11%) patients died unfortunately, as shown in Table 1 .", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159]]], ["Figure 1 depicted the flowchart of disease progress of 101 patients.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["On admission, 1, 86, 11 and 2 of the 101 patients were diagnosed as uncomplicated illness, mild, severe, and critical pneumonia, respectively.", [["illness", "DISEASE", 82, 89], ["pneumonia", "DISEASE", 118, 127], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["uncomplicated illness", "PROBLEM", 68, 89], ["mild, severe", "PROBLEM", 91, 103], ["critical pneumonia", "PROBLEM", 109, 127], ["uncomplicated", "OBSERVATION_MODIFIER", 68, 81], ["illness", "OBSERVATION", 82, 89], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["critical", "OBSERVATION_MODIFIER", 109, 117], ["pneumonia", "OBSERVATION", 118, 127]]], ["Additionally, one woman did not have a clinical stage due to pregnancy.", [["woman", "ORGANISM", 18, 23], ["woman", "SPECIES", 18, 23], ["a clinical stage", "PROBLEM", 37, 53], ["pregnancy", "PROBLEM", 61, 70]]], ["During the course of illness, 44 (51%) mild patients progressed to severe condition within a median time of 4 days (IQR: 1-7), among which nine cases (10%) further worsened to critical pneumonia within 4 days (IQR: 3-8) from severe illness.", [["pneumonia", "DISEASE", 185, 194], ["illness", "DISEASE", 232, 239], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["illness", "PROBLEM", 21, 28], ["severe condition", "PROBLEM", 67, 83], ["critical pneumonia", "PROBLEM", 176, 194], ["severe illness", "PROBLEM", 225, 239], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["pneumonia", "OBSERVATION", 185, 194], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["illness", "OBSERVATION", 232, 239]]], ["While two of the 11 severe patients improved to mild condition, three others deteriorated to critical condition.Radiological characteristics stratified by clinical stagesRadiological abnormalities were found in 121 CT scans.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["mild condition", "PROBLEM", 48, 62], ["Radiological abnormalities", "PROBLEM", 170, 196], ["CT scans", "TEST", 215, 223], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["condition", "OBSERVATION", 53, 62]]], ["The majority of abnormalities were presented with multiple 2Radiological characteristics stratified by clinical stagesMengyao Ji et al. lesions (105, 87%), bilateral lungs affected (97, 80%).", [["lesions", "ANATOMY", 136, 143], ["lungs", "ANATOMY", 166, 171], ["lesions", "PATHOLOGICAL_FORMATION", 136, 143], ["lungs", "ORGAN", 166, 171], ["lesions", "TEST", 136, 143], ["bilateral lungs affected", "PROBLEM", 156, 180], ["abnormalities", "OBSERVATION", 16, 29], ["bilateral", "ANATOMY_MODIFIER", 156, 165], ["lungs", "ANATOMY", 166, 171]]], ["The most common lesions located in the posterior basal segment of the left lower lobe (LLL) (72%), followed by the posterior basal segment of the right lower lobe (RLL) (67%), while the anterior basal segment of the RLL and the anterior segment of the left upper lobe (LUL) were affected the least (36% and 40%).", [["lesions", "ANATOMY", 16, 23], ["posterior basal segment", "ANATOMY", 39, 62], ["left lower lobe", "ANATOMY", 70, 85], ["LLL", "ANATOMY", 87, 90], ["posterior basal segment", "ANATOMY", 115, 138], ["right lower lobe", "ANATOMY", 146, 162], ["RLL", "ANATOMY", 164, 167], ["anterior basal segment", "ANATOMY", 186, 208], ["RLL", "ANATOMY", 216, 219], ["anterior segment", "ANATOMY", 228, 244], ["left upper lobe", "ANATOMY", 252, 267], ["LUL", "ANATOMY", 269, 272], ["lesions", "CANCER", 16, 23], ["posterior basal segment", "MULTI-TISSUE_STRUCTURE", 39, 62], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 75, 85], ["LLL", "CANCER", 87, 90], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 152, 162], ["RLL", "CANCER", 164, 167], ["RLL", "CANCER", 216, 219], ["anterior segment", "MULTI-TISSUE_STRUCTURE", 228, 244], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 257, 267], ["LUL", "CANCER", 269, 272], ["The most common lesions", "PROBLEM", 0, 23], ["most", "OBSERVATION_MODIFIER", 4, 8], ["common", "OBSERVATION_MODIFIER", 9, 15], ["lesions", "OBSERVATION", 16, 23], ["posterior", "ANATOMY_MODIFIER", 39, 48], ["basal", "ANATOMY_MODIFIER", 49, 54], ["segment", "ANATOMY_MODIFIER", 55, 62], ["left lower lobe", "ANATOMY", 70, 85], ["LLL", "ANATOMY_MODIFIER", 87, 90], ["posterior", "ANATOMY_MODIFIER", 115, 124], ["basal", "ANATOMY_MODIFIER", 125, 130], ["segment", "ANATOMY_MODIFIER", 131, 138], ["right lower lobe", "ANATOMY", 146, 162], ["RLL", "ANATOMY_MODIFIER", 164, 167], ["anterior", "ANATOMY_MODIFIER", 186, 194], ["basal", "ANATOMY_MODIFIER", 195, 200], ["segment", "ANATOMY_MODIFIER", 201, 208], ["RLL", "ANATOMY_MODIFIER", 216, 219], ["anterior", "ANATOMY_MODIFIER", 228, 236], ["segment", "ANATOMY_MODIFIER", 237, 244], ["left upper lobe", "ANATOMY", 252, 267], ["LUL", "ANATOMY_MODIFIER", 269, 272], ["least", "OBSERVATION_MODIFIER", 292, 297]]], ["The most common patterns on chest CT were pure ground-glass opacity ((44, 36%), Fig. 2a ) and ground-glass opacities overlapped with striped shadows ((48, 40%), Fig. 2b ).", [["chest", "ANATOMY", 28, 33], ["chest CT", "TEST", 28, 36], ["pure ground-glass opacity", "PROBLEM", 42, 67], ["ground-glass opacities", "PROBLEM", 94, 116], ["striped shadows", "PROBLEM", 133, 148], ["chest", "ANATOMY", 28, 33], ["glass opacity", "OBSERVATION", 54, 67], ["ground", "OBSERVATION_MODIFIER", 94, 100], ["glass opacities", "OBSERVATION", 101, 116], ["striped", "OBSERVATION_MODIFIER", 133, 140], ["shadows", "OBSERVATION_MODIFIER", 141, 148]]], ["In addition, 18 cases showed pulmonary consolidation (Fig. 2c) , four showed reticular patterns (Fig. 2d ) and three mixed patterns (Fig. 2e) .", [["pulmonary", "ANATOMY", 29, 38], ["reticular", "ANATOMY", 77, 86], ["pulmonary", "ORGAN", 29, 38], ["pulmonary consolidation", "PROBLEM", 29, 52], ["reticular patterns", "TEST", 77, 95], ["pulmonary", "ANATOMY", 29, 38], ["consolidation", "OBSERVATION", 39, 52], ["reticular", "ANATOMY_MODIFIER", 77, 86]]], ["Most of the cases (65%) were accompanied by peripheral vessels thickening, followed by air bronchogram (44%), mosaic signs (14%), pleural effusion (14%) and halo signs (13%).", [["peripheral vessels", "ANATOMY", 44, 62], ["air bronchogram", "ANATOMY", 87, 102], ["pleural effusion", "ANATOMY", 130, 146], ["peripheral vessels thickening", "DISEASE", 44, 73], ["air bronchogram", "DISEASE", 87, 102], ["pleural effusion", "DISEASE", 130, 146], ["peripheral vessels", "MULTI-TISSUE_STRUCTURE", 44, 62], ["pleural", "ORGAN", 130, 137], ["peripheral vessels thickening", "PROBLEM", 44, 73], ["air bronchogram", "TEST", 87, 102], ["mosaic signs", "TEST", 110, 122], ["pleural effusion", "PROBLEM", 130, 146], ["halo signs", "TEST", 157, 167], ["peripheral", "ANATOMY_MODIFIER", 44, 54], ["vessels", "ANATOMY", 55, 62], ["thickening", "OBSERVATION", 63, 73], ["air bronchogram", "OBSERVATION", 87, 102], ["pleural", "ANATOMY", 130, 137], ["effusion", "OBSERVATION", 138, 146]]], ["Significant differences were observed in bilateral/left/right lungs of being influenced (P = 0.07), multiple or single lesions (P = 0.033), lesion size (P = 0.003), numbers of influenced pulmonary segments (P < 0.001) and numbers of pulmonary segments with striped shadows (P = 0.017) among groups with different clinical stages ( Table 2) .", [["left/right lungs", "ANATOMY", 51, 67], ["lesions", "ANATOMY", 119, 126], ["lesion", "ANATOMY", 140, 146], ["pulmonary segments", "ANATOMY", 187, 205], ["pulmonary segments", "ANATOMY", 233, 251], ["lungs", "ORGAN", 62, 67], ["lesions", "PATHOLOGICAL_FORMATION", 119, 126], ["pulmonary segments", "MULTI-TISSUE_STRUCTURE", 187, 205], ["pulmonary", "ORGAN", 233, 242], ["Significant differences", "PROBLEM", 0, 23], ["P", "TEST", 89, 90], ["multiple or single lesions", "PROBLEM", 100, 126], ["P", "TEST", 128, 129], ["lesion size", "TEST", 140, 151], ["P", "TEST", 153, 154], ["influenced pulmonary segments", "PROBLEM", 176, 205], ["numbers of pulmonary segments with striped shadows", "PROBLEM", 222, 272], ["P", "TEST", 274, 275], ["bilateral", "ANATOMY_MODIFIER", 41, 50], ["left", "ANATOMY_MODIFIER", 51, 55], ["right", "ANATOMY_MODIFIER", 56, 61], ["lungs", "ANATOMY", 62, 67], ["multiple", "OBSERVATION_MODIFIER", 100, 108], ["single", "OBSERVATION_MODIFIER", 112, 118], ["lesions", "OBSERVATION", 119, 126], ["lesion", "OBSERVATION_MODIFIER", 140, 146], ["size", "OBSERVATION_MODIFIER", 147, 151], ["influenced", "ANATOMY_MODIFIER", 176, 186], ["pulmonary", "ANATOMY", 187, 196], ["segments", "ANATOMY_MODIFIER", 197, 205], ["pulmonary segments", "ANATOMY", 233, 251], ["striped", "OBSERVATION_MODIFIER", 257, 264], ["shadows", "OBSERVATION_MODIFIER", 265, 272]]], ["Note: Data are presented as medians (interquartile ranges, IQR) and N (%). a P value was calculated using Fisher's exact probability instead of \u03c7 2 test.", [["a P value", "TEST", 75, 84]]], ["P value < 0.001.Radiological findings as disease progressedThe average interval between the second, third and fourth CT examinations and the first time was 4, 7 and 10 days, respectively.", [["P value", "TEST", 0, 7], ["disease", "PROBLEM", 41, 48], ["the second, third and fourth CT examinations", "TEST", 88, 132], ["average", "OBSERVATION_MODIFIER", 63, 70]]], ["Besides, single lesion gradually developed to multiple ones in the disease progression, with an increasing trend (P = 0.05) in median affected pulmonary segments (7.0, 9.0, 10.5 and 12.0) ( Table S1 in Supplementary Appendix).", [["lesion", "ANATOMY", 16, 22], ["pulmonary", "ANATOMY", 143, 152], ["pulmonary segments", "MULTI-TISSUE_STRUCTURE", 143, 161], ["single lesion", "PROBLEM", 9, 22], ["the disease progression", "PROBLEM", 63, 86], ["an increasing trend (P = 0.05) in median affected pulmonary segments", "PROBLEM", 93, 161], ["single", "OBSERVATION_MODIFIER", 9, 15], ["lesion", "OBSERVATION", 16, 22], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["disease", "OBSERVATION_MODIFIER", 67, 74], ["progression", "OBSERVATION_MODIFIER", 75, 86], ["increasing", "OBSERVATION_MODIFIER", 96, 106], ["trend", "OBSERVATION_MODIFIER", 107, 112], ["median", "ANATOMY_MODIFIER", 127, 133], ["pulmonary segments", "ANATOMY", 143, 161], ["Supplementary Appendix", "ANATOMY", 202, 224]]], ["In terms of radiological patterns, an upward trend was observed in the numbers of ground-glass opacities overlapped with striped shadows (33%, 42%, 55% and 80%), as shown in Table S1 .", [["radiological patterns", "TEST", 12, 33], ["an upward trend", "PROBLEM", 35, 50], ["ground-glass opacities", "PROBLEM", 82, 104], ["striped shadows", "TEST", 121, 136], ["radiological patterns", "OBSERVATION", 12, 33], ["upward", "OBSERVATION_MODIFIER", 38, 44], ["numbers", "OBSERVATION_MODIFIER", 71, 78], ["ground", "OBSERVATION_MODIFIER", 82, 88], ["glass opacities", "OBSERVATION", 89, 104], ["striped", "OBSERVATION_MODIFIER", 121, 128], ["shadows", "OBSERVATION_MODIFIER", 129, 136], ["S1", "ANATOMY", 180, 182]]], ["Correspondingly, the percentage of pure ground-glass opacities presented with a decreasing trend (45%, 35%, 24% and 13%) for the first time CT scans to the fourth time CT scans within 12 days as the disease progressed.", [["pure ground-glass opacities", "PROBLEM", 35, 62], ["CT scans", "TEST", 140, 148], ["CT scans", "TEST", 168, 176], ["the disease", "PROBLEM", 195, 206], ["percentage", "OBSERVATION_MODIFIER", 21, 31], ["pure", "OBSERVATION_MODIFIER", 35, 39], ["ground-glass opacities", "OBSERVATION", 40, 62], ["decreasing", "OBSERVATION_MODIFIER", 80, 90], ["trend", "OBSERVATION_MODIFIER", 91, 96], ["disease", "OBSERVATION", 199, 206]]], ["Representative radiological findings during course of illness could be found in Figure S1 .Laboratory parameters stratified by clinical stagesSignificant differences were observed among groups of different clinical stages in lactate dehydrogenase (P = 0.001), blood urea (P = 0.03), procalcitonin (P = 0.002) and D-dimer (P < 0.001), prothrombin time (P = 0.003), lymphocyte count (P = 0.001), white blood cells (P = 0.006), neutrophil count (P = 0.001), lymphocyte ratio (P < 0.001), C-reactive protein (P < 0.001), albumin (P < 0.001), prealbumin (P < 0.001) and serum amyloid (P < 0.001) ( Table 3) .", [["blood", "ANATOMY", 260, 265], ["lymphocyte", "ANATOMY", 364, 374], ["white blood cells", "ANATOMY", 394, 411], ["neutrophil", "ANATOMY", 425, 435], ["lymphocyte", "ANATOMY", 455, 465], ["serum", "ANATOMY", 565, 570], ["illness", "DISEASE", 54, 61], ["lactate", "CHEMICAL", 225, 232], ["urea", "CHEMICAL", 266, 270], ["lactate", "CHEMICAL", 225, 232], ["urea", "CHEMICAL", 266, 270], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 225, 246], ["blood", "ORGANISM_SUBSTANCE", 260, 265], ["urea", "SIMPLE_CHEMICAL", 266, 270], ["D-dimer", "SIMPLE_CHEMICAL", 313, 320], ["prothrombin", "GENE_OR_GENE_PRODUCT", 334, 345], ["lymphocyte", "CELL", 364, 374], ["white blood cells", "CELL", 394, 411], ["neutrophil", "CELL", 425, 435], ["lymphocyte", "CELL", 455, 465], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 485, 503], ["albumin", "GENE_OR_GENE_PRODUCT", 517, 524], ["prealbumin", "GENE_OR_GENE_PRODUCT", 538, 548], ["serum", "ORGANISM_SUBSTANCE", 565, 570], ["lactate dehydrogenase", "PROTEIN", 225, 246], ["procalcitonin", "PROTEIN", 283, 296], ["prothrombin", "PROTEIN", 334, 345], ["white blood cells", "CELL_TYPE", 394, 411], ["C-reactive protein", "PROTEIN", 485, 503], ["albumin", "PROTEIN", 517, 524], ["prealbumin", "PROTEIN", 538, 548], ["illness", "PROBLEM", 54, 61], ["Laboratory parameters", "TEST", 91, 112], ["Significant differences", "PROBLEM", 142, 165], ["lactate dehydrogenase", "TEST", 225, 246], ["P", "TEST", 248, 249], ["blood urea", "TEST", 260, 270], ["P", "TEST", 272, 273], ["procalcitonin", "TEST", 283, 296], ["P", "TEST", 298, 299], ["D-dimer", "TEST", 313, 320], ["P", "TEST", 322, 323], ["prothrombin time", "TEST", 334, 350], ["P", "TEST", 352, 353], ["lymphocyte count", "TEST", 364, 380], ["P", "TEST", 382, 383], ["white blood cells", "TEST", 394, 411], ["P", "TEST", 413, 414], ["neutrophil count", "TEST", 425, 441], ["P", "TEST", 443, 444], ["lymphocyte ratio", "TEST", 455, 471], ["P", "TEST", 473, 474], ["C-reactive protein", "TEST", 485, 503], ["P", "TEST", 505, 506], ["albumin", "TEST", 517, 524], ["P", "TEST", 526, 527], ["prealbumin", "TEST", 538, 548], ["serum amyloid", "TEST", 565, 578]]], ["As illustrated in Figure 3 , lymphocytes prealbumin and albumin decreased as disease progressed while an upward trend was witnessed in white blood cells, C-reactive protein, neutrophils and lactate dehydrogenase decrease over time.Laboratory parameters stratified by clinical stagesThe most predominant spectrum of serum amyloid A was 5 \u2212300, >300 and >300 mg/l in mild (60%), severe (46%), critical (71%) conditions, respectively.DiscussionThis retrospective study, to our best knowledge, is the first report to the disease progression of patients with SARA-CoV-2.", [["lymphocytes", "ANATOMY", 29, 40], ["white blood cells", "ANATOMY", 135, 152], ["neutrophils", "ANATOMY", 174, 185], ["serum", "ANATOMY", 315, 320], ["lactate", "CHEMICAL", 190, 197], ["lactate", "CHEMICAL", 190, 197], ["lymphocytes", "CELL", 29, 40], ["prealbumin", "GENE_OR_GENE_PRODUCT", 41, 51], ["albumin", "GENE_OR_GENE_PRODUCT", 56, 63], ["white blood cells", "CELL", 135, 152], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 154, 172], ["neutrophils", "CELL", 174, 185], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 190, 211], ["serum", "ORGANISM_SUBSTANCE", 315, 320], ["amyloid A", "SIMPLE_CHEMICAL", 321, 330], ["patients", "ORGANISM", 540, 548], ["lymphocytes", "CELL_TYPE", 29, 40], ["albumin", "PROTEIN", 56, 63], ["white blood cells", "CELL_TYPE", 135, 152], ["C-reactive protein", "PROTEIN", 154, 172], ["neutrophils", "CELL_TYPE", 174, 185], ["lactate dehydrogenase", "PROTEIN", 190, 211], ["patients", "SPECIES", 540, 548], ["lymphocytes prealbumin", "TEST", 29, 51], ["albumin", "TEST", 56, 63], ["disease", "PROBLEM", 77, 84], ["an upward trend", "TEST", 102, 117], ["white blood cells", "TEST", 135, 152], ["C", "TEST", 154, 155], ["reactive protein", "TEST", 156, 172], ["neutrophils", "TEST", 174, 185], ["lactate dehydrogenase decrease", "PROBLEM", 190, 220], ["Laboratory parameters", "TEST", 231, 252], ["serum amyloid A", "TEST", 315, 330], ["This retrospective study", "TEST", 441, 465], ["reactive protein", "OBSERVATION", 156, 172], ["decrease", "OBSERVATION_MODIFIER", 212, 220], ["amyloid", "OBSERVATION", 321, 328], ["mild", "OBSERVATION_MODIFIER", 365, 369], ["severe", "OBSERVATION_MODIFIER", 377, 383]]], ["As of 28 January 2020, a total of 101 confirmed COVID-19 patients were enrolled in this study, and classified into four different groups (uncomplicated illness, mild, severe and critical pneumonia) according to the disease severity.", [["illness", "DISEASE", 152, 159], ["pneumonia", "DISEASE", 187, 196], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["COVID", "TEST", 48, 53], ["this study", "TEST", 83, 93], ["uncomplicated illness", "PROBLEM", 138, 159], ["mild, severe and critical pneumonia", "PROBLEM", 161, 196], ["the disease severity", "PROBLEM", 211, 231], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["critical", "OBSERVATION_MODIFIER", 178, 186], ["pneumonia", "OBSERVATION", 187, 196], ["disease", "OBSERVATION", 215, 222]]], ["Among these patients, 86 and 11 patients were diagnosed as mild and severe pneumonia, as well as one uncomplicated illness and two critical pneumonia on admission.", [["pneumonia", "DISEASE", 75, 84], ["pneumonia", "DISEASE", 140, 149], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 32, 40], ["mild and severe pneumonia", "PROBLEM", 59, 84], ["one uncomplicated illness", "PROBLEM", 97, 122], ["two critical pneumonia", "PROBLEM", 127, 149], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["pneumonia", "OBSERVATION", 75, 84], ["uncomplicated", "OBSERVATION_MODIFIER", 101, 114], ["illness", "OBSERVATION", 115, 122], ["critical", "OBSERVATION_MODIFIER", 131, 139], ["pneumonia", "OBSERVATION", 140, 149]]], ["The median age of these patients was 51.0 years (IQR 37.0-61.0), 34% were medical staff and 47% has suspected nosocomial infections, this is caused by the rapid person-to-person transmission of COVID-19 with less personal protection.", [["nosocomial infections", "DISEASE", 110, 131], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["person", "SPECIES", 161, 167], ["person", "SPECIES", 171, 177], ["IQR", "TEST", 49, 52], ["nosocomial infections", "PROBLEM", 110, 131], ["COVID", "TREATMENT", 194, 199], ["nosocomial", "OBSERVATION_MODIFIER", 110, 120], ["infections", "OBSERVATION", 121, 131]]], ["Fever (68%), cough (50%), fatigue (23%) and myalgia (16%) are the most symptoms on admission.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 13, 18], ["fatigue", "DISEASE", 26, 33], ["myalgia", "DISEASE", 44, 51], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 13, 18], ["fatigue", "PROBLEM", 26, 33], ["myalgia", "PROBLEM", 44, 51], ["the most symptoms", "PROBLEM", 62, 79]]], ["Fifty-one per cent patients have complications, with hypertension (20%), cardiovascular or cerebrovascular disease (14%) and diabetes (12%), respectively.", [["cardiovascular", "ANATOMY", 73, 87], ["cerebrovascular", "ANATOMY", 91, 106], ["hypertension", "DISEASE", 53, 65], ["cardiovascular or cerebrovascular disease", "DISEASE", 73, 114], ["diabetes", "DISEASE", 125, 133], ["patients", "ORGANISM", 19, 27], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 91, 106], ["patients", "SPECIES", 19, 27], ["complications", "PROBLEM", 33, 46], ["hypertension", "PROBLEM", 53, 65], ["cardiovascular or cerebrovascular disease", "PROBLEM", 73, 114], ["diabetes", "PROBLEM", 125, 133], ["complications", "OBSERVATION", 33, 46], ["hypertension", "OBSERVATION", 53, 65], ["cardiovascular", "ANATOMY", 73, 87], ["cerebrovascular", "ANATOMY", 91, 106], ["disease", "OBSERVATION", 107, 114]]], ["The most common patterns on chest CT were pure ground-glass opacity (36%) and groundglass opacities overlapped with striped shadows (40%).", [["chest", "ANATOMY", 28, 33], ["opacities", "DISEASE", 90, 99], ["chest CT", "TEST", 28, 36], ["pure ground-glass opacity", "PROBLEM", 42, 67], ["groundglass opacities", "PROBLEM", 78, 99], ["striped shadows", "PROBLEM", 116, 131], ["chest", "ANATOMY", 28, 33], ["glass opacity", "OBSERVATION", 54, 67], ["groundglass", "OBSERVATION_MODIFIER", 78, 89], ["opacities", "OBSERVATION", 90, 99], ["striped", "OBSERVATION_MODIFIER", 116, 123], ["shadows", "OBSERVATION_MODIFIER", 124, 131]]], ["About 26% patients underwent the mechanical ventilation.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["the mechanical ventilation", "TREATMENT", 29, 55], ["mechanical ventilation", "OBSERVATION", 33, 55]]], ["These findings conform with the previous study of COVID-19 in Wuhan, China [5, 13] .", [["the previous study", "TEST", 28, 46], ["COVID", "TEST", 50, 55]]], ["As of 8 February 2020, more than one-third (37, 37%) of patients were cured and discharged, a half (53, 52%) were still hospitalised, while 11 (11%) patients died unfortunately.", [["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 149, 157]]], ["The median time from initial symptoms to diagnosis was 7 days (IQR 5-13), Note: Data are presented as medians (interquartile ranges, IQR) and N (%).", [["initial symptoms", "PROBLEM", 21, 37]]], ["P value < 0.001.Epidemiology and Infectionas well as 4.0 days (IQR 2-7) for median time from admission to diagnosis.", [["P value", "TEST", 0, 7]]], ["However, the median time from initial symptoms to diagnosis was shortened greatly during January ( Figure S2 ), this is due to the substantial supplies of SARS-Cov-2 detection kit.", [["SARS", "DISEASE", 155, 159], ["Cov-2", "GENE_OR_GENE_PRODUCT", 160, 165], ["initial symptoms", "PROBLEM", 30, 46], ["SARS", "PROBLEM", 155, 159]]], ["Notable, the majority (72%) of the non-medical-staff patients had complications, which primarily were cardiovascular diseases and diabetes.", [["cardiovascular", "ANATOMY", 102, 116], ["cardiovascular diseases", "DISEASE", 102, 125], ["diabetes", "DISEASE", 130, 138], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["complications", "PROBLEM", 66, 79], ["cardiovascular diseases", "PROBLEM", 102, 125], ["diabetes", "PROBLEM", 130, 138], ["majority", "OBSERVATION_MODIFIER", 13, 21], ["cardiovascular diseases", "OBSERVATION", 102, 125], ["diabetes", "OBSERVATION", 130, 138]]], ["This proportion was higher than SARS but close to MERS [14] , suggesting that patients with pre-existing conditions should get well-prepared for the prevention of SARS-CoV-2.", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 163, 167], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 163, 171], ["SARS", "PROBLEM", 32, 36], ["pre-existing conditions", "PROBLEM", 92, 115], ["SARS", "PROBLEM", 163, 167], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["On admission, most patients had fever (68%), the most common symptom of the disease in the study.", [["fever", "DISEASE", 32, 37], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["fever", "PROBLEM", 32, 37], ["the disease in the study", "PROBLEM", 72, 96], ["disease", "OBSERVATION", 76, 83]]], ["Importantly, a significant proportion of patients without fever in an early stage, and were more vulnerable to be ignored, indicating that more attention should be given to patients without fever when screening and diagnosing COVID-19.Epidemiology and InfectionAdditionally, 86 of the 101 patients were diagnosed with mild pneumonia on admission, 42 of the 86 patients maintained or improved.", [["fever", "DISEASE", 58, 63], ["fever", "DISEASE", 190, 195], ["pneumonia", "DISEASE", 323, 332], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 289, 297], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 289, 297], ["patients", "SPECIES", 360, 368], ["fever", "PROBLEM", 58, 63], ["fever", "PROBLEM", 190, 195], ["screening", "TEST", 201, 210], ["diagnosing COVID", "TEST", 215, 231], ["InfectionAdditionally", "TEST", 252, 273], ["mild pneumonia", "PROBLEM", 318, 332], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["without", "UNCERTAINTY", 50, 57], ["fever", "OBSERVATION", 58, 63], ["mild", "OBSERVATION_MODIFIER", 318, 322], ["pneumonia", "OBSERVATION", 323, 332], ["improved", "OBSERVATION_MODIFIER", 383, 391]]], ["Meanwhile, 19 of 42 get cured in a short period and no death occurred.", [["death", "DISEASE", 55, 60], ["death", "PROBLEM", 55, 60], ["no", "UNCERTAINTY", 52, 54]]], ["While, 44 of the 86 mild pneumonia patients progressed to severe condition within 4 days, among which 13 were cured and 11 died.", [["pneumonia", "DISEASE", 25, 34], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["the 86 mild pneumonia", "PROBLEM", 13, 34], ["severe condition", "PROBLEM", 58, 74], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["pneumonia", "OBSERVATION", 25, 34], ["severe", "OBSERVATION_MODIFIER", 58, 64]]], ["This suggested that we should pay more attention to the disease at an early stage, rather than neglecting the mild illness.", [["the disease", "PROBLEM", 52, 63], ["the mild illness", "PROBLEM", 106, 122], ["mild", "OBSERVATION_MODIFIER", 110, 114], ["illness", "OBSERVATION", 115, 122]]], ["Besides, we could see that COVID-19 progresses rapidly within 4 days from mild-to-severe condition, further illustrated by variations in radiological characteristics over time in this study.", [["COVID", "TEST", 27, 32], ["mild-to-severe condition", "PROBLEM", 74, 98], ["this study", "TEST", 179, 189], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["-to-severe", "OBSERVATION_MODIFIER", 78, 88], ["condition", "OBSERVATION", 89, 98]]], ["Indeed, it is significantly crucial to speed up the diagnosis process of suspected cases and make sure all potential patients are able to get access to hospitals for observation and treatment at an early stage.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["observation", "TEST", 166, 177], ["treatment", "TREATMENT", 182, 191]]], ["Furthermore, patients with complications could highly develop severe and critical illness as disease progressed.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["complications", "PROBLEM", 27, 40], ["severe and critical illness", "PROBLEM", 62, 89], ["disease", "PROBLEM", 93, 100], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["critical", "OBSERVATION_MODIFIER", 73, 81], ["illness", "OBSERVATION", 82, 89]]], ["Also whether or not having dyspnoea as initial symptoms and the respiratory frequency in physical examination on admission were both significantly different among groups of different clinical stages (higher probability observed in severe or critical stage than the mild one), suggesting that attention should be paid to the patient's underlying disease and first symptoms when treating COVID-19 [8, [15] [16] [17] .Epidemiology and InfectionMoreover, most patients presented with patchy, lumpy or segmental ground-glass shadows in the subpleural area in an early stage.", [["respiratory", "ANATOMY", 64, 75], ["subpleural area", "ANATOMY", 535, 550], ["dyspnoea", "DISEASE", 27, 35], ["COVID", "DISEASE", 386, 391], ["COVID-19", "CHEMICAL", 386, 394], ["patient", "ORGANISM", 324, 331], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 399, 413], ["patients", "ORGANISM", 456, 464], ["subpleural area", "MULTI-TISSUE_STRUCTURE", 535, 550], ["patient", "SPECIES", 324, 331], ["patients", "SPECIES", 456, 464], ["dyspnoea", "PROBLEM", 27, 35], ["initial symptoms", "PROBLEM", 39, 55], ["the respiratory frequency", "PROBLEM", 60, 85], ["physical examination", "TEST", 89, 109], ["the patient's underlying disease", "PROBLEM", 320, 352], ["first symptoms", "PROBLEM", 357, 371], ["COVID", "TEST", 386, 391], ["patchy, lumpy or segmental ground-glass shadows in the subpleural area", "PROBLEM", 480, 550], ["severe", "OBSERVATION_MODIFIER", 231, 237], ["patchy", "OBSERVATION_MODIFIER", 480, 486], ["lumpy", "OBSERVATION_MODIFIER", 488, 493], ["segmental", "OBSERVATION_MODIFIER", 497, 506], ["ground-glass shadows", "OBSERVATION", 507, 527], ["subpleural", "ANATOMY_MODIFIER", 535, 545], ["early", "OBSERVATION_MODIFIER", 557, 562], ["stage", "OBSERVATION_MODIFIER", 563, 568]]], ["Also, the most common lesions were on the posterior and lateral sides of the lower pulmonary lobe.", [["lesions", "ANATOMY", 22, 29], ["posterior", "ANATOMY", 42, 51], ["lateral sides", "ANATOMY", 56, 69], ["lower pulmonary lobe", "ANATOMY", 77, 97], ["lesions", "CANCER", 22, 29], ["posterior", "MULTI-TISSUE_STRUCTURE", 42, 51], ["lateral sides", "MULTI-TISSUE_STRUCTURE", 56, 69], ["lower pulmonary lobe", "MULTI-TISSUE_STRUCTURE", 77, 97], ["the most common lesions", "PROBLEM", 6, 29], ["most", "OBSERVATION_MODIFIER", 10, 14], ["common", "OBSERVATION_MODIFIER", 15, 21], ["lesions", "OBSERVATION", 22, 29], ["posterior", "ANATOMY_MODIFIER", 42, 51], ["lateral", "ANATOMY_MODIFIER", 56, 63], ["sides", "ANATOMY_MODIFIER", 64, 69], ["lower pulmonary lobe", "ANATOMY", 77, 97]]], ["Yet it was light in the shadows of infiltration of inflammation in lung lobe at the beginning, mainly related to its pathological changes, still suggesting that the SARS-CoV-2 already affected the lung before symptoms were being recognised.", [["lung lobe", "ANATOMY", 67, 76], ["lung", "ANATOMY", 197, 201], ["inflammation", "DISEASE", 51, 63], ["SARS", "DISEASE", 165, 169], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 67, 76], ["SARS-CoV-2", "ORGANISM", 165, 175], ["lung", "ORGAN", 197, 201], ["inflammation in lung lobe", "PROBLEM", 51, 76], ["its pathological changes", "PROBLEM", 113, 137], ["the SARS-CoV", "PROBLEM", 161, 173], ["symptoms", "PROBLEM", 209, 217], ["light", "OBSERVATION_MODIFIER", 11, 16], ["shadows", "OBSERVATION_MODIFIER", 24, 31], ["infiltration", "OBSERVATION", 35, 47], ["inflammation", "OBSERVATION", 51, 63], ["lung", "ANATOMY", 67, 71], ["lobe", "ANATOMY_MODIFIER", 72, 76], ["mainly related to", "UNCERTAINTY", 95, 112], ["pathological", "OBSERVATION", 117, 129], ["lung", "ANATOMY", 197, 201]]], ["As the disease progressed, an upward trend was observed in the numbers of ground-glass opacities overlapped with striped shadows, of affected pulmonary segments, illustrating that pulmonary fibrosis became more severe and to some extent further suggesting that patients are at risk of irreversible damage to lung function in the future, which may further lead to functional disability and affect the quality of life.", [["pulmonary segments", "ANATOMY", 142, 160], ["pulmonary", "ANATOMY", 180, 189], ["lung", "ANATOMY", 308, 312], ["pulmonary fibrosis", "DISEASE", 180, 198], ["functional disability", "DISEASE", 363, 384], ["pulmonary segments", "MULTI-TISSUE_STRUCTURE", 142, 160], ["pulmonary", "ORGAN", 180, 189], ["patients", "ORGANISM", 261, 269], ["lung", "ORGAN", 308, 312], ["patients", "SPECIES", 261, 269], ["the disease", "PROBLEM", 3, 14], ["an upward trend", "PROBLEM", 27, 42], ["ground-glass opacities", "PROBLEM", 74, 96], ["striped shadows", "PROBLEM", 113, 128], ["affected pulmonary segments", "PROBLEM", 133, 160], ["pulmonary fibrosis", "PROBLEM", 180, 198], ["irreversible damage to lung function", "PROBLEM", 285, 321], ["functional disability", "PROBLEM", 363, 384], ["disease", "OBSERVATION", 7, 14], ["upward", "OBSERVATION_MODIFIER", 30, 36], ["trend", "OBSERVATION_MODIFIER", 37, 42], ["numbers", "OBSERVATION_MODIFIER", 63, 70], ["ground-glass opacities", "OBSERVATION", 74, 96], ["striped shadows", "OBSERVATION", 113, 128], ["affected", "OBSERVATION_MODIFIER", 133, 141], ["pulmonary segments", "ANATOMY", 142, 160], ["pulmonary", "ANATOMY", 180, 189], ["fibrosis", "OBSERVATION", 190, 198], ["more severe", "OBSERVATION_MODIFIER", 206, 217], ["some extent", "OBSERVATION_MODIFIER", 225, 236], ["irreversible", "OBSERVATION_MODIFIER", 285, 297], ["damage", "OBSERVATION", 298, 304], ["lung", "ANATOMY", 308, 312]]], ["Such sequelae occurred in both patients infected with SARS or MERS [11, 18] .", [["SARS", "DISEASE", 54, 58], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Such sequelae", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 54, 58], ["sequelae", "OBSERVATION_MODIFIER", 5, 13], ["infected", "OBSERVATION_MODIFIER", 40, 48]]], ["Hence, adding supportive treatment to the therapeutic regimen should be taken into consideration to improve patient's immunity, to weaken the damages to the lungs caused by viral pneumonia and to reduce the risk of sequelae.", [["lungs", "ANATOMY", 157, 162], ["pneumonia", "DISEASE", 179, 188], ["patient", "ORGANISM", 108, 115], ["lungs", "ORGAN", 157, 162], ["patient", "SPECIES", 108, 115], ["supportive treatment", "TREATMENT", 14, 34], ["the therapeutic regimen", "TREATMENT", 38, 61], ["the damages to the lungs", "PROBLEM", 138, 162], ["viral pneumonia", "PROBLEM", 173, 188], ["sequelae", "PROBLEM", 215, 223], ["lungs", "ANATOMY", 157, 162], ["viral", "OBSERVATION_MODIFIER", 173, 178], ["pneumonia", "OBSERVATION", 179, 188], ["sequelae", "OBSERVATION", 215, 223]]], ["In addition, no significant difference was shown in typical radiological patterns among groups of different clinical stages but mosaic signs and pleural effusion, which might relate to prognosis.", [["pleural effusion", "ANATOMY", 145, 161], ["pleural effusion", "DISEASE", 145, 161], ["pleural", "ORGAN", 145, 152], ["different clinical stages", "PROBLEM", 98, 123], ["mosaic signs", "PROBLEM", 128, 140], ["pleural effusion", "PROBLEM", 145, 161], ["no", "UNCERTAINTY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["difference", "OBSERVATION", 28, 38], ["mosaic", "OBSERVATION_MODIFIER", 128, 134], ["signs", "OBSERVATION_MODIFIER", 135, 140], ["pleural", "ANATOMY", 145, 152], ["effusion", "OBSERVATION", 153, 161]]], ["Meanwhile, AI-based diagnosis system showed similar results in assessment of lesions size as what was evaluated by the radiologists.", [["lesions", "ANATOMY", 77, 84], ["lesions", "PATHOLOGICAL_FORMATION", 77, 84], ["lesions size", "PROBLEM", 77, 89], ["lesions", "OBSERVATION", 77, 84], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["It is also worth mentioning that such AI system greatly improved diagnostic efficiency of COVID-19, alleviating the surge in demand of radiologists when the virus is stalking China.", [["COVID", "TEST", 90, 95], ["the virus", "PROBLEM", 153, 162]]], ["Mengyao Ji et al.Epidemiology and InfectionIn this study, significant differences were found in lactate dehydrogenase, D-dimer, prothrombin, lymphocyte count, white blood cell count, neutrophil count, C-reactive protein, albumin and serum amyloid A as the disease progressed.", [["lymphocyte", "ANATOMY", 141, 151], ["white blood cell", "ANATOMY", 159, 175], ["neutrophil", "ANATOMY", 183, 193], ["serum", "ANATOMY", 233, 238], ["lactate", "CHEMICAL", 96, 103], ["lactate", "CHEMICAL", 96, 103], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 96, 117], ["D-dimer", "SIMPLE_CHEMICAL", 119, 126], ["prothrombin", "GENE_OR_GENE_PRODUCT", 128, 139], ["lymphocyte", "CELL", 141, 151], ["white blood cell", "CELL", 159, 175], ["neutrophil", "CELL", 183, 193], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 201, 219], ["albumin", "GENE_OR_GENE_PRODUCT", 221, 228], ["serum", "ORGANISM_SUBSTANCE", 233, 238], ["amyloid A", "SIMPLE_CHEMICAL", 239, 248], ["lactate dehydrogenase", "PROTEIN", 96, 117], ["D-dimer", "PROTEIN", 119, 126], ["prothrombin", "PROTEIN", 128, 139], ["C-reactive protein", "PROTEIN", 201, 219], ["albumin", "PROTEIN", 221, 228], ["serum amyloid A", "PROTEIN", 233, 248], ["this study", "TEST", 46, 56], ["lactate dehydrogenase", "TEST", 96, 117], ["D-dimer", "TEST", 119, 126], ["prothrombin", "TEST", 128, 139], ["lymphocyte count", "TEST", 141, 157], ["white blood cell count", "TEST", 159, 181], ["neutrophil count", "TEST", 183, 199], ["C", "TEST", 201, 202], ["reactive protein", "TEST", 203, 219], ["albumin", "TEST", 221, 228], ["serum amyloid A", "PROBLEM", 233, 248], ["the disease", "PROBLEM", 252, 263], ["neutrophil count", "OBSERVATION", 183, 199]]], ["Some of those indicators were inconsistent with previous studies [13] .", [["previous studies", "TEST", 48, 64]]], ["In addition, we observed that the amount of albumin and prealbumin in critically or severely ill patients were significantly lower than those of mild ones.", [["critically or severely ill", "DISEASE", 70, 96], ["albumin", "GENE_OR_GENE_PRODUCT", 44, 51], ["prealbumin", "GENE_OR_GENE_PRODUCT", 56, 66], ["patients", "ORGANISM", 97, 105], ["albumin", "PROTEIN", 44, 51], ["patients", "SPECIES", 97, 105], ["albumin", "TREATMENT", 44, 51], ["prealbumin", "TEST", 56, 66], ["severely ill", "PROBLEM", 84, 96], ["mild ones", "PROBLEM", 145, 154], ["mild", "OBSERVATION_MODIFIER", 145, 149]]], ["Such differences might relate to the cytokine storm caused by the virus at the late stage of the disease and other factors, such as subsequent hypoxia, gastrointestinal dysfunction, endocrine and metabolic disorders, insufficient nutrition intake and the use of ventilator with positive pressure, and increased energy consumption in the body.", [["gastrointestinal", "ANATOMY", 152, 168], ["endocrine", "ANATOMY", 182, 191], ["body", "ANATOMY", 337, 341], ["hypoxia", "DISEASE", 143, 150], ["gastrointestinal dysfunction", "DISEASE", 152, 180], ["endocrine and metabolic disorders", "DISEASE", 182, 215], ["gastrointestinal", "ORGAN", 152, 168], ["body", "ORGANISM_SUBDIVISION", 337, 341], ["cytokine", "PROTEIN", 37, 45], ["the cytokine storm", "PROBLEM", 33, 51], ["the virus", "PROBLEM", 62, 71], ["the disease", "PROBLEM", 93, 104], ["subsequent hypoxia", "PROBLEM", 132, 150], ["gastrointestinal dysfunction", "PROBLEM", 152, 180], ["endocrine and metabolic disorders", "PROBLEM", 182, 215], ["ventilator", "TREATMENT", 262, 272], ["positive pressure", "TREATMENT", 278, 295], ["increased energy consumption in the body", "PROBLEM", 301, 341], ["cytokine storm", "OBSERVATION", 37, 51], ["late stage", "OBSERVATION_MODIFIER", 79, 89], ["disease", "OBSERVATION", 97, 104], ["hypoxia", "OBSERVATION", 143, 150], ["gastrointestinal", "ANATOMY", 152, 168], ["dysfunction", "OBSERVATION", 169, 180], ["metabolic disorders", "OBSERVATION", 196, 215], ["pressure", "OBSERVATION_MODIFIER", 287, 295], ["increased", "OBSERVATION_MODIFIER", 301, 310], ["energy consumption", "OBSERVATION", 311, 329], ["body", "ANATOMY", 337, 341]]], ["Eventually, malnutrition would be caused or aggravated.", [["malnutrition", "DISEASE", 12, 24], ["malnutrition", "PROBLEM", 12, 24], ["malnutrition", "OBSERVATION", 12, 24]]], ["As a negative acute phase response protein and a kind of substance in non-specific host defense, prealbumin can clear the toxic metabolites released in the circulation during the infection process, and therefore its amount reduced in blood as it was gradually consumed.", [["blood", "ANATOMY", 234, 239], ["infection", "DISEASE", 179, 188], ["prealbumin", "GENE_OR_GENE_PRODUCT", 97, 107], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["prealbumin", "PROTEIN", 97, 107], ["a negative acute phase response protein", "PROBLEM", 3, 42], ["substance in non-specific host defense", "PROBLEM", 57, 95], ["prealbumin", "TEST", 97, 107], ["the toxic metabolites", "PROBLEM", 118, 139], ["the infection process", "PROBLEM", 175, 196], ["negative", "OBSERVATION_MODIFIER", 5, 13], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["toxic", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 179, 188], ["amount", "OBSERVATION_MODIFIER", 216, 222], ["reduced", "OBSERVATION_MODIFIER", 223, 230]]], ["This reminds us to provide nutrition support for these kind of patients [19] .", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["nutrition support", "TREATMENT", 27, 44]]], ["Meanwhile, we found that some inflammation indicators, such as C-reactive protein, and serum amyloid A, increased in the early stage of the disease, but higher amounts of them were observed in severe and critical patients than that of mild cases.", [["serum", "ANATOMY", 87, 92], ["inflammation", "DISEASE", 30, 42], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 63, 81], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["amyloid A", "GENE_OR_GENE_PRODUCT", 93, 102], ["patients", "ORGANISM", 213, 221], ["C-reactive protein", "PROTEIN", 63, 81], ["serum amyloid A", "PROTEIN", 87, 102], ["patients", "SPECIES", 213, 221], ["some inflammation indicators", "PROBLEM", 25, 53], ["C-reactive protein", "PROBLEM", 63, 81], ["serum amyloid A", "PROBLEM", 87, 102], ["the disease", "PROBLEM", 136, 147], ["mild cases", "PROBLEM", 235, 245], ["some", "OBSERVATION_MODIFIER", 25, 29], ["inflammation", "OBSERVATION", 30, 42], ["reactive protein", "OBSERVATION", 65, 81], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["early stage", "OBSERVATION_MODIFIER", 121, 132], ["disease", "OBSERVATION", 140, 147], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["mild", "OBSERVATION_MODIFIER", 235, 239], ["cases", "OBSERVATION", 240, 245]]], ["This might indicate the patients were in the state of acute stress with elevated serum amyloid A and C-reactive protein, which are able to bind various microorganisms' polysaccharides and tissue cells' phospholipids and nucleic acids to activate the immune system, improving immunity and mediating inflammatory responses.Epidemiology and InfectionNo difference on treatment effect of various drugs was observed for patients with different disease progression states; it might be due to the fact that there is no specific treatment guideline for patients with novel coronavirus pneumonia at different states, which might be the main causes for the death of severe and critical patients.", [["serum", "ANATOMY", 81, 86], ["tissue cells", "ANATOMY", 188, 200], ["immune system", "ANATOMY", 250, 263], ["nucleic acids", "CHEMICAL", 220, 233], ["coronavirus pneumonia", "DISEASE", 565, 586], ["death", "DISEASE", 647, 652], ["patients", "ORGANISM", 24, 32], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["amyloid A", "SIMPLE_CHEMICAL", 87, 96], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 101, 119], ["polysaccharides", "CELL", 168, 183], ["tissue cells", "CELL", 188, 200], ["phospholipids", "SIMPLE_CHEMICAL", 202, 215], ["nucleic acids", "SIMPLE_CHEMICAL", 220, 233], ["patients", "ORGANISM", 415, 423], ["patients", "ORGANISM", 545, 553], ["coronavirus", "ORGANISM", 565, 576], ["patients", "ORGANISM", 676, 684], ["serum amyloid A", "PROTEIN", 81, 96], ["C-reactive protein", "PROTEIN", 101, 119], ["tissue cells", "CELL_TYPE", 188, 200], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 415, 423], ["patients", "SPECIES", 545, 553], ["patients", "SPECIES", 676, 684], ["acute stress", "PROBLEM", 54, 66], ["elevated serum amyloid A", "PROBLEM", 72, 96], ["C-reactive protein", "PROBLEM", 101, 119], ["tissue cells' phospholipids", "TEST", 188, 215], ["nucleic acids", "TEST", 220, 233], ["various drugs", "TREATMENT", 384, 397], ["different disease progression states", "PROBLEM", 429, 465], ["novel coronavirus pneumonia", "PROBLEM", 559, 586], ["the death of severe and critical patients", "PROBLEM", 643, 684], ["reactive protein", "OBSERVATION", 103, 119], ["inflammatory", "OBSERVATION_MODIFIER", 298, 310], ["coronavirus", "OBSERVATION_MODIFIER", 565, 576], ["pneumonia", "OBSERVATION", 577, 586]]], ["In addition, the evidences collected in this study cannot confirm which treatment can obviously control the disease progression among current clinical treatment regimens.", [["this study", "TEST", 40, 50], ["the disease progression", "PROBLEM", 104, 127], ["current clinical treatment regimens", "TREATMENT", 134, 169]]], ["Therefore, pro-active actions should be taken to accelerate the clinical trial for potential effect drugs, such as Remdesivir, and various drug combinations [9, 20] ; meanwhile, more existing drugs on the market, which can enhance immune response, reduce immunopathology and prevent or suppress ARDS, such as metformin, glitazone, sartans, atorvastin and relative nutritional supplements and biologics, might be effective treatment options for this disease [4, [21] [22] [23] .Epidemiology and InfectionThis study has several limitations.", [["Remdesivir", "CHEMICAL", 115, 125], ["immunopathology", "DISEASE", 255, 270], ["ARDS", "DISEASE", 295, 299], ["metformin", "CHEMICAL", 309, 318], ["glitazone", "CHEMICAL", 320, 329], ["sartans", "CHEMICAL", 331, 338], ["atorvastin", "CHEMICAL", 340, 350], ["Infection", "DISEASE", 494, 503], ["Remdesivir", "CHEMICAL", 115, 125], ["metformin", "CHEMICAL", 309, 318], ["glitazone", "CHEMICAL", 320, 329], ["sartans", "CHEMICAL", 331, 338], ["atorvastin", "CHEMICAL", 340, 350], ["Remdesivir", "SIMPLE_CHEMICAL", 115, 125], ["metformin", "SIMPLE_CHEMICAL", 309, 318], ["glitazone", "SIMPLE_CHEMICAL", 320, 329], ["sartans", "SIMPLE_CHEMICAL", 331, 338], ["atorvastin", "SIMPLE_CHEMICAL", 340, 350], ["[21] [22] [23]", "SIMPLE_CHEMICAL", 461, 475], ["pro-active actions", "TREATMENT", 11, 29], ["potential effect drugs", "TREATMENT", 83, 105], ["Remdesivir", "TREATMENT", 115, 125], ["various drug combinations", "TREATMENT", 131, 156], ["immunopathology", "PROBLEM", 255, 270], ["ARDS", "PROBLEM", 295, 299], ["metformin", "TREATMENT", 309, 318], ["glitazone", "TREATMENT", 320, 329], ["sartans", "TREATMENT", 331, 338], ["atorvastin", "TREATMENT", 340, 350], ["relative nutritional supplements", "TREATMENT", 355, 387], ["biologics", "TREATMENT", 392, 401], ["treatment options", "TREATMENT", 422, 439], ["this disease", "PROBLEM", 444, 456], ["This study", "TEST", 503, 513], ["Infection", "OBSERVATION", 494, 503]]], ["Firstly, only 48 of the 101 patients included in the study currently have an endpoint, and the others are still under treatment, therefore no indicators related to prognosis could be selected and further explored.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the study", "TEST", 49, 58]]], ["Secondly, despite the fact that we believed that cellular and humoral immunity play an important role in the disease process, it was not used as a routine test, as we did not fully understand the disease at an early stage, making these important indicators impossible to analyse.", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57], ["the disease process", "PROBLEM", 105, 124], ["a routine test", "TEST", 145, 159], ["the disease", "PROBLEM", 192, 203], ["humoral immunity", "OBSERVATION", 62, 78]]], ["Nevertheless, we were to collect relevant information for further analysis.", [["further analysis", "TEST", 58, 74]]], ["Thirdly, data samples are limited because we need to continually and actively fight and treat SARS-CoV-2.ConclusionThe COVID-2019 progresses rapidly and early intervention and treatment are critically crucial for patients' prognosis.ConclusionRadiological patterns and laboratory parameters can timely reflect disease's progression, providing useful help for disease's diagnosis and treatment.ConclusionSupplementary material.", [["samples", "ANATOMY", 14, 21], ["SARS", "DISEASE", 94, 98], ["CoV-2", "ORGANISM", 99, 104], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 94, 102], ["data samples", "TEST", 9, 21], ["SARS", "PROBLEM", 94, 98], ["early intervention", "TREATMENT", 153, 171], ["treatment", "TREATMENT", 176, 185], ["laboratory parameters", "TEST", 269, 290], ["disease's progression", "PROBLEM", 310, 331], ["disease's diagnosis", "TEST", 359, 378], ["treatment", "TREATMENT", 383, 392]]], ["The supplementary material for this article can be found at https://doi.org/10.1017/S0950268820000977.Author contributions.Ji, MY, Yuan, L, Shen, W, Lv, JW and Shi, L had devised the idea, designed the study and had full access to all data during the study and have taken the responsibility for the integrity of the data and the accuracy of the data analysis.", [["the study", "TEST", 198, 207], ["the study", "TEST", 247, 256], ["the data analysis", "TEST", 341, 358], ["Lv", "ANATOMY", 149, 151]]], ["Ji, MY contributed to critical revision of the report.", [["revision", "OBSERVATION", 31, 39]]], ["Yuan, L and Li, M contributed to collect the data.", [["the data", "TEST", 41, 49], ["L", "ANATOMY_MODIFIER", 6, 7], ["Li", "ANATOMY", 12, 14]]], ["Li, Y, Hu, LH and Lu, XF contributed to read the CT pictures.", [["Li", "CHEMICAL", 0, 2], ["Hu", "GENE_OR_GENE_PRODUCT", 7, 9], ["LH", "GENE_OR_GENE_PRODUCT", 11, 13], ["the CT pictures", "TEST", 45, 60], ["LH", "ANATOMY", 11, 13], ["Lu", "ANATOMY", 18, 20]]], ["Xie, WJ and Shen, W contributed to the statistical analysis.", [["the statistical analysis", "TEST", 35, 59]]], ["All authors contributed to data acquisition, data analysis or data interpretation, and reviewed and approved the final version.Author contributions.Financial support.", [["data acquisition", "TEST", 27, 43], ["data analysis", "TEST", 45, 58], ["data interpretation", "TEST", 62, 81], ["Financial support", "TREATMENT", 148, 165]]], ["National Natural Science Foundation of China (81901817); Natural Science Foundation of Hubei Province (2018CFB136); Innovation Seed Funding of Wuhan University (TFZZ2018020).Conflicts of interest.No conflict of interest.", [["conflict", "OBSERVATION", 199, 207]]]], "PMC2866802": [["Study subjects and study design ::: MethodsThe study was approved by the Human Subjects Committee of the School of Medicine and Public Health, University of Wisconsin\u2013Madison.", [["Human", "ORGANISM", 73, 78], ["Human", "SPECIES", 73, 78], ["Methods", "TREATMENT", 36, 43], ["The study", "TEST", 43, 52]]], ["Fifty-eight children aged 6 to 8 years with asthma were enrolled in this study.", [["asthma", "DISEASE", 44, 50], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["asthma", "PROBLEM", 44, 50], ["this study", "TEST", 68, 78], ["asthma", "OBSERVATION", 44, 50]]], ["Skin prick testing was performed on each subject at the time of enrollment, as well as fluoroenzyme immunoassays with an automated instrument (Unicap 100; Phadia, Uppsala, Sweden) to determine total and allergen-specific IgE levels in plasma.", [["Skin", "ANATOMY", 0, 4], ["plasma", "ANATOMY", 235, 241], ["Skin", "ORGAN", 0, 4], ["IgE", "GENE_OR_GENE_PRODUCT", 221, 224], ["plasma", "ORGANISM_SUBSTANCE", 235, 241], ["IgE", "PROTEIN", 221, 224], ["Skin prick testing", "TEST", 0, 18], ["fluoroenzyme immunoassays", "TEST", 87, 112], ["an automated instrument", "TEST", 118, 141], ["Unicap", "TEST", 143, 149]]], ["The allergens evaluated by means of skin prick testing were Alternaria species, tree fluid, Cladosporium species, grass mix, Aspergillus species, ragweed, Dermatophagoides farinae, Dermatophagoides pteronyssinus, weed mix, dog dander, cat dander, and cockroach (Greer Laboratories, Lenoir, NC).", [["skin", "ANATOMY", 36, 40], ["skin", "ORGAN", 36, 40], ["Dermatophagoides farinae", "ORGANISM", 155, 179], ["Dermatophagoides pteronyssinus", "ORGANISM", 181, 211], ["dog", "ORGANISM", 223, 226], ["dander", "ORGANISM_SUBDIVISION", 227, 233], ["cat", "ORGANISM", 235, 238], ["dander", "ORGANISM_SUBDIVISION", 239, 245], ["cockroach", "ORGANISM_SUBDIVISION", 251, 260], ["Dermatophagoides farinae", "SPECIES", 155, 179], ["Dermatophagoides pteronyssinus", "SPECIES", 181, 211], ["dog dander", "SPECIES", 223, 233], ["cat dander", "SPECIES", 235, 245], ["Dermatophagoides farinae", "SPECIES", 155, 179], ["Dermatophagoides pteronyssinus", "SPECIES", 181, 211], ["dog dander", "SPECIES", 223, 233], ["cat dander", "SPECIES", 235, 245], ["The allergens", "PROBLEM", 0, 13], ["skin prick testing", "TEST", 36, 54], ["Alternaria species", "PROBLEM", 60, 78], ["tree fluid", "PROBLEM", 80, 90], ["Cladosporium species", "PROBLEM", 92, 112], ["grass mix", "TREATMENT", 114, 123], ["Aspergillus species", "PROBLEM", 125, 144], ["ragweed", "PROBLEM", 146, 153], ["skin", "ANATOMY", 36, 40], ["tree fluid", "OBSERVATION", 80, 90], ["Aspergillus species", "OBSERVATION", 125, 144], ["cockroach", "ANATOMY", 251, 260]]], ["In addition, allergen-specific IgE levels to D farinae, D pteronyssinus, cat, dog, Alternaria species, ragweed, silver birch, timothy grass, cockroach, egg, and peanut were measured (ImmunoCAP FEIA, Phadia).Study subjects and study design ::: MethodsIn April 2006, nasal samples were collected every other week for a total of 6 weeks.", [["egg", "ANATOMY", 152, 155], ["nasal samples", "ANATOMY", 265, 278], ["silver", "CHEMICAL", 112, 118], ["IgE", "GENE_OR_GENE_PRODUCT", 31, 34], ["D farinae", "ORGANISM", 45, 54], ["D pteronyssinus", "ORGANISM", 56, 71], ["cat", "ORGANISM", 73, 76], ["dog", "ORGANISM", 78, 81], ["Alternaria species", "ORGANISM", 83, 101], ["ragweed", "ORGANISM_SUBDIVISION", 103, 110], ["silver birch", "ORGANISM", 112, 124], ["timothy", "ORGANISM", 126, 133], ["grass", "ORGANISM_SUBDIVISION", 134, 139], ["cockroach", "ORGANISM_SUBDIVISION", 141, 150], ["egg", "ORGANISM_SUBSTANCE", 152, 155], ["peanut", "ORGANISM_SUBDIVISION", 161, 167], ["nasal samples", "CANCER", 265, 278], ["IgE", "PROTEIN", 31, 34], ["D farinae", "SPECIES", 45, 54], ["D pteronyssinus", "SPECIES", 56, 71], ["cat", "SPECIES", 73, 76], ["dog", "SPECIES", 78, 81], ["timothy", "SPECIES", 126, 133], ["peanut", "SPECIES", 161, 167], ["D farinae", "SPECIES", 45, 54], ["D pteronyssinus", "SPECIES", 56, 71], ["allergen", "TEST", 13, 21], ["specific IgE levels", "TEST", 22, 41], ["Alternaria species", "PROBLEM", 83, 101], ["peanut", "TEST", 161, 167], ["MethodsIn April", "TREATMENT", 243, 258], ["nasal samples", "TREATMENT", 265, 278], ["Alternaria species", "OBSERVATION", 83, 101], ["egg", "ANATOMY", 152, 155]]], ["Because of the high frequency of distinct infections, specimen collection was increased to five specimens at weekly intervals during September 2006 and 2007 and April 2007 and 2008.", [["specimen", "ANATOMY", 54, 62], ["specimens", "ANATOMY", 96, 105], ["infections", "DISEASE", 42, 52], ["distinct infections", "PROBLEM", 33, 52], ["specimen collection", "TEST", 54, 73], ["high", "OBSERVATION_MODIFIER", 15, 19], ["distinct", "OBSERVATION_MODIFIER", 33, 41], ["infections", "OBSERVATION", 42, 52]]], ["Children and their parents recorded information on daily diary cards.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["The diary cards consisted of a calendar, and each day had spaces to place a sticker for cold and asthma symptoms, as well as a blank for recording morning peak expiratory flow (PEF) and albuterol use.Study subjects and study design ::: MethodsAll samples were included for the viral analysis.", [["samples", "ANATOMY", 247, 254], ["asthma symptoms", "DISEASE", 97, 112], ["albuterol", "CHEMICAL", 186, 195], ["albuterol", "CHEMICAL", 186, 195], ["albuterol", "SIMPLE_CHEMICAL", 186, 195], ["cold and asthma symptoms", "PROBLEM", 88, 112], ["albuterol use", "TREATMENT", 186, 199], ["Methods", "TREATMENT", 236, 243], ["All samples", "TEST", 243, 254], ["the viral analysis", "TEST", 273, 291]]], ["For the comparison of rates of infection with respiratory symptoms, we included only children who collected 5 sequential weekly nasal specimens and were missing less than 1 week of diary card data in any given season.", [["respiratory", "ANATOMY", 46, 57], ["nasal specimens", "ANATOMY", 128, 143], ["infection", "DISEASE", 31, 40], ["respiratory symptoms", "DISEASE", 46, 66], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["infection", "PROBLEM", 31, 40], ["respiratory symptoms", "PROBLEM", 46, 66], ["infection", "OBSERVATION", 31, 40]]], ["Of the 58 children enrolled, there were 2 children who did not complete any series information.", [["children", "ORGANISM", 10, 18], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 10, 18], ["children", "SPECIES", 42, 50]]], ["Included in the final analyses were 42 (75%) of the 56 children who completed at least 1 season, of whom 19 (34%) completed 2 seasons.Collection of nasal samples ::: MethodsAt the first study visit, subjects were taught to collect samples of their own nasal mucus using a \u201cnose-blowing\u201d technique.12, 13 Briefly, participants sprayed saline into each nostril, alternately occluded each nare, and blew into a \u201cbaggie.\u201d", [["nasal samples", "ANATOMY", 148, 161], ["nasal mucus", "ANATOMY", 252, 263], ["nostril", "ANATOMY", 351, 358], ["children", "ORGANISM", 55, 63], ["nasal samples", "CANCER", 148, 161], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 252, 263], ["nose", "ORGANISM_SUBDIVISION", 273, 277], ["saline", "SIMPLE_CHEMICAL", 334, 340], ["nostril", "ORGAN", 351, 358], ["children", "SPECIES", 55, 63], ["participants", "SPECIES", 313, 325], ["a \u201cnose-blowing\u201d technique", "TREATMENT", 270, 296], ["participants sprayed saline into each nostril", "TREATMENT", 313, 358], ["nasal", "ANATOMY", 148, 153], ["nasal mucus", "ANATOMY", 252, 263], ["nostril", "ANATOMY", 351, 358], ["occluded", "OBSERVATION", 372, 380]]], ["Two milliliters of a solution containing buffered saline (pH 7.4) along with 0.5% gelatin was then added to the baggie, which was then sealed and placed into a container in the freezer.", [["gelatin", "CHEMICAL", 82, 89], ["saline", "SIMPLE_CHEMICAL", 50, 56], ["gelatin", "SIMPLE_CHEMICAL", 82, 89], ["a solution containing buffered saline (pH", "TREATMENT", 19, 60], ["0.5% gelatin", "TREATMENT", 77, 89], ["the baggie", "TREATMENT", 108, 118]]], ["Study materials and diaries were distributed to the homes for biweekly collection.", [["Study materials", "TEST", 0, 15], ["biweekly collection", "TEST", 62, 81]]], ["The stability of HRV collected and stored under these conditions was confirmed in preliminary experiments: HRV was detectable even at low concentrations (100 PFU of HRV16 per milliliter), as might be seen in asymptomatic children, and samples were left at room temperature, 4 \u00b0C (refrigerated), and \u221220 \u00b0C (home freezer) for up to 5 weeks.Identification of respiratory viruses ::: MethodsDiagnostic virology was performed for all nasal samples irrespective of whether a child had symptoms.", [["samples", "ANATOMY", 235, 242], ["nasal samples", "ANATOMY", 430, 443], ["respiratory viruses", "DISEASE", 357, 376], ["children", "ORGANISM", 221, 229], ["nasal samples", "CANCER", 430, 443], ["children", "SPECIES", 221, 229], ["HRV", "TEST", 17, 20], ["HRV", "PROBLEM", 107, 110], ["MethodsDiagnostic virology", "TEST", 381, 407], ["symptoms", "PROBLEM", 480, 488], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["respiratory viruses", "OBSERVATION", 357, 376]]], ["A highly sensitive multiplex PCR-based assay (Respiratory Multicode Assay, EraGen Biosciences, Madison, Wis) was used to test for the following viruses: respiratory syncytial virus (groups A and B), HRV, parainfluenza (1, 2, 3, 4a, and 4b), influenza (A and B), adenovirus (B, C, and E), coronavirus (229E, NL63, OC43, and SARS), enterovirus, and human metapneumovirus.14 Bocavirus detection primers were also added to the Respiratory Multicode Assay mixture for the purposes of this study.Molecular typing assay ::: MethodsMolecular typing of HRV was performed as previously described.3 Briefly, a 260-bp variable region at the 5\u2032 noncoding region of HRV was amplified from the cDNA from nasal specimens by means of seminested PCR.", [["nasal specimens", "ANATOMY", 689, 704], ["respiratory syncytial virus", "DISEASE", 153, 180], ["parainfluenza", "DISEASE", 204, 217], ["influenza", "DISEASE", 241, 250], ["SARS), enterovirus, and human metapneumovirus", "DISEASE", 323, 368], ["respiratory syncytial virus", "ORGANISM", 153, 180], ["parainfluenza", "ORGANISM", 204, 217], ["B", "GENE_OR_GENE_PRODUCT", 258, 259], ["adenovirus", "ORGANISM", 262, 272], ["B, C, and E)", "ORGANISM", 274, 286], ["coronavirus", "ORGANISM", 288, 299], ["NL63", "GENE_OR_GENE_PRODUCT", 307, 311], ["OC43", "GENE_OR_GENE_PRODUCT", 313, 317], ["enterovirus", "ORGANISM", 330, 341], ["human", "ORGANISM", 347, 352], ["metapneumovirus", "ORGANISM", 353, 368], ["nasal specimens", "CANCER", 689, 704], ["260-bp variable region", "DNA", 599, 621], ["5\u2032 noncoding region", "DNA", 629, 648], ["HRV", "DNA", 652, 655], ["cDNA", "DNA", 679, 683], ["respiratory syncytial virus", "SPECIES", 153, 180], ["parainfluenza", "SPECIES", 204, 217], ["coronavirus", "SPECIES", 288, 299], ["human", "SPECIES", 347, 352], ["metapneumovirus", "SPECIES", 353, 368], ["respiratory syncytial virus", "SPECIES", 153, 180], ["HRV", "SPECIES", 199, 202], ["adenovirus", "SPECIES", 262, 272], ["human metapneumovirus", "SPECIES", 347, 368], ["multiplex PCR", "TEST", 19, 32], ["respiratory syncytial virus", "PROBLEM", 153, 180], ["HRV", "TEST", 199, 202], ["parainfluenza", "PROBLEM", 204, 217], ["influenza", "PROBLEM", 241, 250], ["adenovirus (B, C", "TEST", 262, 278], ["coronavirus", "PROBLEM", 288, 299], ["NL63", "TEST", 307, 311], ["OC43", "TEST", 313, 317], ["SARS", "PROBLEM", 323, 327], ["enterovirus", "PROBLEM", 330, 341], ["human metapneumovirus", "PROBLEM", 347, 368], ["Bocavirus detection primers", "TREATMENT", 372, 399], ["this study", "TEST", 479, 489], ["MethodsMolecular typing", "TEST", 517, 540], ["HRV", "TEST", 544, 547], ["bp variable region", "PROBLEM", 603, 621], ["the cDNA", "TEST", 675, 683], ["nasal specimens", "TEST", 689, 704], ["seminested PCR", "TREATMENT", 717, 731], ["respiratory syncytial", "ANATOMY", 153, 174], ["nasal", "ANATOMY", 689, 694]]], ["The 260-bp fragment was cloned and sequenced.", [["260-bp fragment", "DNA", 4, 19], ["The 260-bp fragment", "TREATMENT", 0, 19]]], ["The identity of each sequence was verified by means of comparison with the 5\u2032 sequences of the 101 reference HRV serotypes, as well as a number of sequences from newly identified strains.5", [["5\u2032 sequences", "DNA", 75, 87], ["the 5\u2032 sequences", "TEST", 71, 87], ["HRV serotypes", "TEST", 109, 122], ["newly identified strains", "PROBLEM", 162, 186]]]], "PMC7197564": [["In 2008, the UK government published its first National Risk Register as the initial step in providing advice on how people and employers could better prepare for civil emergencies [1].", [["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123]]], ["The relative likelihood of pandemic influenza was judged to be higher than that of flooding, roughly equal to severe weather but less likely than attacks on transport or in crowded places.", [["influenza", "DISEASE", 36, 45], ["pandemic influenza", "PROBLEM", 27, 45], ["attacks", "PROBLEM", 146, 153], ["pandemic", "OBSERVATION_MODIFIER", 27, 35], ["influenza", "OBSERVATION", 36, 45], ["less likely", "UNCERTAINTY", 129, 140]]], ["However, the relative impact of pandemic influenza was judged to be the greatest of all risks facing the UK.", [["influenza", "DISEASE", 41, 50], ["UK", "GENE_OR_GENE_PRODUCT", 105, 107], ["pandemic influenza", "PROBLEM", 32, 50]]], ["The apparent lack of preparedness for Coronavirus Disease 2019 (COVID-19) such as the lack of sufficient personal protective equipment for health and social care workers is a matter for after-action analysis during the recovery phase when the risk to life has subsided.", [["Coronavirus Disease", "DISEASE", 38, 57], ["Coronavirus Disease", "PROBLEM", 38, 57], ["COVID", "TEST", 64, 69], ["action analysis", "TEST", 192, 207]]], ["That is also when it is important to look for opportunities to \u2018build back better\u2019; a concept which refers to measures to make communities more resilient to future disasters, for example, by designing buildings to withstand earthquakes.", [["earthquakes", "DISEASE", 224, 235]]], ["This is especially the case when the most foreseeable risks include communicable disease outbreaks [4].", [["communicable disease outbreaks", "PROBLEM", 68, 98]]]], "819e7acc5ff5ebc39db48a4d4fc27806421a6232": [["SARS-CoV-2 pandemic which caused Coronavirus disease (COVID-19) appearedin the Wuhan city of China and spread to the whole world.", [["SARS-CoV-2 pandemic", "DISEASE", 0, 19], ["Coronavirus disease", "DISEASE", 33, 52], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "TEST", 0, 4], ["pandemic", "PROBLEM", 11, 19], ["Coronavirus disease", "PROBLEM", 33, 52], ["Coronavirus disease", "OBSERVATION", 33, 52]]], ["1, 2 Although COVID-19 appeared late in Turkey, it showed quick progress.", [["COVID", "TEST", 14, 19], ["quick", "OBSERVATION_MODIFIER", 58, 63]]], ["3 A large number of preventive measures were taken in Turkey including the international travel ban, transition to distance education system, social distancing, restrictions for gathering and transportation and the campaign which encouraged everyone to \"stay home\".", [["preventive measures", "TREATMENT", 20, 39], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["4 As a result of the \"stay home\" policy, there has been a decrease in the number of patient requests for visits to the dermatology outpatient clinic.", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["decrease", "OBSERVATION_MODIFIER", 58, 66]]], ["5 The hair cycle consists of three stages: anagen, catagen, and telogen.", [["hair", "ANATOMY", 6, 10]]], ["The anagen phase is the growth phase of the hair cycle.", [["hair", "ANATOMY", 44, 48], ["hair", "ORGAN", 44, 48]]], ["Approximately 85% of hairs are in the anagen phase at a time and this phase lasts between two to six years.", [["hairs", "ANATOMY", 21, 26], ["hairs", "MULTI-TISSUE_STRUCTURE", 21, 26]]], ["The Catagen phase is the transition phase which occurs when anagenic follicle receives a signal and it ends the growth phase.", [["anagenic follicle", "ANATOMY", 60, 77], ["anagenic follicle", "MULTI-TISSUE_STRUCTURE", 60, 77], ["transition phase", "OBSERVATION_MODIFIER", 25, 41]]], ["The telogen phase, which is also known as the resting phase, is the last stage of the hair cycle.", [["hair", "ANATOMY", 86, 90], ["The telogen phase", "TEST", 0, 17], ["telogen phase", "OBSERVATION_MODIFIER", 4, 17]]], ["6, 7 Telogen effluvium (TE) is a very common form of hair loss that is characterized This article is protected by copyright.", [["hair", "ANATOMY", 53, 57], ["hair loss", "DISEASE", 53, 62], ["Telogen effluvium", "SIMPLE_CHEMICAL", 5, 22], ["hair", "ORGAN", 53, 57], ["hair loss", "PROBLEM", 53, 62], ["hair loss", "OBSERVATION", 53, 62]]], ["All rights reserved. by a diffuse hair loss resulting from the hair's entering the telogen phase early.", [["hair", "ANATOMY", 34, 38], ["hair", "ANATOMY", 63, 67], ["hair loss", "DISEASE", 34, 43], ["hair", "TISSUE", 34, 38], ["hair", "ORGAN", 63, 67], ["a diffuse hair loss", "PROBLEM", 24, 43], ["diffuse", "OBSERVATION_MODIFIER", 26, 33], ["hair loss", "OBSERVATION", 34, 43]]], ["Inducing factors can be listed as systemic diseases, stressful events, drugs, nutritional deficiencies, and major surgery.", [["nutritional deficiencies", "DISEASE", 78, 102], ["systemic diseases", "PROBLEM", 34, 51], ["stressful events", "PROBLEM", 53, 69], ["drugs", "TREATMENT", 71, 76], ["nutritional deficiencies", "PROBLEM", 78, 102], ["major surgery", "TREATMENT", 108, 121], ["nutritional deficiencies", "OBSERVATION", 78, 102], ["surgery", "OBSERVATION", 114, 121]]], ["It occurs three months after the event that causes hair loss and it generally restricts itself, it lasts for about 6 months (acute TE).", [["hair", "ANATOMY", 51, 55], ["hair loss", "DISEASE", 51, 60], ["hair", "ORGAN", 51, 55], ["hair loss", "PROBLEM", 51, 60], ["hair loss", "OBSERVATION", 51, 60]]], ["There is also a chronic form of TE in which the period of hair loss exceeds 6 months.", [["hair", "ANATOMY", 58, 62], ["hair loss", "DISEASE", 58, 67], ["hair", "ORGAN", 58, 62], ["hair loss", "PROBLEM", 58, 67], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["hair loss", "OBSERVATION", 58, 67]]], ["[8] [9] [10] Alopecia areata (AA) is a chronic inflammatory disease with sudden hair loss coursing with spontaneous remission and exacerbation.", [["hair", "ANATOMY", 80, 84], ["Alopecia areata", "DISEASE", 13, 28], ["AA", "DISEASE", 30, 32], ["sudden hair loss", "DISEASE", 73, 89], ["[8] [9] [10] Alopecia areata", "SIMPLE_CHEMICAL", 0, 28], ["hair", "ORGAN", 80, 84], ["Alopecia areata (AA", "PROBLEM", 13, 32], ["a chronic inflammatory disease", "PROBLEM", 37, 67], ["sudden hair loss", "PROBLEM", 73, 89], ["spontaneous remission", "PROBLEM", 104, 125], ["exacerbation", "PROBLEM", 130, 142], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["inflammatory", "OBSERVATION", 47, 59], ["hair loss", "OBSERVATION", 80, 89], ["spontaneous remission", "OBSERVATION", 104, 125]]], ["11, 12 There is strong evidence that AA is a tissuespecific autoimmune disease that develops based on genetic predisposition.", [["AA", "CHEMICAL", 37, 39], ["autoimmune disease", "DISEASE", 60, 78], ["AA", "SIMPLE_CHEMICAL", 37, 39], ["a tissuespecific autoimmune disease", "PROBLEM", 43, 78], ["tissuespecific", "OBSERVATION_MODIFIER", 45, 59], ["autoimmune", "OBSERVATION", 60, 70]]], ["13 In several patients, acute or chronic psycho-emotional stress may be causing the initiation and/or progress of AA.", [["AA", "DISEASE", 114, 116], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["acute or chronic psycho-emotional stress", "PROBLEM", 24, 64], ["AA", "PROBLEM", 114, 116], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 33, 40]]], ["14 It is suggested that psychological stress can trigger or exacerbate inflammatory skin diseases through the neuroendocrine system which is an important connection between the brain and the skin.", [["skin", "ANATOMY", 84, 88], ["neuroendocrine system", "ANATOMY", 110, 131], ["brain", "ANATOMY", 177, 182], ["skin", "ANATOMY", 191, 195], ["skin diseases", "DISEASE", 84, 97], ["skin", "ORGAN", 84, 88], ["neuroendocrine system", "ANATOMICAL_SYSTEM", 110, 131], ["brain", "ORGAN", 177, 182], ["skin", "ORGAN", 191, 195], ["psychological stress", "PROBLEM", 24, 44], ["inflammatory skin diseases through the neuroendocrine system", "PROBLEM", 71, 131], ["neuroendocrine system", "ANATOMY", 110, 131], ["brain", "ANATOMY", 177, 182], ["skin", "ANATOMY", 191, 195]]], ["15 Seborrheic dermatitis (SD) is one of the most common skin conditions.", [["skin", "ANATOMY", 56, 60], ["Seborrheic dermatitis", "DISEASE", 3, 24], ["SD", "DISEASE", 26, 28], ["skin", "ORGAN", 56, 60], ["Seborrheic dermatitis", "PROBLEM", 3, 24], ["Seborrheic", "OBSERVATION_MODIFIER", 3, 13], ["dermatitis", "OBSERVATION", 14, 24], ["skin", "ANATOMY", 56, 60], ["conditions", "OBSERVATION", 61, 71]]], ["It is seen in skin areas rich in sebaceous glands and manifests as red, sharp-edged lesions with greasy looking scales.SARS-CoV-2 pandemic which caused Coronavirus disease (COVID-19) appearedThe scalp is almost inevitably affected.", [["skin areas", "ANATOMY", 14, 24], ["sebaceous glands", "ANATOMY", 33, 49], ["lesions", "ANATOMY", 84, 91], ["scalp", "ANATOMY", 195, 200], ["SARS", "DISEASE", 119, 123], ["Coronavirus disease", "DISEASE", 152, 171], ["skin", "ORGAN", 14, 18], ["sebaceous glands", "ORGAN", 33, 49], ["lesions", "PATHOLOGICAL_FORMATION", 84, 91], ["SARS-CoV-2", "ORGANISM", 119, 129], ["scalp", "ORGAN", 195, 200], ["red, sharp-edged lesions", "PROBLEM", 67, 91], ["greasy looking scales", "PROBLEM", 97, 118], ["SARS", "TEST", 119, 123], ["pandemic", "PROBLEM", 130, 138], ["Coronavirus disease", "PROBLEM", 152, 171], ["skin", "ANATOMY", 14, 18], ["areas", "ANATOMY_MODIFIER", 19, 24], ["sebaceous glands", "ANATOMY", 33, 49], ["red", "OBSERVATION_MODIFIER", 67, 70], ["sharp", "OBSERVATION_MODIFIER", 72, 77], ["edged", "OBSERVATION_MODIFIER", 78, 83], ["lesions", "OBSERVATION", 84, 91], ["greasy", "OBSERVATION_MODIFIER", 97, 103], ["Coronavirus disease", "OBSERVATION", 152, 171], ["scalp", "ANATOMY", 195, 200], ["almost", "OBSERVATION_MODIFIER", 204, 210], ["inevitably", "OBSERVATION_MODIFIER", 211, 221], ["affected", "OBSERVATION", 222, 230]]], ["Although the face and the chest are also commonly involved areas, the present study focuses on the seborrheic dermatitis of the scalp together with TE and AA.", [["face", "ANATOMY", 13, 17], ["chest", "ANATOMY", 26, 31], ["scalp", "ANATOMY", 128, 133], ["seborrheic dermatitis", "DISEASE", 99, 120], ["AA", "CHEMICAL", 155, 157], ["chest", "ORGAN", 26, 31], ["scalp", "ORGAN", 128, 133], ["the present study", "TEST", 66, 83], ["the seborrheic dermatitis of the scalp", "PROBLEM", 95, 133], ["face", "ANATOMY", 13, 17], ["chest", "ANATOMY", 26, 31], ["seborrheic", "OBSERVATION_MODIFIER", 99, 109], ["dermatitis", "OBSERVATION", 110, 120], ["scalp", "ANATOMY", 128, 133]]], ["On the scalp, SD presents as dry, scaly desquamation (dandruff) or erythema and yellow, greasy scaling.", [["scalp", "ANATOMY", 7, 12], ["erythema", "ANATOMY", 67, 75], ["SD", "DISEASE", 14, 16], ["desquamation", "DISEASE", 40, 52], ["dandruff", "DISEASE", 54, 62], ["erythema", "DISEASE", 67, 75], ["scalp", "ORGAN", 7, 12], ["scaly desquamation", "PROBLEM", 34, 52], ["dandruff", "PROBLEM", 54, 62], ["erythema", "PROBLEM", 67, 75], ["yellow, greasy scaling", "PROBLEM", 80, 102], ["scalp", "ANATOMY", 7, 12], ["SD", "OBSERVATION", 14, 16], ["dry", "OBSERVATION_MODIFIER", 29, 32], ["scaly", "OBSERVATION_MODIFIER", 34, 39], ["desquamation", "OBSERVATION", 40, 52], ["erythema", "OBSERVATION", 67, 75], ["yellow", "OBSERVATION_MODIFIER", 80, 86], ["greasy", "OBSERVATION_MODIFIER", 88, 94], ["scaling", "OBSERVATION_MODIFIER", 95, 102]]], ["Dandruff is a term commonly used for the mild seborrheic dermatitis of the scalp.", [["seborrheic", "ANATOMY", 46, 56], ["scalp", "ANATOMY", 75, 80], ["Dandruff", "DISEASE", 0, 8], ["seborrheic dermatitis", "DISEASE", 46, 67], ["scalp", "ORGAN", 75, 80], ["the mild seborrheic dermatitis of the scalp", "PROBLEM", 37, 80], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["seborrheic", "OBSERVATION_MODIFIER", 46, 56], ["dermatitis", "OBSERVATION", 57, 67], ["scalp", "ANATOMY", 75, 80]]], ["However, any scalp condition that produces squama can be called dandruff.", [["scalp", "ANATOMY", 13, 18], ["squama", "ANATOMY", 43, 49], ["squama", "DISEASE", 43, 49], ["any scalp condition", "PROBLEM", 9, 28], ["dandruff", "PROBLEM", 64, 72], ["scalp", "ANATOMY", 13, 18]]], ["16 Current quarantine conditions are a difficult process for most individuals and they can contribute to worsened psychological reactions (emotional exhaustion, anxiety, This article is protected by copyright.", [["anxiety", "DISEASE", 161, 168], ["worsened psychological reactions", "PROBLEM", 105, 137], ["emotional exhaustion", "PROBLEM", 139, 159], ["anxiety", "PROBLEM", 161, 168]]], ["All rights reserved.SARS-CoV-2 pandemic which caused Coronavirus disease (COVID-19) appearedagitation, increased anger).", [["SARS", "DISEASE", 20, 24], ["Coronavirus disease", "DISEASE", 53, 72], ["SARS-CoV-2", "ORGANISM", 20, 30], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["pandemic", "PROBLEM", 31, 39], ["Coronavirus disease", "PROBLEM", 53, 72], ["COVID", "TEST", 74, 79], ["Coronavirus disease", "OBSERVATION", 53, 72]]], ["17, 18 Increased psychosocial stress can have an impact on the course of many common \"stress-sensitive\" skin conditions that lead to actual or perceived exacerbation of the disease.", [["skin", "ANATOMY", 104, 108], ["skin", "ORGAN", 104, 108], ["Increased psychosocial stress", "PROBLEM", 7, 36], ["sensitive\" skin conditions", "PROBLEM", 93, 119], ["the disease", "PROBLEM", 169, 180], ["skin", "ANATOMY", 104, 108], ["disease", "OBSERVATION", 173, 180]]], ["17, 19 This is valid especially for TE, which is a disease caused by stressful events.", [["a disease", "PROBLEM", 49, 58], ["stressful events", "PROBLEM", 69, 85], ["disease", "OBSERVATION", 51, 58]]], ["20, 21 The significance of the brain-skin axis has been emphasized continually.", [["brain", "ANATOMY", 31, 36], ["skin", "ANATOMY", 37, 41], ["brain", "ORGAN", 31, 36], ["skin", "ORGAN", 37, 41], ["brain", "ANATOMY", 31, 36], ["skin axis", "ANATOMY", 37, 46]]], ["17, 21 The relationship between a stressor and any subsequent changes in the hair growth cycle has led to the determination of brain-hair follicle axis.", [["hair", "ANATOMY", 77, 81], ["brain", "ANATOMY", 127, 132], ["hair follicle", "ANATOMY", 133, 146], ["hair", "MULTI-TISSUE_STRUCTURE", 77, 81], ["brain", "ORGAN", 127, 132], ["hair follicle", "MULTI-TISSUE_STRUCTURE", 133, 146], ["a stressor", "PROBLEM", 32, 42], ["any subsequent changes in the hair growth cycle", "PROBLEM", 47, 94], ["brain", "ANATOMY", 127, 132], ["hair follicle axis", "OBSERVATION", 133, 151]]], ["In particular, the release of specific neuropeptides, neurotransmitters, and hormones along this brain-hair follicle axis can promote significant changes in the hair growth cycle by stimulating the transition of anagen hair into the telogen phase.", [["brain", "ANATOMY", 97, 102], ["hair follicle", "ANATOMY", 103, 116], ["hair", "ANATOMY", 161, 165], ["anagen hair", "ANATOMY", 212, 223], ["brain", "ORGAN", 97, 102], ["hair follicle", "MULTI-TISSUE_STRUCTURE", 103, 116], ["hair", "ORGAN", 161, 165], ["anagen hair", "MULTI-TISSUE_STRUCTURE", 212, 223], ["significant changes in the hair growth cycle", "PROBLEM", 134, 178], ["brain", "ANATOMY", 97, 102], ["significant", "OBSERVATION_MODIFIER", 134, 145]]], ["A new psychodermatology sub-field called \"Trichopsychodermatology\" emphasizes the psychosocial aspects of hair disorders.", [["hair", "ANATOMY", 106, 110], ["hair disorders", "DISEASE", 106, 120], ["hair", "MULTI-TISSUE_STRUCTURE", 106, 110], ["hair disorders", "PROBLEM", 106, 120], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["22 This study examined the possible effects of COVID-19 on hair and scalp diseases such as TE, AA, and seborrheic dermatitis (SD) in individuals who had to stay at home for a long time in Turkey and the patients' methods of dealing with these diseases.Participants and questionnaireThe design of this study is an observational cross-sectional type.", [["hair", "ANATOMY", 59, 63], ["scalp", "ANATOMY", 68, 73], ["seborrheic", "ANATOMY", 103, 113], ["COVID-19", "CHEMICAL", 47, 55], ["scalp diseases", "DISEASE", 68, 82], ["AA", "DISEASE", 95, 97], ["seborrheic dermatitis", "DISEASE", 103, 124], ["SD", "DISEASE", 126, 128], ["COVID-19", "CHEMICAL", 47, 55], ["hair", "MULTI-TISSUE_STRUCTURE", 59, 63], ["scalp", "ORGAN", 68, 73], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["Participants", "SPECIES", 252, 264], ["This study", "TEST", 3, 13], ["COVID", "TEST", 47, 52], ["hair and scalp diseases", "PROBLEM", 59, 82], ["TE, AA", "PROBLEM", 91, 97], ["seborrheic dermatitis", "PROBLEM", 103, 124], ["these diseases", "PROBLEM", 237, 251], ["this study", "TEST", 296, 306], ["scalp", "ANATOMY", 68, 73], ["diseases", "OBSERVATION", 74, 82], ["seborrheic", "OBSERVATION_MODIFIER", 103, 113], ["dermatitis", "OBSERVATION", 114, 124], ["diseases", "OBSERVATION", 243, 251]]], ["The study was carried out by using an online questionnaire.", [["The study", "TEST", 0, 9]]], ["All the individuals who participated in the study were asked questions about pre and post-pandemic TE, alopecia areata on the scalp (SAA), alopecia areata on the face (FAA), and scalp seborrheic dermatitis.", [["scalp", "ANATOMY", 126, 131], ["face", "ANATOMY", 162, 166], ["scalp", "ANATOMY", 178, 183], ["alopecia areata", "DISEASE", 103, 118], ["SAA", "DISEASE", 133, 136], ["alopecia areata", "DISEASE", 139, 154], ["seborrheic dermatitis", "DISEASE", 184, 205], ["individuals", "ORGANISM", 8, 19], ["scalp", "ORGAN", 126, 131], ["the study", "TEST", 40, 49], ["pre and post-pandemic TE", "TREATMENT", 77, 101], ["alopecia areata", "PROBLEM", 103, 118], ["alopecia areata", "PROBLEM", 139, 154], ["scalp seborrheic dermatitis", "PROBLEM", 178, 205], ["alopecia", "OBSERVATION", 103, 111], ["scalp", "ANATOMY", 126, 131], ["SAA", "ANATOMY", 133, 136], ["alopecia areata", "OBSERVATION", 139, 154], ["face", "ANATOMY", 162, 166], ["FAA", "ANATOMY", 168, 171], ["scalp", "ANATOMY", 178, 183], ["seborrheic dermatitis", "OBSERVATION", 184, 205]]], ["After they were asked whether they had these complaints, those who answered yes were asked what kind of a treatment they had.Participants and questionnaireThis article is protected by copyright.", [["Participants", "SPECIES", 125, 137], ["a treatment", "TREATMENT", 104, 115]]], ["All rights reserved.Data analysesPower analysis revealed a minimum of 527 respondents with a margin of error of 0.05, the confidence level of 98%, and the response distribution of 0.50.", [["Data analyses", "TEST", 20, 33], ["Power analysis", "TEST", 33, 47], ["the confidence level", "TEST", 118, 138], ["the response distribution", "TEST", 151, 176]]], ["In the current study, 563 participants, which was higher than the calculated minimum sample size, were enrolled to increase the reliability of the findings to be drawn from this research.Data analysesQualitative data were given as number and percentage, and quantitative data wereResultsThis article is protected by copyright.", [["participants", "ORGANISM", 26, 38], ["participants", "SPECIES", 26, 38], ["the current study", "TEST", 3, 20], ["Data analysesQualitative data", "TEST", 187, 216], ["quantitative data", "TEST", 258, 275], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["All rights reserved.ResultsOf the 563 individuals who participated in the study, 316 (56.1%) were male, while 247 (43.9%) were female.", [["individuals", "ORGANISM", 38, 49], ["the study", "TEST", 70, 79]]], ["192 (34.1%) of the participants were students, 114 (20.2%) were healthcare professional and 133 (23.6%) were officers.", [["participants", "ORGANISM", 19, 31], ["participants", "SPECIES", 19, 31]]], ["437 (77.6%) of the participants were license or Graduate-PhD (Table 1) .ResultsDuring the pandemic, TE was seen in 27.9% of the patients, SAA was seen in 2.8%, FAA was seen in 2.5%, and SD was seen on the scalp in 19.9%.", [["scalp", "ANATOMY", 205, 210], ["SAA", "DISEASE", 138, 141], ["SD", "DISEASE", 186, 188], ["participants", "ORGANISM", 19, 31], ["patients", "ORGANISM", 128, 136], ["SAA", "CANCER", 138, 141], ["scalp", "ORGAN", 205, 210], ["SAA", "PROTEIN", 138, 141], ["participants", "SPECIES", 19, 31], ["patients", "SPECIES", 128, 136], ["TE", "TEST", 100, 102], ["SAA", "TEST", 138, 141], ["FAA", "TEST", 160, 163], ["scalp", "ANATOMY", 205, 210]]], ["The presence of the same complaints in the pre-pandemic period was also asked and no significant difference was found when compared with the pandemic process (p=0.223, p=0.064, p=0.210, p=0.894, respectively) ( Table 2 ).", [["p", "TEST", 168, 169], ["p", "TEST", 177, 178], ["p", "TEST", 186, 187]]], ["In the comparison of what kind of treatment the participants received for these complaints before and during the pandemic, it was found that referring to a dermatologist during the pandemic decreased significantly in four disease groups (Table 3) .", [["participants", "SPECIES", 48, 60], ["treatment", "TREATMENT", 34, 43], ["the pandemic", "PROBLEM", 177, 189]]], ["When a comparison was made in terms of genders, it was found that TE was statistically significantly higher in female patients when compared with male patients before and during the pandemic (p<0.001, p<0.001, respectively) ( Tables 4 and 5 ).DiscussionIn this study, the incidence of hair diseases in individuals who could not go out in social environments due to the \"stay home\" policy was examined through a questionnaire and compared with the pre-pandemic period.", [["hair", "ANATOMY", 285, 289], ["hair diseases", "DISEASE", 285, 298], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 151, 159], ["hair", "ORGAN", 285, 289], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 151, 159], ["this study", "TEST", 256, 266], ["hair diseases", "PROBLEM", 285, 298], ["higher", "OBSERVATION_MODIFIER", 101, 107]]], ["As far as we could scan, we could not find a study on this during the COVID-19 pandemic.", [["a study", "TEST", 43, 50], ["the COVID", "TEST", 66, 75], ["pandemic", "PROBLEM", 79, 87]]], ["TE and SD were found to increase to some extent during the pandemic, although not statistically significant.", [["SD", "DISEASE", 7, 9], ["some extent", "OBSERVATION_MODIFIER", 36, 47]]], ["Kutlu et al. in a study they conducted in our country, they compared the frequency of AA patients in the period of May This article is protected by copyright.", [["AA", "CHEMICAL", 86, 88], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["a study", "TEST", 16, 23]]], ["2020 and May 2019 and reported that AA patient density was significantly higher in the COVID-19 pandemic period compared to a year ago.", [["AA", "CHEMICAL", 36, 38], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["density", "OBSERVATION", 47, 54], ["higher", "OBSERVATION_MODIFIER", 73, 79]]], ["With these results, they stated that stress-related autoimmune diseases may increase during the COVID-19 outbreak.", [["autoimmune diseases", "DISEASE", 52, 71], ["stress-related autoimmune diseases", "PROBLEM", 37, 71], ["the COVID", "TEST", 92, 101]]], ["23 In this study, we investigated a short two-month epidemic process; we detected the incidence of AA on the scalp and face at 2.8% and 2.5%, respectively.", [["scalp", "ANATOMY", 109, 114], ["AA", "CHEMICAL", 99, 101], ["scalp", "ORGAN", 109, 114], ["this study", "TEST", 6, 16], ["scalp", "ANATOMY", 109, 114], ["face", "ANATOMY_MODIFIER", 119, 123]]], ["The rate of AA development on the scalp and facial area in the pre-pandemic life of our participants in our study was found as 4.4% and 3.6%, respectively.", [["scalp", "ANATOMY", 34, 39], ["facial area", "ANATOMY", 44, 55], ["AA", "CHEMICAL", 12, 14], ["scalp", "ORGAN", 34, 39], ["facial area", "MULTI-TISSUE_STRUCTURE", 44, 55], ["participants", "SPECIES", 88, 100], ["our study", "TEST", 104, 113], ["AA", "OBSERVATION_MODIFIER", 12, 14], ["development", "OBSERVATION_MODIFIER", 15, 26], ["scalp", "ANATOMY", 34, 39], ["facial", "ANATOMY", 44, 50], ["area", "ANATOMY_MODIFIER", 51, 55]]], ["It is stated that 1.7-2% of individuals have AA at some point in their lives.", [["AA", "CHEMICAL", 45, 47], ["individuals", "ORGANISM", 28, 39]]], ["27 The data obtained in our study are compatible with the literature.", [["The data", "TEST", 3, 11], ["our study", "TEST", 24, 33]]], ["The fact that questions about how much of these diseases seen during the pandemic were the continuation of previous situations and how much of these were new cases is a limitation of our study.", [["these diseases", "PROBLEM", 42, 56], ["our study", "TEST", 183, 192], ["diseases", "OBSERVATION", 48, 56]]], ["Besides, another limitation of our study can be considered as the fact that the participants were not examined by a dermatologist and the results were based on the examination and diagnosis of the participants.DiscussionIn a study conducted in our country, Kutlu et al. examined the diagnoses of the patients who applied to the dermatology outpatient clinic before and during the COVID-19 pandemic.", [["participants", "ORGANISM", 80, 92], ["patients", "ORGANISM", 300, 308], ["participants", "SPECIES", 80, 92], ["participants", "SPECIES", 197, 209], ["patients", "SPECIES", 300, 308], ["our study", "TEST", 31, 40], ["the examination", "TEST", 160, 175], ["a study", "TEST", 223, 230], ["the COVID", "TEST", 376, 385], ["pandemic", "PROBLEM", 389, 397]]], ["They found a statistically significant negative correlation between the number of deaths due to COVID-19 in the country and the number of patients who visited the dermatology polyclinic in secondary and tertiary hospitals.", [["deaths", "DISEASE", 82, 88], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["COVID", "TEST", 96, 101], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["negative", "OBSERVATION", 39, 47]]], ["5 In our study, the individuals' states of applying to dermatology or looking for another treatment were examined.", [["our study", "TEST", 5, 14], ["another treatment", "TREATMENT", 82, 99]]], ["It was found that the rates of applying to a dermatologist for these four disease groups before the pandemic were found to vary between 15 and 28%, while these rates were between 2.5 and 12.5% during the This article is protected by copyright.", [["these four disease groups", "PROBLEM", 63, 88], ["these rates", "TEST", 154, 165]]], ["Similar to the results of Kutlu et al.'s study, it was found that almost 80% of the participants did not look for any treatment during the pandemic.", [["participants", "SPECIES", 84, 96], ["Kutlu et al.'s study", "TEST", 26, 46], ["any treatment", "TREATMENT", 114, 127], ["the pandemic", "PROBLEM", 135, 147]]], ["Considering the positive developments in the health system of our country in recent years and the fact that a great majority of the society got the opportunity to be treated for free with general health insurance, we think that the rate of referring to a dermatologist was very low especially during the pandemic.", [["positive", "OBSERVATION_MODIFIER", 16, 24]]], ["Considering these low rates, we think that the \"teledermatology\" method, which came up recently, can be used in the assessment and follow-up of patients at least in special situations such as a pandemic.DiscussionIn their study Rivetti and Barruscotti conducted face-to-face interviews with TE patients by using video consultation method during real-time COVID-19 pandemic, they confirmed that teledermatology method was useful.", [["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 294, 302], ["the assessment", "TEST", 112, 126], ["a pandemic", "PROBLEM", 192, 202], ["video consultation method", "TEST", 312, 337], ["teledermatology method", "TEST", 394, 416], ["low rates", "OBSERVATION_MODIFIER", 18, 27]]], ["8 In conclusion, the data obtained in our study showed that there were a large number of especially TE patients during the short pandemic process and that a great majority of these patients did not receive treatment to avoid the risk of COVID-19.", [["COVID-19", "CHEMICAL", 237, 245], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 181, 189], ["the data", "TEST", 17, 25], ["our study", "TEST", 38, 47], ["the short pandemic process", "PROBLEM", 119, 145], ["treatment", "TREATMENT", 206, 215], ["COVID", "TEST", 237, 242], ["large", "OBSERVATION_MODIFIER", 73, 78], ["number", "OBSERVATION_MODIFIER", 79, 85], ["great", "OBSERVATION_MODIFIER", 157, 162]]], ["Considering that TE increases three months after stressful situations, we think that the number of patients will increase gradually in the future and that the teledermatology method will become more important.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["the teledermatology method", "TREATMENT", 155, 181]]]], "PMC7482471": [["Armed conflict and child healthThe devastating impact of armed conflict on child health is well recognised.1\u20134 It is estimated that one in nine children worldwide lives in an area of armed conflict.2 Children may experience physical injury or death directly from trauma but also may experience problems with malnutrition or sepsis as a secondary effect of armed conflict.", [["1\u20134", "CHEMICAL", 107, 110], ["physical injury", "DISEASE", 224, 239], ["death", "DISEASE", 243, 248], ["trauma", "DISEASE", 263, 269], ["malnutrition", "DISEASE", 308, 320], ["sepsis", "DISEASE", 324, 330], ["children", "ORGANISM", 144, 152], ["Children", "ORGANISM", 200, 208], ["children", "SPECIES", 144, 152], ["Children", "SPECIES", 200, 208], ["physical injury", "PROBLEM", 224, 239], ["death", "PROBLEM", 243, 248], ["trauma", "PROBLEM", 263, 269], ["malnutrition", "PROBLEM", 308, 320], ["sepsis", "PROBLEM", 324, 330], ["armed conflict", "PROBLEM", 356, 370], ["conflict", "OBSERVATION", 6, 14], ["devastating", "OBSERVATION_MODIFIER", 35, 46], ["impact", "OBSERVATION_MODIFIER", 47, 53], ["armed conflict", "OBSERVATION", 57, 71], ["one", "OBSERVATION_MODIFIER", 132, 135], ["injury", "OBSERVATION", 233, 239], ["sepsis", "OBSERVATION", 324, 330]]], ["A wide array of mental health trauma is also associated with conflict.", [["trauma", "DISEASE", 30, 36], ["mental health trauma", "PROBLEM", 16, 36], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Some of the devastating impacts are illustrated in table 1.5\u201316 The table is not a comprehensive review of the effects of armed conflict, as recent systematic reviews have documented this.1 4 It simply illustrates the devastating effect of armed conflict on child health.Armed conflict and child healthEven after the armed conflict has ceased in a given area, children may experience significant health problems.", [["children", "ORGANISM", 360, 368], ["children", "SPECIES", 360, 368], ["significant health problems", "PROBLEM", 384, 411], ["devastating", "OBSERVATION_MODIFIER", 12, 23], ["impacts", "OBSERVATION_MODIFIER", 24, 31], ["devastating", "OBSERVATION_MODIFIER", 218, 229], ["conflict", "OBSERVATION", 277, 285]]], ["These may be associated with a loss of health and educational facilities or shortages of food and/or water.12\u201316Armed conflict and child healthThe global trade in weapons exacerbates this situation.", [["global", "OBSERVATION_MODIFIER", 147, 153], ["trade", "OBSERVATION_MODIFIER", 154, 159]]], ["Landmines and cluster munitions are a particular problem in certain regions, causing untold immediate and long-term suffering.6 An additional problem is the widespread availability of firearms of a variety of types.17 The aim of this narrative review is to explore the effects of the arms trade on child health.", [["Landmines and cluster munitions", "TREATMENT", 0, 31], ["widespread", "OBSERVATION_MODIFIER", 157, 167], ["variety", "OBSERVATION_MODIFIER", 198, 205]]], ["It is not a systematic review, but rather a narrative review of the arms trade.Military expenditure and child healthThe sums spent on military expenditure are colossal and are beyond the comprehension of most people.", [["people", "ORGANISM", 209, 215], ["people", "SPECIES", 209, 215], ["a systematic review", "TEST", 10, 29], ["arms", "ANATOMY", 68, 72], ["colossal", "OBSERVATION", 159, 167]]], ["In 2019, world military expenditure was estimated to have been US$1917 billion by the Stockholm International Peace Research Institute.18 That is $250 for every person on the planet.Military expenditure and child healthThe USA accounted for more than one third of global military expenditure (US$732 billion).", [["person", "SPECIES", 161, 167], ["The USA", "TEST", 219, 226]]], ["The USA does not have universal healthcare for children or pregnant women.", [["children", "ORGANISM", 47, 55], ["women", "ORGANISM", 68, 73], ["children", "SPECIES", 47, 55], ["women", "SPECIES", 68, 73]]], ["It also has higher child mortality rates than neighbouring Canada and Cuba.19Military expenditure and child healthChina, Saudi Arabia, India and France were the other largest contributors to military spending.", [["higher", "OBSERVATION_MODIFIER", 12, 18]]], ["In Saudi Arabia, military expenditure reached 8.0% of Gross Domestic Product (GDP) in 2019.20 India spent US$71.1 billion and was the third highest spender on the military in 2019.20 India increased its military expenditure by 6.8% in 2019.20 India spends more on the military than on health (US$21.2 billion) despite having a high child mortality rate alongside high levels of child malnutrition.", [["GDP", "CHEMICAL", 78, 81], ["malnutrition", "DISEASE", 384, 396], ["military expenditure", "TEST", 17, 37], ["a high child mortality rate", "PROBLEM", 325, 352], ["child malnutrition", "PROBLEM", 378, 396], ["malnutrition", "OBSERVATION", 384, 396]]], ["Data from UNICEF for 2018 show that the under 5 child mortality rate for India was 37.19 This is higher than neighbouring Bangladesh (30) and Nepal (32), both of which are considerably poorer than India.19 Over a third of children under the age of 5 years in India have malnutrition.19Military expenditure and child healthThe sustainable development goals (SDGs) have been agreed as important by the international community.", [["malnutrition", "DISEASE", 270, 282], ["children", "ORGANISM", 222, 230], ["children", "SPECIES", 222, 230], ["malnutrition", "PROBLEM", 270, 282], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["considerably", "OBSERVATION_MODIFIER", 172, 184], ["poorer", "OBSERVATION_MODIFIER", 185, 191], ["malnutrition", "OBSERVATION", 270, 282]]], ["The cost of SDG 3 which relates to health and well-being and SDG 6 which relates to clean water and sanitation are, however, significantly less than the military spending of one country alone\u2014the USA! (table 2).21 22Political priorities\u2014child health or military expenditure?Most people, and parents in particular, would prioritise spending on healthcare rather than spending on weapons, whether it be weapons of mass destruction such as nuclear weapons or conventional weapons.", [["nuclear", "ANATOMY", 437, 444], ["SDG 3", "CHEMICAL", 12, 17], ["people", "ORGANISM", 279, 285], ["people", "SPECIES", 279, 285], ["mass destruction", "PROBLEM", 412, 428], ["mass", "OBSERVATION", 412, 416]]], ["The arms trade, both nuclear and conventional, detrimentally impacts child health in three primary inter-related ways: the diversion of resources towards military spending and away from child health spending both directly and indirectly (on poverty alleviation, nutrition, shelter, education and so on); the resources wasted by the pervasive corruption in the arms trade, as well as the corroding of the rule of law and democracy that follows; and the life-threatening and humanitarian crises engendered by conflict.", [["arms", "ANATOMY_MODIFIER", 4, 8]]], ["It has been estimated that the cost of funding the SDGs is $195 per person, which is less than that of the annual military expenditure of $250 per person.23 The importance of prioritising child health has been emphasised by both WHO and UNICEF.23Political priorities\u2014child health or military expenditure?The costs of nuclear weapons are astronomical.", [["nuclear", "ANATOMY", 317, 324], ["nuclear", "CELLULAR_COMPONENT", 317, 324], ["person", "SPECIES", 68, 74], ["person", "SPECIES", 147, 153], ["nuclear", "OBSERVATION_MODIFIER", 317, 324], ["weapons", "OBSERVATION", 325, 332]]], ["Britain is in the process of upgrading its nuclear arsenal at a cost of over \u00a3200 billion, but was unable to provide basic protective equipment to frontline health staff for the first 2 months of the COVID-19 pandemic.", [["nuclear", "ANATOMY", 43, 50], ["the COVID", "TEST", 196, 205], ["pandemic", "PROBLEM", 209, 217]]], ["Nuclear weapons cannot be used without causing indiscriminate loss of civilian life which is recognised to be against Geneva Conventions and therefore to constitute a war crime.", [["weapons", "OBSERVATION", 8, 15]]], ["The increase in nuclear weapons by India and Pakistan is of major concern.24 A nuclear attack by either country could result in the death of millions of people, and also changes to the atmosphere, crop failures and a worldwide famine.24 The United Nations passed the treaty on the prohibition of nuclear weapons in July 2017.25 Unfortunately, the nuclear powers and the North Atlantic Treaty Organisation (NATO) have all resisted the implementation of the treaty.", [["nuclear", "ANATOMY", 16, 23], ["nuclear", "ANATOMY", 79, 86], ["death", "DISEASE", 132, 137], ["nuclear", "CELLULAR_COMPONENT", 16, 23], ["nuclear", "CELLULAR_COMPONENT", 79, 86], ["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["A nuclear attack", "PROBLEM", 77, 93], ["crop failures", "PROBLEM", 197, 210], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["nuclear weapons", "OBSERVATION", 16, 31], ["crop failures", "OBSERVATION", 197, 210]]], ["Biological and chemical weapons have previously been outlawed and it will hopefully only be a matter of time before nuclear weapons are outlawed too.Why do we buy and sell so many weapons to kill?", [["nuclear", "ANATOMY", 116, 123]]], ["Arms trade and corruptionThe profits involved in selling arms are huge and as a consequence, the trade in weapons is thought to account for 40% of all corruption in global trade.26 The defence companies, the state in its broadest form, assorted, often dubious intermediaries and, crucially, individual politicians and political parties, negotiate multi-billion dollar arms deals, conducted behind a veil of national security imposed secrecy.27 28 Such a system encourages corruption.Why do we buy and sell so many weapons to kill?", [["corruption", "OBSERVATION", 15, 25], ["huge", "OBSERVATION", 66, 70], ["global trade", "OBSERVATION", 165, 177]]], ["Arms trade and corruptionThis system was explicitly revealed in the world\u2019s most corrupt commercial transaction, an arms deal between Britain and Saudi Arabia known as the Al Yamamah deal.29 It is alleged that \u00a36 billion of commissions (bribes) were paid to members of the Saudi royal family, and individuals in the UK through a number of intermediaries.29Why do we buy and sell so many weapons to kill?", [["corruption", "OBSERVATION", 15, 25]]], ["Arms trade and corruptionThe close and opaque relationships between the weapons makers, governments, political parties and individual politicians means that the trade operates with inadequate legal scrutiny.", [["corruption", "OBSERVATION", 15, 25]]], ["The Serious Fraud Office abruptly discontinued its inquiry in December 2006 citing the need to safeguard national and international security.30 The prime minister at the time, Tony Blair supported this decision.", [["Serious", "OBSERVATION_MODIFIER", 4, 11]]], ["In 2010, BAE Systems, the arms company involved in the Al Yamamah deal pleaded guilty in the USA of conspiring to making false statements in relation to the Al Yamamah agreement and contracts with the Hungarian and Czech governments.30 BAE was given a US$400 million fine by the US Department of Justice.30 In 2011, BAE agreed to pay the US State Department up to US$79 million for violating military export rules.31Why do we buy and sell so many weapons to kill?", [["arms", "ANATOMY", 26, 30]]], ["This requires them to overstate the national security threats faced by their countries, which has the consequence of de-emphasising a number of very real, non-military threats, including health pandemics, climate change, poverty and inequality.", [["pandemics", "DISEASE", 194, 203]]], ["Multi-billion dollar deals for inappropriate or unnecessary equipment are common place in the global arms trade.", [["Multi-billion dollar deals", "TREATMENT", 0, 26], ["unnecessary equipment", "TREATMENT", 48, 69]]], ["This is exemplified by the F-35 jet (estimated cost $80 million per plane!), which has had numerous technical problems, despite the arms manufacturer Lockheed Martin receiving a $6 billion advance payment.32 33Why do we buy and sell so many weapons to kill?", [["numerous technical problems", "PROBLEM", 91, 118], ["a $6 billion advance payment", "TREATMENT", 176, 204]]], ["Arms trade and corruptionThe detrimental socioeconomic and health sequelae of the arms trade are starkly illustrated by an arms deal undertaken by the newly democratic government of South Africa in the late 1990s.", [["The detrimental socioeconomic and health sequelae of the arms trade", "PROBLEM", 25, 92], ["corruption", "OBSERVATION", 15, 25], ["detrimental", "OBSERVATION_MODIFIER", 29, 40], ["socioeconomic", "OBSERVATION_MODIFIER", 41, 54], ["arms", "ANATOMY", 82, 86]]], ["A mere 4 years after the end of apartheid, the government spent $5 billion on weapons on new fighter jets, helicopters, submarines and warships that it did not need.34 To date, two politicians/business men have been found guilty of accepting bribes and ex-president Zuma has been charged with corruption.34 35 For the cost of the weapons, the government could have provided anti-retroviral medication to the six million South Africans living with HIV or AIDS.YemenThe conflict in Yemen is arguably the most horrific manifestation of the human consequences of the trade in weapons.", [["Zuma", "CHEMICAL", 266, 270], ["HIV or AIDS", "DISEASE", 447, 458], ["men", "ORGANISM", 202, 205], ["Africans", "ORGANISM", 426, 434], ["human", "ORGANISM", 537, 542], ["men", "SPECIES", 202, 205], ["HIV", "SPECIES", 447, 450], ["human", "SPECIES", 537, 542], ["HIV", "SPECIES", 447, 450], ["human", "SPECIES", 537, 542], ["anti-retroviral medication", "TREATMENT", 374, 400], ["AIDS", "PROBLEM", 454, 458]]], ["The United Nations verified 11 799 grave violations against children in Yemen between April 2013 and December 2018.36 The report highlights the brutal violence suffered by children.", [["violence", "DISEASE", 151, 159], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 172, 180]]], ["Almost half the violations occurred during air strikes.", [["violations", "OBSERVATION", 16, 26], ["air strikes", "OBSERVATION", 43, 54]]], ["UNICEF describes Yemen as the largest humanitarian crisis in the world, suggesting that more than 24 million people, including more than 12 million children, are in need of humanitarian assistance.37YemenDespite the catastrophic human situation, the UK is thought to have sold over \u00a35 billion of weapons to Saudi Arabia since 2015.38 Arms sales to Saudi Arabia were declared illegal by the court of appeal in June 2019.36 The court felt that government ministers had illegally signed off on arms exports without properly assessing the risk to civilians.39 Despite the judgement by the court of appeal, sales to Saudi Arabia appear to have continued.40 In mid-July 2020, the British government announced the full resumption of arms sales to Saudi Arabia, claiming that it has addressed the concerns of the court.Small armsIt is estimated that there are more than one billion firearms worldwide which are responsible for over half a million deaths a year.5 The vast majority of these are owned by civilians.5 In the USA, firearm-related deaths are greater than those due to road traffic collisions.41 Following armed conflict, small firearms usually remain with communities.", [["37YemenDespite", "CHEMICAL", 197, 211], ["deaths", "DISEASE", 939, 945], ["deaths", "DISEASE", 1035, 1041], ["people", "ORGANISM", 109, 115], ["children", "ORGANISM", 148, 156], ["human", "ORGANISM", 229, 234], ["UK", "GENE_OR_GENE_PRODUCT", 250, 252], ["people", "SPECIES", 109, 115], ["children", "SPECIES", 148, 156], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 229, 234], ["humanitarian assistance", "TREATMENT", 173, 196], ["Small arms", "PROBLEM", 811, 821], ["firearm-related deaths", "PROBLEM", 1019, 1041], ["catastrophic", "OBSERVATION_MODIFIER", 216, 228], ["arms", "ANATOMY", 817, 821], ["more", "OBSERVATION_MODIFIER", 852, 856], ["greater", "OBSERVATION_MODIFIER", 1046, 1053], ["traffic collisions", "OBSERVATION", 1077, 1095], ["small", "OBSERVATION_MODIFIER", 1125, 1130], ["firearms", "OBSERVATION", 1131, 1139]]], ["Their widespread availability, especially in regions affected by conflict, means it is easy for informal militias and criminal gangs to obtain small firearms.", [["widespread", "OBSERVATION_MODIFIER", 6, 16]]], ["This increases their adverse effect on communities trying to recover from violent conflicts.", [["adverse", "OBSERVATION_MODIFIER", 21, 28], ["effect", "OBSERVATION_MODIFIER", 29, 35]]], ["The longevity of weapons is illustrated by the Mannlicher M-95, a rifle produced for the Austro-Hungarian Army in World War I. It is thought to have been used in conflicts in Africa 50 years later!42 Despite the huge number of guns in circulation, arms manufacturers are keen to maximise profits by continuing to promote sales.", [["longevity", "OBSERVATION_MODIFIER", 4, 13], ["huge", "OBSERVATION_MODIFIER", 212, 216], ["number", "OBSERVATION_MODIFIER", 217, 223], ["circulation", "ANATOMY", 235, 246]]], ["It is estimated that over half a million military small arms are produced each year.5Small armsPoliticians in the USA have largely supported the country\u2019s inexplicably lax gun controls, despite continuous, tragic gun-related killings in the country.", [["Small armsPoliticians in the USA", "PROBLEM", 85, 117], ["small", "OBSERVATION_MODIFIER", 50, 55], ["arms", "ANATOMY", 56, 60], ["armsPoliticians", "OBSERVATION", 91, 106]]], ["Weak, often non-existent, arms export controls result in small and light weapons being available wherever there is conflict in the world.", [["small", "OBSERVATION_MODIFIER", 57, 62]]], ["However, it has been documented that the number of people involved in producing weapons is less than 0.7% of the total UK workforce.45 Many if not all the engineers involved in producing weapons could be re-employed in the renewable energy industry, which would also help to combat the climate emergency.46Priorities and political willThe secretive trade in weapons is under-regulated, corrupt and operates largely above the law.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57]]], ["This has created a reality in which our political leaders favour conflict over diplomacy, and profits over people.", [["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113]]], ["National security threats are blown out of all proportion, while climate change, health risks and other very real threats to human security are deemed secondary and consequently underfunded.", [["human", "ORGANISM", 125, 130], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130]]], ["The impact on child health is devastating.Priorities and political willIndividuals cannot compete against the lobbying of the major arms manufacturers or NATO which calls for military expenditure of 2% GDP for each member state.47 It is therefore essential that professional organisations of health professionals raise the issue of the need to reduce military expenditure and the production of weapons, whether it be firearms, cluster bombs, land mines or nuclear weapons (box 1).", [["nuclear", "ANATOMY", 456, 463], ["GDP", "CHEMICAL", 202, 205], ["GDP", "CHEMICAL", 202, 205], ["GDP", "SIMPLE_CHEMICAL", 202, 205], ["devastating", "OBSERVATION_MODIFIER", 30, 41]]], ["Physicians in the USA, where there is an epidemic of firearm-related injuries, have raised the importance of recognising firearm injury as a public health issue.", [["injuries", "DISEASE", 69, 77], ["firearm injury", "DISEASE", 121, 135]]], ["The WHO has reported on the need to both reduce violence and to reduce the global arms trade.48Priorities and political willThe United Nations has shown the way forward with its treaty on the prohibition of nuclear weapons.Priorities and political willAdditionally, the call for a global ceasefire by the UN secretary general is to be both welcomed and supported.49 Organisations such as Medact and the International Society for Social Paediatrics and Child Health have demonstrated that health professionals can play a key role in promoting both peace and social justice.4 50 51 We suggest that professional organisations of health professionals working with children call for the recognition that the arms trade is detrimental to child health and support actions to reduce arms sales (box 1).", [["nuclear", "ANATOMY", 207, 214], ["children", "ORGANISM", 660, 668], ["children", "SPECIES", 660, 668]]]], "PMC7405490": [["We provide care in the nation's second\u2010largest children's hospital, with \u224840,000 dental encounters per year.", [["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55]]], ["The pandemic drastically affected the way we provided care to our patients.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["Recommendations and mandates from federal, state, organized dentistry, and hospital entities made us reconsider how to provide urgent dental treatment while keeping our workforce healthy during unprecedented times.PROBLEMCommunity mitigation measures have been proposed to slow the spread of disease such as a novel influenza virus,1delay the pandemic peak until pharmaceutical interventions, such as vaccines, are available, and to reduce stress on health care systems.2However, social distancing techniques, such as working from home and spacing of 6 feet, are not applicable for clinical dentistry.", [["influenza virus", "DISEASE", 316, 331], ["influenza virus", "SPECIES", 316, 331], ["urgent dental treatment", "TREATMENT", 127, 150], ["PROBLEMCommunity mitigation measures", "TREATMENT", 214, 250], ["disease", "PROBLEM", 292, 299], ["a novel influenza virus", "PROBLEM", 308, 331], ["pharmaceutical interventions", "TREATMENT", 363, 391], ["vaccines", "TREATMENT", 401, 409], ["disease", "OBSERVATION", 292, 299]]], ["Under normal operations, this entails trainees and faculty interacting and comingling daily, along with staff and members in other departments.", [["normal operations", "OBSERVATION", 6, 23]]], ["Pandemic guidance for healthcare settings has primarily focused on provider and patient screening and engineering controls, such as personal protective equipment.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["patient screening", "TEST", 80, 97], ["personal protective equipment", "TREATMENT", 132, 161]]], ["These precautions do not prevent community spread of virus from being transmitted in the workplace, threatening an entire department of exposure and quarantine.SOLUTIONAs our usual method of providing patient care could have potentially spread severe acute respiratory coronavirus\u20102 (SARS\u2010CoV\u20102) quickly throughout our entire department if 1 member were to become infected, we divided our faculty and trainees into discrete teams, with weekly rotations to cover hospital emergency clinic, sedation and inpatient care clinic, general anesthesia, and teledentistry.", [["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["These precautions", "TREATMENT", 0, 17], ["virus", "PROBLEM", 53, 58], ["spread severe acute respiratory coronavirus\u20102", "PROBLEM", 237, 282], ["sedation", "TREATMENT", 489, 497], ["general anesthesia", "TREATMENT", 525, 543], ["virus", "OBSERVATION", 53, 58]]], ["These teams, consisting of a faculty leader and either 2 or 3 trainees, occupied separate physical spaces while providing treatment, maintaining as much physical distance as possible.", [["treatment", "TREATMENT", 122, 131]]], ["Subsequently, any member who contracted SARS\u2010CoV\u20102 would be unable to infect anyone beyond his/her team.", [["SARS", "DISEASE", 40, 44], ["CoV", "ORGANISM", 45, 48], ["SARS\u2010CoV", "SPECIES", 40, 48]]], ["Additionally, as some teams worked on administrative and didactic tasks when not assigned to clinical venues, we were able to substitute these teams in the place of any team that fell ill.", [["didactic tasks", "TREATMENT", 57, 71]]], ["Our agility allowed us to maintain our commitments to patients while allowing for the possibility of quarantine and recovery time.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["We continuously re\u2010evaluated the need and structure for our teams as patient care restrictions were eased, patient volume increased, and our clinical care gradually resumed to what became a new normal.RESULTSAfter we had formed teams, subsequent publications recommended separation of healthcare workers.", [["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 107, 114], ["new", "OBSERVATION_MODIFIER", 190, 193], ["normal", "OBSERVATION", 194, 200]]], ["Most of these broad recommendations involved segregating teams caring for coronavirus disease 2019 (COVID\u201019) patients from other workers.3Others advocated for small teams to reduce the impact on personnel if quarantine were needed4and to separate individuals with overlapping skill sets.5Our mitigation plans concurred with this guidance.", [["coronavirus disease", "DISEASE", 74, 93], ["coronavirus", "ORGANISM", 74, 85], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["coronavirus disease", "PROBLEM", 74, 93]]], ["We kept our department safe, healthy, and agile with a team approach.", [["a team approach", "TREATMENT", 53, 68]]], ["To date, we have had no infections among faculty or trainees.", [["infections", "DISEASE", 24, 34], ["infections", "PROBLEM", 24, 34]]]], "PMC7405862": [["IntroductionA novel coronavirus infection in severe acute respiratory syndrome (SARS), named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) (World Health Organization, 2020a), has been spreading rapidly to the whole of China and other countries since the end of 2019.", [["coronavirus infection", "DISEASE", 20, 41], ["acute respiratory syndrome", "DISEASE", 52, 78], ["SARS", "DISEASE", 80, 84], ["coronavirus disease", "DISEASE", 93, 112], ["coronavirus", "ORGANISM", 20, 31], ["coronavirus", "SPECIES", 20, 31], ["IntroductionA novel coronavirus infection", "PROBLEM", 0, 41], ["severe acute respiratory syndrome", "PROBLEM", 45, 78], ["SARS", "PROBLEM", 80, 84], ["named coronavirus disease", "PROBLEM", 87, 112], ["coronavirus infection", "OBSERVATION", 20, 41], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["coronavirus disease", "OBSERVATION", 93, 112]]], ["Data from the WHO show that there are more than 83000 confirmed cases in 49 countries/regions, and 78959 confirmed cases, including 2791 deaths by February 28, 2020 in China (World Health Organization, 2020b).", [["deaths", "DISEASE", 137, 143]]], ["The total number of COVID-19 cases worldwide has already far outnumbered that of SARS in 2003, clearly showing the present epidemic is a major global threat to public health (Roosa et al., 2020).IntroductionThe source of infection and intermediate host of COVID-19 are not yet identified.", [["SARS", "DISEASE", 81, 85], ["infection", "DISEASE", 221, 230], ["COVID-19", "GENE_OR_GENE_PRODUCT", 256, 264], ["COVID-19", "DNA", 256, 264], ["COVID", "TREATMENT", 20, 25], ["SARS", "PROBLEM", 81, 85], ["infection", "PROBLEM", 221, 230], ["COVID", "TEST", 256, 261], ["total", "OBSERVATION_MODIFIER", 4, 9], ["epidemic", "OBSERVATION", 123, 131], ["infection", "OBSERVATION", 221, 230]]], ["Studies found that severe acute respiratory coronavirus-2 (SARS-CoV-2) is 96% identical at the whole-genome level to the Chinese horseshoe bat coronavirus, thus, they conjectured that the Chinese horseshoe bat might be the natural host of the novel coronavirus (Zhou et al., 2020).", [["acute respiratory coronavirus-2", "ORGANISM", 26, 57], ["SARS-CoV-2", "ORGANISM", 59, 69], ["horseshoe bat coronavirus", "ORGANISM", 129, 154], ["horseshoe bat", "ORGANISM", 196, 209], ["coronavirus", "ORGANISM", 249, 260], ["respiratory coronavirus", "SPECIES", 32, 55], ["horseshoe bat coronavirus", "SPECIES", 129, 154], ["SARS-CoV-2", "SPECIES", 59, 69], ["Chinese horseshoe bat coronavirus", "SPECIES", 121, 154], ["Chinese horseshoe bat", "SPECIES", 188, 209], ["Studies", "TEST", 0, 7], ["severe acute respiratory coronavirus", "PROBLEM", 19, 55], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["the Chinese horseshoe bat coronavirus", "PROBLEM", 117, 154], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["respiratory coronavirus", "OBSERVATION", 32, 55], ["Chinese horseshoe bat", "ANATOMY", 121, 142], ["coronavirus", "OBSERVATION", 143, 154]]], ["Pangolins (Li et al., 2020c), snakes (Ji et al., 2020), mink (Guo et al., 2020) and turtles (C. picta bellii, C. mydas, and P. sinensis) (Liu et al., 2020) are all potentially considered as intermediate hosts.IntroductionSARS-CoV-2 infects lung alveolar epithelial cells by binding the spike protein (S) to angiotensin-converting enzyme-2 (ACE2) (Huang et al., 2020; Li et al., 2003; Li et al., 2019; Zhou et al., 2020), reducing the level of ACE2 and the production of active peptide angiotensin-(1-7) [Ang-(1-7)] in the lung and the whole body to induce lung injury and multiple organ damage, which are attributed to the possible pathological mechanisms such as inflammation, oxidative stress and apoptosis.", [["lung alveolar epithelial cells", "ANATOMY", 240, 270], ["lung", "ANATOMY", 522, 526], ["body", "ANATOMY", 541, 545], ["lung", "ANATOMY", 556, 560], ["organ", "ANATOMY", 581, 586], ["Pangolins", "CHEMICAL", 0, 9], ["Li", "CHEMICAL", 11, 13], ["angiotensin", "CHEMICAL", 307, 318], ["angiotensin-(1-7)", "CHEMICAL", 485, 502], ["Ang-(1-7)", "CHEMICAL", 504, 513], ["lung injury", "DISEASE", 556, 567], ["organ damage", "DISEASE", 581, 593], ["inflammation", "DISEASE", 664, 676], ["Pangolins", "CHEMICAL", 0, 9], ["Pangolins", "SIMPLE_CHEMICAL", 0, 9], ["turtles", "ORGANISM", 84, 91], ["C. picta bellii", "ORGANISM", 93, 108], ["C. mydas", "ORGANISM", 110, 118], ["P. sinensis", "ORGANISM", 124, 135], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 209, 231], ["lung alveolar epithelial cells", "CELL", 240, 270], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 307, 338], ["ACE2", "GENE_OR_GENE_PRODUCT", 340, 344], ["ACE2", "GENE_OR_GENE_PRODUCT", 443, 447], ["angiotensin-(1-7", "GENE_OR_GENE_PRODUCT", 485, 501], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 504, 512], ["lung", "ORGAN", 522, 526], ["body", "ORGANISM_SUBDIVISION", 541, 545], ["lung", "ORGAN", 556, 560], ["organ", "ORGAN", 581, 586], ["lung alveolar epithelial cells", "CELL_TYPE", 240, 270], ["spike protein (S)", "PROTEIN", 286, 303], ["angiotensin-converting enzyme-2", "PROTEIN", 307, 338], ["ACE2", "PROTEIN", 340, 344], ["ACE2", "PROTEIN", 443, 447], ["mink", "SPECIES", 56, 60], ["C. picta bellii", "SPECIES", 93, 108], ["C. mydas", "SPECIES", 110, 118], ["P. sinensis", "SPECIES", 124, 135], ["C. picta bellii", "SPECIES", 93, 108], ["C. mydas", "SPECIES", 110, 118], ["P. sinensis", "SPECIES", 124, 135], ["IntroductionSARS", "TEST", 209, 225], ["CoV", "TEST", 226, 229], ["lung alveolar epithelial cells", "PROBLEM", 240, 270], ["the spike protein", "TEST", 282, 299], ["angiotensin", "TEST", 307, 318], ["ACE2", "TEST", 443, 447], ["active peptide angiotensin", "PROBLEM", 470, 496], ["Ang", "TEST", 504, 507], ["lung injury", "PROBLEM", 556, 567], ["multiple organ damage", "PROBLEM", 572, 593], ["pathological mechanisms", "PROBLEM", 632, 655], ["inflammation", "PROBLEM", 664, 676], ["oxidative stress", "PROBLEM", 678, 694], ["apoptosis", "PROBLEM", 699, 708], ["lung", "ANATOMY", 240, 244], ["alveolar", "ANATOMY_MODIFIER", 245, 253], ["epithelial cells", "OBSERVATION", 254, 270], ["lung", "ANATOMY", 522, 526], ["lung", "ANATOMY", 556, 560], ["injury", "OBSERVATION", 561, 567], ["multiple", "OBSERVATION_MODIFIER", 572, 580], ["organ", "ANATOMY", 581, 586], ["damage", "OBSERVATION", 587, 593], ["inflammation", "OBSERVATION", 664, 676], ["oxidative stress", "OBSERVATION", 678, 694], ["apoptosis", "OBSERVATION_MODIFIER", 699, 708]]], ["Since there are not yet any vaccines or drugs approved to fight against SARS-CoV-2, the Chinese government has decided to apply complementary and alternative medicine to treat COVID-19 by using TCM, which functions effectively in organ protection via anti-inflammation, antioxidant and anti-apoptotic actions (Li et al., 2018; Liu et al., 2018a; Yang et al., 2019a).", [["organ", "ANATOMY", 230, 235], ["SARS", "DISEASE", 72, 76], ["COVID-19", "CHEMICAL", 176, 184], ["COVID-19", "CHEMICAL", 176, 184], ["SARS-CoV-2", "ORGANISM", 72, 82], ["organ", "ORGAN", 230, 235], ["SARS-CoV", "SPECIES", 72, 80], ["any vaccines", "TREATMENT", 24, 36], ["drugs", "TREATMENT", 40, 45], ["alternative medicine", "TREATMENT", 146, 166], ["COVID", "TREATMENT", 176, 181], ["anti-inflammation", "TREATMENT", 251, 268], ["antioxidant", "TREATMENT", 270, 281], ["anti-apoptotic actions", "TREATMENT", 286, 308]]], ["Preliminary clinical studies showed the beneficial effects of TCM decoction on COVID-19 (Ling, 2020) as indicated by the shortening of hospitalization duration and the reduction in the number of mild and moderate cases developed into severe ones (Luo et al., 2020).IntroductionA study has shown that serious complications are more likely to occur in COVID-19 patients who simultaneously suffer from other chronic diseases (Cao et al., 2020).", [["TCM decoction", "CHEMICAL", 62, 75], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 359, 367], ["Preliminary clinical studies", "TEST", 0, 28], ["TCM decoction", "TREATMENT", 62, 75], ["COVID", "TEST", 79, 84], ["mild and moderate cases", "PROBLEM", 195, 218], ["IntroductionA study", "TEST", 265, 284], ["serious complications", "PROBLEM", 300, 321], ["other chronic diseases", "PROBLEM", 399, 421], ["reduction", "OBSERVATION_MODIFIER", 168, 177], ["mild", "OBSERVATION_MODIFIER", 195, 199], ["moderate", "OBSERVATION_MODIFIER", 204, 212], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["serious", "OBSERVATION_MODIFIER", 300, 307], ["chronic", "OBSERVATION_MODIFIER", 405, 412], ["diseases", "OBSERVATION", 413, 421]]], ["The high incidence of acute organ injury closely contributed to the increased mortality rate (Cao et al., 2020; Wang et al., 2020a).", [["organ", "ANATOMY", 28, 33], ["acute organ injury", "DISEASE", 22, 40], ["organ", "ORGAN", 28, 33], ["acute organ injury", "PROBLEM", 22, 40], ["the increased mortality rate", "PROBLEM", 64, 92], ["high", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["organ", "ANATOMY", 28, 33], ["injury", "OBSERVATION", 34, 40], ["increased", "OBSERVATION_MODIFIER", 68, 77]]], ["Inflammatory storm, oxidative stress, and apoptosis are important hallmarks of the transition of COVID-19 patients from mild to severe or even critical periods, and these mechanisms greatly increase the risk of organ damage, especially for patients with chronic diseases (Qin et al., 2020).", [["organ", "ANATOMY", 211, 216], ["organ damage", "DISEASE", 211, 223], ["chronic diseases", "DISEASE", 254, 270], ["patients", "ORGANISM", 106, 114], ["organ", "ORGAN", 211, 216], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 240, 248], ["Inflammatory storm", "PROBLEM", 0, 18], ["oxidative stress", "PROBLEM", 20, 36], ["apoptosis", "PROBLEM", 42, 51], ["COVID", "TEST", 97, 102], ["mild to severe", "PROBLEM", 120, 134], ["organ damage", "PROBLEM", 211, 223], ["chronic diseases", "PROBLEM", 254, 270], ["storm", "OBSERVATION", 13, 18], ["oxidative stress", "OBSERVATION", 20, 36], ["mild", "OBSERVATION_MODIFIER", 120, 124], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["organ", "ANATOMY", 211, 216], ["damage", "OBSERVATION", 217, 223]]], ["Therefore, this review will discuss the protective effect of TCM recommended in China on viscera from the perspectives of inflammatory storm, oxidative stress and apoptosis.Medication recommended in ChinaMonoclonal antibodies, interferon therapies, and small molecule drugs are commonly used in Western medicine to combat HIV, HBV, and MERS (Li and Clercq, 2020), but the long-term usage of these drugs is often accompanied by low selectivity and adverse side effects.", [["viscera", "ANATOMY", 89, 96], ["TCM", "CHEMICAL", 61, 64], ["Li", "CHEMICAL", 342, 344], ["viscera", "ORGAN", 89, 96], ["HIV", "ORGANISM", 322, 325], ["HBV", "ORGANISM", 327, 330], ["ChinaMonoclonal antibodies", "PROTEIN", 199, 225], ["interferon", "PROTEIN", 227, 237], ["HIV", "SPECIES", 322, 325], ["HIV", "SPECIES", 322, 325], ["HBV", "SPECIES", 327, 330], ["TCM", "TREATMENT", 61, 64], ["inflammatory storm", "PROBLEM", 122, 140], ["oxidative stress", "PROBLEM", 142, 158], ["apoptosis", "PROBLEM", 163, 172], ["Medication", "TREATMENT", 173, 183], ["ChinaMonoclonal antibodies", "TREATMENT", 199, 225], ["interferon therapies", "TREATMENT", 227, 247], ["small molecule drugs", "TREATMENT", 253, 273], ["HIV", "PROBLEM", 322, 325], ["HBV", "PROBLEM", 327, 330], ["these drugs", "TREATMENT", 391, 402], ["low selectivity", "PROBLEM", 427, 442], ["adverse side effects", "PROBLEM", 447, 467], ["viscera", "ANATOMY", 89, 96], ["inflammatory storm", "OBSERVATION", 122, 140], ["low selectivity", "OBSERVATION_MODIFIER", 427, 442]]], ["A report recently published in The Lancet demonstrated no significant clinical improvement in severe COVID-19 patients treated with remdesivir as compared with the placebo-controlled group, indicating the limitation of the application alone with western medicine (Wang et al., 2020b).", [["COVID", "DISEASE", 101, 106], ["remdesivir", "CHEMICAL", 132, 142], ["remdesivir", "CHEMICAL", 132, 142], ["patients", "ORGANISM", 110, 118], ["remdesivir", "SIMPLE_CHEMICAL", 132, 142], ["patients", "SPECIES", 110, 118], ["severe COVID", "PROBLEM", 94, 106], ["remdesivir", "TREATMENT", 132, 142], ["western medicine", "TREATMENT", 246, 262], ["no", "UNCERTAINTY", 55, 57], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["severe", "OBSERVATION_MODIFIER", 94, 100]]], ["The Chinese National Health Commision has figured out an essential strategy, a combination of TCM and Western medicine, to combat COVID-19, and successively published seriate versions of the diagnosis and treatment protocol.", [["Western medicine", "TREATMENT", 102, 118], ["COVID", "TEST", 130, 135], ["treatment protocol", "TREATMENT", 205, 223]]], ["This section will start with the latest version (Trial Version 7) of the Diagnosis and Treatment Protocol for COVID-19 (in short \"the Protocol\") (National Health Commission of the People's Republic of China, 2020), and introduce TCM formulas and Chinese patent medicine recommended for each developing stage of COVID-19 in the Protocol (Table 1).", [["This section", "TREATMENT", 0, 12], ["Treatment Protocol", "TREATMENT", 87, 105], ["COVID", "TEST", 110, 115], ["TCM formulas", "TREATMENT", 229, 241], ["Chinese patent medicine", "TREATMENT", 246, 269], ["COVID", "TEST", 311, 316]]], ["COVID-19 can be roughly divided into three stages, the medical observation stage, the clinical treatment stage and the stage of convalescence.", [["the clinical treatment stage", "TREATMENT", 82, 110]]], ["The treatment stage is further subdivided into mild, moderate, severe and critical based on the severity of the disease.Medication recommended in ChinaIn the medical observation stage, patent Chinese medicine such as Huoxiang Zhengqi capsules (symptom with fatigue and gastrointestinal upset) or Lianhua Qingwen capsules (symptom with fever and weakness) are administered to suspected COVID-19 patients.Medication recommended in ChinaIn the clinical medication stage, patients of mild COVID-19 often have mild fever and respiratory symptoms.", [["gastrointestinal", "ANATOMY", 269, 285], ["respiratory", "ANATOMY", 520, 531], ["fatigue", "DISEASE", 257, 264], ["fever", "DISEASE", 335, 340], ["weakness", "DISEASE", 345, 353], ["fever", "DISEASE", 510, 515], ["respiratory symptoms", "DISEASE", 520, 540], ["gastrointestinal", "ORGANISM_SUBDIVISION", 269, 285], ["patients", "ORGANISM", 394, 402], ["patients", "ORGANISM", 468, 476], ["patients", "SPECIES", 394, 402], ["patients", "SPECIES", 468, 476], ["The treatment stage", "TREATMENT", 0, 19], ["further subdivided into mild, moderate, severe", "PROBLEM", 23, 69], ["the disease", "PROBLEM", 108, 119], ["Medication", "TREATMENT", 120, 130], ["patent Chinese medicine", "TREATMENT", 185, 208], ["Huoxiang Zhengqi capsules", "TREATMENT", 217, 242], ["symptom", "PROBLEM", 244, 251], ["fatigue", "PROBLEM", 257, 264], ["gastrointestinal upset", "PROBLEM", 269, 291], ["Lianhua Qingwen capsules", "TREATMENT", 296, 320], ["symptom", "PROBLEM", 322, 329], ["fever", "PROBLEM", 335, 340], ["weakness", "PROBLEM", 345, 353], ["Medication", "TREATMENT", 403, 413], ["mild COVID", "PROBLEM", 480, 490], ["mild fever", "PROBLEM", 505, 515], ["respiratory symptoms", "PROBLEM", 520, 540], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["critical", "OBSERVATION_MODIFIER", 74, 82], ["disease", "OBSERVATION", 112, 119], ["patent", "OBSERVATION", 185, 191], ["gastrointestinal", "ANATOMY", 269, 285], ["mild", "OBSERVATION_MODIFIER", 480, 484], ["mild", "OBSERVATION_MODIFIER", 505, 509], ["fever", "OBSERVATION", 510, 515], ["respiratory symptoms", "OBSERVATION", 520, 540]]], ["The recommended decoction mainly includes single Chinese herb such as Magnolia officinalis, Scutellaria baicalensis, and licorice.", [["Magnolia officinalis, Scutellaria baicalensis", "CHEMICAL", 70, 115], ["licorice", "CHEMICAL", 121, 129], ["Magnolia officinalis", "ORGANISM", 70, 90], ["Scutellaria baicalensis", "ORGANISM", 92, 115], ["licorice", "SIMPLE_CHEMICAL", 121, 129], ["Magnolia officinalis", "SPECIES", 70, 90], ["Scutellaria baicalensis", "SPECIES", 92, 115], ["Magnolia officinalis", "SPECIES", 70, 90], ["Scutellaria baicalensis", "SPECIES", 92, 115], ["decoction", "TREATMENT", 16, 25], ["single Chinese herb", "TREATMENT", 42, 61], ["Magnolia officinalis", "TREATMENT", 70, 90], ["Scutellaria baicalensis", "TREATMENT", 92, 115], ["licorice", "TREATMENT", 121, 129], ["Scutellaria baicalensis", "ANATOMY", 92, 115]]], ["Patients of moderate COVID-19 with mild fever and exacerbated respiratory symptoms are recommended to be prescribed with medicine such as licorice, Magnolia officinalis and Atractylodes rhizome.", [["respiratory", "ANATOMY", 62, 73], ["fever", "DISEASE", 40, 45], ["respiratory symptoms", "DISEASE", 62, 82], ["Patients", "ORGANISM", 0, 8], ["licorice", "SIMPLE_CHEMICAL", 138, 146], ["Magnolia officinalis", "ORGANISM", 148, 168], ["Atractylodes rhizome", "ORGANISM", 173, 193], ["Patients", "SPECIES", 0, 8], ["Magnolia officinalis", "SPECIES", 148, 168], ["Atractylodes rhizome", "SPECIES", 173, 193], ["Magnolia officinalis", "SPECIES", 148, 168], ["moderate COVID", "PROBLEM", 12, 26], ["mild fever", "PROBLEM", 35, 45], ["exacerbated respiratory symptoms", "PROBLEM", 50, 82], ["medicine", "TREATMENT", 121, 129], ["licorice", "TREATMENT", 138, 146], ["Magnolia officinalis", "TREATMENT", 148, 168], ["Atractylodes rhizome", "TREATMENT", 173, 193], ["moderate", "OBSERVATION_MODIFIER", 12, 20], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["fever", "OBSERVATION", 40, 45]]], ["Patients of severe COVID-19 with respiratory symptoms manifested as respiratory distress are recommended to take TCM and herbal decoction including Rheum officinale, Salvia miltiorrhiza, Astragalus membranaceus, Lonicera japonica Thunb, Magnolia officinalis, and licorice.", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 68, 79], ["COVID", "DISEASE", 19, 24], ["respiratory symptoms", "DISEASE", 33, 53], ["respiratory distress", "DISEASE", 68, 88], ["Rheum officinale, Salvia miltiorrhiza", "CHEMICAL", 148, 185], ["Patients", "ORGANISM", 0, 8], ["Rheum officinale", "ORGANISM", 148, 164], ["Salvia miltiorrhiza", "ORGANISM", 166, 185], ["Astragalus membranaceus", "ORGANISM", 187, 210], ["Lonicera japonica", "ORGANISM", 212, 229], ["Thunb", "ORGANISM", 230, 235], ["Magnolia officinalis", "ORGANISM", 237, 257], ["licorice", "ORGANISM_SUBDIVISION", 263, 271], ["Patients", "SPECIES", 0, 8], ["Rheum officinale", "SPECIES", 148, 164], ["Salvia miltiorrhiza", "SPECIES", 166, 185], ["Astragalus membranaceus", "SPECIES", 187, 210], ["Lonicera japonica", "SPECIES", 212, 229], ["Magnolia officinalis", "SPECIES", 237, 257], ["licorice", "SPECIES", 263, 271], ["Rheum officinale", "SPECIES", 148, 164], ["Salvia miltiorrhiza", "SPECIES", 166, 185], ["Astragalus membranaceus", "SPECIES", 187, 210], ["Lonicera japonica", "SPECIES", 212, 229], ["Magnolia officinalis", "SPECIES", 237, 257], ["severe COVID", "PROBLEM", 12, 24], ["respiratory symptoms", "PROBLEM", 33, 53], ["respiratory distress", "PROBLEM", 68, 88], ["TCM", "TREATMENT", 113, 116], ["herbal decoction", "TREATMENT", 121, 137], ["Rheum officinale", "TREATMENT", 148, 164], ["Salvia miltiorrhiza", "TREATMENT", 166, 185], ["Astragalus membranaceus", "TREATMENT", 187, 210], ["Lonicera japonica Thunb", "TREATMENT", 212, 235], ["Magnolia officinalis", "TREATMENT", 237, 257], ["licorice", "TREATMENT", 263, 271], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["respiratory distress", "OBSERVATION", 68, 88], ["Rheum", "ANATOMY", 148, 153], ["Salvia miltiorrhiza", "ANATOMY", 166, 185], ["Astragalus membranaceus", "ANATOMY", 187, 210], ["Magnolia officinalis", "OBSERVATION", 237, 257]]], ["For the critically ill patients who are characterized by respiratory failure, auxiliary ventilation is required.", [["respiratory", "ANATOMY", 57, 68], ["critically ill", "DISEASE", 8, 22], ["respiratory failure", "DISEASE", 57, 76], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["respiratory failure", "PROBLEM", 57, 76], ["auxiliary ventilation", "TREATMENT", 78, 99], ["respiratory failure", "OBSERVATION", 57, 76], ["auxiliary ventilation", "OBSERVATION", 78, 99]]], ["At this stage, the joint use of TCM decoction and patent Chinese medicine will achieve better therapeutic efficacy (National Health Commission of the People's Republic of China, 2020).Medication recommended in ChinaIn accordance with the clinical observations of doctors in various locations, the Qingfei Paidu decoction recommended by the Protocol is applicable to mild, moderate and severe cases, and could also be used in critically ill patients in consideration with their actual conditions.", [["TCM decoction", "CHEMICAL", 32, 45], ["critically ill", "DISEASE", 425, 439], ["patients", "ORGANISM", 440, 448], ["patients", "SPECIES", 440, 448], ["TCM decoction", "TREATMENT", 32, 45], ["patent Chinese medicine", "TREATMENT", 50, 73], ["Medication", "TREATMENT", 184, 194], ["the Qingfei Paidu decoction", "TREATMENT", 293, 320], ["mild, moderate and severe cases", "PROBLEM", 366, 397], ["joint", "ANATOMY", 19, 24], ["patent", "OBSERVATION", 50, 56], ["moderate", "OBSERVATION_MODIFIER", 372, 380], ["severe", "OBSERVATION_MODIFIER", 385, 391]]], ["Qingfei Paidu decoction is a combination of Chinese prescriptions that include Maxing Shigan decoction, Shegan Mahuang decoction, Xiao Chaihu decoction, and Wuling powder.", [["Qingfei Paidu decoction", "CHEMICAL", 0, 23], ["Shegan Mahuang decoction", "CHEMICAL", 104, 128], ["Xiao Chaihu decoction", "CHEMICAL", 130, 151], ["Qingfei Paidu decoction", "TREATMENT", 0, 23], ["Chinese prescriptions", "TREATMENT", 44, 65], ["Maxing Shigan decoction", "TREATMENT", 79, 102], ["Xiao Chaihu decoction", "TREATMENT", 130, 151], ["Wuling powder", "TREATMENT", 157, 170]]], ["Its broad application in different stages of COVID-19 stems not only from the combination of various Chinese prescriptions, but also from its acting on multiple potential targets through distinct intervention pathways.", [["Its broad application", "TREATMENT", 0, 21], ["COVID", "TEST", 45, 50], ["various Chinese prescriptions", "TREATMENT", 93, 122], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["different stages", "OBSERVATION_MODIFIER", 25, 41], ["19 stems", "OBSERVATION_MODIFIER", 51, 59]]], ["Patients who had repeated fever and cough with obscure respiratory rales of both lungs before receiving this treatment had their body temperature returned to normal on the night of the administration of Qingfei Paidu decoction and chest CT scan showed improvement after 6 days of treatment (Zhang and Zhu, 2020).", [["respiratory", "ANATOMY", 55, 66], ["lungs", "ANATOMY", 81, 86], ["body", "ANATOMY", 129, 133], ["fever", "DISEASE", 26, 31], ["cough", "DISEASE", 36, 41], ["Qingfei Paidu decoction", "CHEMICAL", 203, 226], ["Patients", "ORGANISM", 0, 8], ["lungs", "ORGAN", 81, 86], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["chest", "ORGAN", 231, 236], ["Patients", "SPECIES", 0, 8], ["repeated fever", "PROBLEM", 17, 31], ["cough", "PROBLEM", 36, 41], ["obscure respiratory rales of both lungs", "PROBLEM", 47, 86], ["this treatment", "TREATMENT", 104, 118], ["their body temperature", "TEST", 123, 145], ["Qingfei Paidu decoction", "TREATMENT", 203, 226], ["chest CT scan", "TEST", 231, 244], ["treatment", "TREATMENT", 280, 289], ["cough", "OBSERVATION", 36, 41], ["respiratory", "ANATOMY", 55, 66], ["rales", "OBSERVATION", 67, 72], ["both", "ANATOMY_MODIFIER", 76, 80], ["lungs", "ANATOMY", 81, 86], ["normal", "OBSERVATION", 158, 164], ["chest", "ANATOMY", 231, 236], ["improvement", "OBSERVATION_MODIFIER", 252, 263]]], ["The total effective rate for confirmed COVID-19 patients using this prescription in the 4 pilot provinces of China is over 90% by February 6, 2020 (National Administration of Traditional Chinese Medicine, 2020).Medication recommended in ChinaConvalescence is a period when a patient has just recovered from illness and is recuperating while the body is still weak.", [["body", "ANATOMY", 345, 349], ["COVID", "DISEASE", 39, 44], ["illness", "DISEASE", 307, 314], ["patients", "ORGANISM", 48, 56], ["patient", "ORGANISM", 275, 282], ["body", "ORGANISM_SUBDIVISION", 345, 349], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 275, 282], ["COVID", "TEST", 39, 44], ["this prescription", "TREATMENT", 63, 80], ["Traditional Chinese Medicine", "TREATMENT", 175, 203], ["Medication", "TREATMENT", 211, 221], ["illness", "PROBLEM", 307, 314], ["still weak", "PROBLEM", 353, 363], ["weak", "OBSERVATION", 359, 363]]], ["Intervention of TCM at this point could help patients speed up their recovery.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Intervention", "TREATMENT", 0, 12], ["TCM", "TREATMENT", 16, 19]]], ["The Protocol recommends the application of Salvia miltiorrhiza, licorice and so on in this stage (National Health Commission of the People's Republic of China, 2020).Medication recommended in ChinaTCM and Chinese patent medicine have contributed a lot in combating with the SARS-CoV in 2003 by their antiviral and immunomodulatory effects (Luo et al., 2020).", [["Salvia miltiorrhiza", "CHEMICAL", 43, 62], ["ChinaTCM", "CHEMICAL", 192, 200], ["SARS", "DISEASE", 274, 278], ["Salvia miltiorrhiza", "ORGANISM", 43, 62], ["licorice", "SIMPLE_CHEMICAL", 64, 72], ["SARS-CoV", "ORGANISM", 274, 282], ["Salvia miltiorrhiza", "SPECIES", 43, 62], ["Salvia miltiorrhiza", "SPECIES", 43, 62], ["SARS-CoV", "SPECIES", 274, 282], ["The Protocol", "TREATMENT", 0, 12], ["Salvia miltiorrhiza", "TREATMENT", 43, 62], ["licorice", "TREATMENT", 64, 72], ["Medication", "TREATMENT", 166, 176], ["Chinese patent medicine", "TREATMENT", 205, 228], ["the SARS", "PROBLEM", 270, 278]]], ["Some of the traditional herbs recommended in the Protocol possess antiviral property, such as Lonicera japonica Thunb, Scutellaria baicalensis, Astragalus membranaceus, and Salvia miltiorrhiza (Chen et al., 2020b).", [["Lonicera japonica Thunb, Scutellaria baicalensis", "CHEMICAL", 94, 142], ["Lonicera japonica", "ORGANISM", 94, 111], ["Thunb", "ORGANISM", 112, 117], ["Scutellaria baicalensis", "ORGANISM", 119, 142], ["Astragalus membranaceus", "ORGANISM", 144, 167], ["Salvia miltiorrhiza", "ORGANISM", 173, 192], ["Lonicera japonica", "SPECIES", 94, 111], ["Scutellaria baicalensis", "SPECIES", 119, 142], ["Astragalus membranaceus", "SPECIES", 144, 167], ["Salvia miltiorrhiza", "SPECIES", 173, 192], ["Lonicera japonica", "SPECIES", 94, 111], ["Scutellaria baicalensis", "SPECIES", 119, 142], ["Astragalus membranaceus", "SPECIES", 144, 167], ["Salvia miltiorrhiza", "SPECIES", 173, 192], ["the traditional herbs", "TREATMENT", 8, 29], ["the Protocol", "TREATMENT", 45, 57], ["antiviral property", "TREATMENT", 66, 84], ["Lonicera japonica Thunb", "TREATMENT", 94, 117], ["Scutellaria baicalensis", "TREATMENT", 119, 142], ["Astragalus membranaceus", "TREATMENT", 144, 167], ["Salvia miltiorrhiza", "TREATMENT", 173, 192], ["Scutellaria baicalensis", "ANATOMY", 119, 142], ["Astragalus membranaceus", "ANATOMY", 144, 167], ["Salvia miltiorrhiza", "ANATOMY", 173, 192]]], ["The underlying antiviral mechanisms can be roughly divided into the following two: (1) direct inhibition of viruses.", [["The underlying antiviral mechanisms", "TREATMENT", 0, 35], ["direct inhibition of viruses", "PROBLEM", 87, 115], ["antiviral mechanisms", "OBSERVATION", 15, 35], ["viruses", "OBSERVATION", 108, 115]]], ["Based on TCM principles, most of the herbs exert heat-clearing and detoxifying properties, such as Lonicera japonica Thunb and Scutellaria baicalensis; (2) indirect antiviral effect or inhibition of virus-mediated inflammatory response via modulating immune function, such as Astragalus membranaceus and Salvia miltiorrhiza.", [["Lonicera japonica", "ORGANISM", 99, 116], ["Thunb", "ORGANISM", 117, 122], ["Scutellaria baicalensis", "ORGANISM", 127, 150], ["Astragalus membranaceus", "ORGANISM", 276, 299], ["Salvia miltiorrhiza", "ORGANISM", 304, 323], ["Lonicera japonica", "SPECIES", 99, 116], ["Scutellaria baicalensis", "SPECIES", 127, 150], ["Astragalus membranaceus", "SPECIES", 276, 299], ["Salvia miltiorrhiza", "SPECIES", 304, 323], ["Lonicera japonica", "SPECIES", 99, 116], ["Scutellaria baicalensis", "SPECIES", 127, 150], ["Astragalus membranaceus", "SPECIES", 276, 299], ["Salvia miltiorrhiza", "SPECIES", 304, 323], ["TCM principles", "TREATMENT", 9, 23], ["Lonicera japonica Thunb", "TREATMENT", 99, 122], ["Scutellaria baicalensis", "PROBLEM", 127, 150], ["indirect antiviral effect", "TREATMENT", 156, 181], ["virus", "PROBLEM", 199, 204], ["inflammatory response", "PROBLEM", 214, 235], ["modulating immune function", "PROBLEM", 240, 266], ["Astragalus membranaceus", "PROBLEM", 276, 299], ["Salvia miltiorrhiza", "PROBLEM", 304, 323], ["clearing", "OBSERVATION", 54, 62], ["Scutellaria baicalensis", "ANATOMY", 127, 150], ["inflammatory", "OBSERVATION_MODIFIER", 214, 226], ["immune function", "OBSERVATION", 251, 266], ["Astragalus membranaceus", "ANATOMY", 276, 299], ["Salvia miltiorrhiza", "OBSERVATION", 304, 323]]], ["However, the use of antiviral herbal medicine only could not effectively prevent tissue injuries due to inflammatory storm, oxidative stress or apoptosis caused by excessive immune response associated with COVID-19.", [["tissue", "ANATOMY", 81, 87], ["injuries", "DISEASE", 88, 96], ["COVID-19", "CHEMICAL", 206, 214], ["tissue", "TISSUE", 81, 87], ["antiviral herbal medicine", "TREATMENT", 20, 45], ["tissue injuries", "PROBLEM", 81, 96], ["inflammatory storm", "PROBLEM", 104, 122], ["oxidative stress", "PROBLEM", 124, 140], ["apoptosis", "PROBLEM", 144, 153], ["excessive immune response", "PROBLEM", 164, 189], ["COVID", "TEST", 206, 211], ["inflammatory storm", "OBSERVATION", 104, 122]]], ["Thereafter, we will discuss the protective effects of TCM on organ damages from the anti-inflammatory, antioxidant and anti-apoptosis perspectives.Medication recommended in ChinaTCM theory demonstrates that traditional herbal medicine pays special attention to the overall regulation of the body and the differentiation of clinical syndromes (Fan et al., 2020).", [["organ", "ANATOMY", 61, 66], ["body", "ANATOMY", 291, 295], ["TCM", "CHEMICAL", 54, 57], ["organ damages", "DISEASE", 61, 74], ["organ", "ORGAN", 61, 66], ["body", "ORGANISM_SUBDIVISION", 291, 295], ["TCM", "PROBLEM", 54, 57], ["organ damages", "TREATMENT", 61, 74], ["the anti-inflammatory, antioxidant", "TREATMENT", 80, 114], ["anti-apoptosis perspectives", "TREATMENT", 119, 146], ["Medication", "TREATMENT", 147, 157], ["traditional herbal medicine", "TREATMENT", 207, 234], ["clinical syndromes", "PROBLEM", 323, 341]]], ["The decision which particular TCM formula and/or Chinese patent medicine is to be used is based on the specific Chinese medicine syndrome associated with disease.", [["TCM formula", "TREATMENT", 30, 41], ["Chinese patent medicine", "TREATMENT", 49, 72], ["the specific Chinese medicine syndrome", "PROBLEM", 99, 137], ["disease", "PROBLEM", 154, 161]]], ["Therefore, compared with the use of single TCM compound, TCM formula and Chinese patent medicine are more widely applied in fighting against this epidemic as combination of multiple herbs could not only cure diseases but also correct Chinese medicine syndromes through acting on multiple targets via diverse regulation pathways.Medication recommended in ChinaIt will take a long time to develop vaccines and specific medicines targeting SARA-CoV-2.", [["SARA-CoV-2", "GENE_OR_GENE_PRODUCT", 437, 447], ["SARA", "PROTEIN", 437, 441], ["single TCM compound", "TREATMENT", 36, 55], ["TCM formula", "TREATMENT", 57, 68], ["Chinese patent medicine", "TREATMENT", 73, 96], ["multiple herbs", "PROBLEM", 173, 187], ["cure diseases", "PROBLEM", 203, 216], ["Chinese medicine syndromes", "PROBLEM", 234, 260], ["diverse regulation pathways", "TREATMENT", 300, 327], ["Medication", "TREATMENT", 328, 338], ["vaccines", "TREATMENT", 395, 403], ["specific medicines", "TREATMENT", 408, 426], ["multiple", "OBSERVATION_MODIFIER", 173, 181], ["herbs", "OBSERVATION", 182, 187]]], ["At the present stage, TCM intervention could elevate COVID-19 recovery rate with no adverse side effects.", [["TCM intervention", "TREATMENT", 22, 38], ["COVID", "TEST", 53, 58], ["adverse side effects", "PROBLEM", 84, 104]]], ["The Chinese government has actively encouraged the application of TCM in fighting against the epidemic (Zhang et al., 2020a).Anti-inflammatory effect of TCM ::: Mechanisms of TCM function in treating COVID-19The inhibition of lymphocytes by TCM in severe COVID-19 patients was shown by the lowered CD4+T and CD8+T, both of which are closely associated with the inflammation (Wan et al., 2020).", [["lymphocytes", "ANATOMY", 226, 237], ["CD4+T", "ANATOMY", 298, 303], ["CD8+T", "ANATOMY", 308, 313], ["TCM", "CHEMICAL", 66, 69], ["TCM", "CHEMICAL", 241, 244], ["COVID", "DISEASE", 255, 260], ["inflammation", "DISEASE", 361, 373], ["lymphocytes", "CELL", 226, 237], ["TCM", "CELL", 241, 244], ["patients", "ORGANISM", 264, 272], ["CD4", "GENE_OR_GENE_PRODUCT", 298, 301], ["CD8+T", "GENE_OR_GENE_PRODUCT", 308, 313], ["lymphocytes", "CELL_TYPE", 226, 237], ["CD4", "PROTEIN", 298, 301], ["CD8", "PROTEIN", 308, 311], ["patients", "SPECIES", 264, 272], ["TCM", "TREATMENT", 66, 69], ["TCM function", "PROBLEM", 175, 187], ["COVID", "TEST", 200, 205], ["lymphocytes", "PROBLEM", 226, 237], ["TCM", "TEST", 241, 244], ["severe COVID", "TEST", 248, 260], ["the inflammation", "PROBLEM", 357, 373], ["TCM function", "OBSERVATION", 175, 187], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["inflammation", "OBSERVATION", 361, 373]]], ["Patients infected with SARS-CoV-2 had higher concentrations of IL-1\u03b2, IL-7, IL-8, IFN-\u03b3, IP10, and MCP1 than those in healthy adults.", [["SARS", "DISEASE", 23, 27], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 23, 33], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 63, 68], ["IL-7", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL-8", "GENE_OR_GENE_PRODUCT", 76, 80], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 82, 87], ["IP10", "GENE_OR_GENE_PRODUCT", 89, 93], ["MCP1", "GENE_OR_GENE_PRODUCT", 99, 103], ["IFN", "PROTEIN", 82, 85], ["\u03b3", "PROTEIN", 86, 87], ["IP10", "PROTEIN", 89, 93], ["MCP1", "PROTEIN", 99, 103], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["IL", "TEST", 63, 65], ["IL", "TEST", 70, 72], ["IL", "TEST", 76, 78], ["IFN", "TEST", 82, 85], ["IP10", "TREATMENT", 89, 93], ["infected", "OBSERVATION", 9, 17]]], ["Moreover, severe COVID-19 patients showed higher circulating levels of GCSF, IP10, MCP1, MIP1A, and TNF-\u03b1, suggesting that cytokine storm had occurred during the development of COVID-19 (Huang et al., 2020).", [["patients", "ORGANISM", 26, 34], ["GCSF", "GENE_OR_GENE_PRODUCT", 71, 75], ["IP10", "GENE_OR_GENE_PRODUCT", 77, 81], ["MCP1", "GENE_OR_GENE_PRODUCT", 83, 87], ["MIP1A", "GENE_OR_GENE_PRODUCT", 89, 94], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["GCSF", "PROTEIN", 71, 75], ["IP10", "PROTEIN", 77, 81], ["MCP1", "PROTEIN", 83, 87], ["MIP1A", "PROTEIN", 89, 94], ["TNF-\u03b1", "PROTEIN", 100, 105], ["cytokine", "PROTEIN", 123, 131], ["patients", "SPECIES", 26, 34], ["severe COVID", "TEST", 10, 22], ["GCSF", "TEST", 71, 75], ["IP10", "TEST", 77, 81], ["MCP1", "TEST", 83, 87], ["MIP1A", "TEST", 89, 94], ["TNF", "TEST", 100, 103], ["cytokine storm", "PROBLEM", 123, 137], ["COVID", "TEST", 177, 182], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["GCSF", "OBSERVATION_MODIFIER", 71, 75], ["TNF", "ANATOMY", 100, 103], ["cytokine storm", "OBSERVATION", 123, 137]]], ["Inflammation associated with cytokine storm begins at a local site and spreads to the whole body via the systemic circulation (Medzhitov, 2008).Anti-inflammatory effect of TCM ::: Mechanisms of TCM function in treating COVID-19According to the Protocol, Chinese herbs with anti-inflammatory activity such as Rheum officinale, Scutellaria baicalensis, patchouli, ginseng, Salvia miltiorrhiza, and gypsum, are clinically applied to treat COVID-19 (Table 2) (National Health Commission of the People's Republic of China, 2020).", [["body", "ANATOMY", 92, 96], ["Inflammation", "DISEASE", 0, 12], ["COVID-19According", "CHEMICAL", 219, 236], ["Rheum officinale, Scutellaria baicalensis, patchouli, ginseng, Salvia miltiorrhiza", "CHEMICAL", 308, 390], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["Rheum officinale", "ORGANISM", 308, 324], ["Scutellaria baicalensis", "ORGANISM", 326, 349], ["patchouli", "SIMPLE_CHEMICAL", 351, 360], ["ginseng", "ORGANISM", 362, 369], ["Salvia miltiorrhiza", "ORGANISM", 371, 390], ["cytokine", "PROTEIN", 29, 37], ["Rheum officinale", "SPECIES", 308, 324], ["Scutellaria baicalensis", "SPECIES", 326, 349], ["ginseng", "SPECIES", 362, 369], ["Salvia miltiorrhiza", "SPECIES", 371, 390], ["Rheum officinale", "SPECIES", 308, 324], ["Scutellaria baicalensis", "SPECIES", 326, 349], ["Salvia miltiorrhiza", "SPECIES", 371, 390], ["Inflammation", "PROBLEM", 0, 12], ["cytokine storm", "PROBLEM", 29, 43], ["TCM function", "PROBLEM", 194, 206], ["COVID", "TEST", 219, 224], ["the Protocol", "TREATMENT", 240, 252], ["Chinese herbs", "TREATMENT", 254, 267], ["anti-inflammatory activity", "TREATMENT", 273, 299], ["Rheum officinale", "TREATMENT", 308, 324], ["Scutellaria baicalensis", "TREATMENT", 326, 349], ["patchouli", "PROBLEM", 351, 360], ["Salvia miltiorrhiza", "TREATMENT", 371, 390], ["COVID", "TEST", 436, 441], ["cytokine storm", "OBSERVATION", 29, 43], ["systemic circulation", "ANATOMY", 105, 125], ["TCM function", "OBSERVATION", 194, 206], ["anti-inflammatory activity", "OBSERVATION", 273, 299], ["Rheum", "ANATOMY", 308, 313], ["Scutellaria baicalensis", "ANATOMY", 326, 349], ["Salvia miltiorrhiza", "ANATOMY", 371, 390]]], ["The Lianhua Qingwen capsule recommended in the Protocol could dose-dependently inhibit the mRNA expression of the inflammatory cytokines, such as TNF-\u03b1, MCP-1 and IL-6, in host cells infected by SARS-CoV-19 (Li et al., 2020b).Anti-inflammatory effect of TCM ::: Mechanisms of TCM function in treating COVID-19Many herb-derived natural products are excellent anti-inflammatory agents.", [["cells", "ANATOMY", 177, 182], ["COVID-19Many herb", "CHEMICAL", 301, 318], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 146, 151], ["MCP-1", "GENE_OR_GENE_PRODUCT", 153, 158], ["IL-6", "GENE_OR_GENE_PRODUCT", 163, 167], ["host cells", "CELL", 172, 182], ["SARS-CoV-19", "ORGANISM", 195, 206], ["COVID-19Many herb-derived natural products", "SIMPLE_CHEMICAL", 301, 343], ["inflammatory cytokines", "PROTEIN", 114, 136], ["TNF", "PROTEIN", 146, 149], ["MCP-1", "PROTEIN", 153, 158], ["IL-6", "PROTEIN", 163, 167], ["host cells", "CELL_TYPE", 172, 182], ["SARS-CoV-19", "SPECIES", 195, 206], ["The Lianhua Qingwen capsule", "TREATMENT", 0, 27], ["the Protocol", "TREATMENT", 43, 55], ["the inflammatory cytokines", "PROBLEM", 110, 136], ["TNF", "TEST", 146, 149], ["MCP", "TEST", 153, 156], ["IL", "TEST", 163, 165], ["SARS", "TEST", 195, 199], ["CoV", "TEST", 200, 203], ["TCM function", "PROBLEM", 276, 288], ["COVID", "TEST", 301, 306], ["herb", "TREATMENT", 314, 318], ["natural products", "TREATMENT", 327, 343], ["excellent anti-inflammatory agents", "TREATMENT", 348, 382], ["inflammatory cytokines", "OBSERVATION", 114, 136], ["TCM function", "OBSERVATION", 276, 288], ["anti-inflammatory agents", "OBSERVATION", 358, 382]]], ["The anti-inflammatory activity of emodin, the biologically active constituent of the Chinese herb Rheum officinale, has been reported using in vitro and in vivo models (Shrimali et al., 2013).", [["emodin", "CHEMICAL", 34, 40], ["emodin", "CHEMICAL", 34, 40], ["emodin", "SIMPLE_CHEMICAL", 34, 40], ["Rheum officinale", "ORGANISM", 98, 114], ["Rheum officinale", "SPECIES", 98, 114], ["Chinese herb Rheum officinale", "SPECIES", 85, 114], ["emodin", "TREATMENT", 34, 40], ["anti-inflammatory activity", "OBSERVATION", 4, 30]]], ["It could attenuate IL-1\u03b2 secretion via the inhibition of the activation of the NLR family pyrin containing domain 3 (NLRP3) inflammasome, a member of the NOD-like receptor family (Xia et al., 2019), and alleviate lipopolysaccharide (LPS)-triggered liver cell inflammatory injury by suppressing NF-\u03baB pathway (Xie et al., 2019).", [["liver cell", "ANATOMY", 248, 258], ["lipopolysaccharide", "CHEMICAL", 213, 231], ["LPS", "CHEMICAL", 233, 236], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 19, 24], ["NLR family pyrin containing domain 3", "GENE_OR_GENE_PRODUCT", 79, 115], ["NLRP3", "GENE_OR_GENE_PRODUCT", 117, 122], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 154, 171], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 213, 231], ["LPS", "SIMPLE_CHEMICAL", 233, 236], ["liver cell", "CELL", 248, 258], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 294, 299], ["IL-1\u03b2", "PROTEIN", 19, 24], ["NLR family pyrin containing domain 3 (NLRP3) inflammasome", "PROTEIN", 79, 136], ["NOD-like receptor family", "PROTEIN", 154, 178], ["NF-\u03baB", "PROTEIN", 294, 299], ["the NLR family pyrin containing domain", "TREATMENT", 75, 113], ["lipopolysaccharide (LPS", "TREATMENT", 213, 236], ["liver cell inflammatory injury", "PROBLEM", 248, 278], ["liver", "ANATOMY", 248, 253], ["cell", "OBSERVATION", 254, 258], ["inflammatory injury", "OBSERVATION", 259, 278]]], ["Baicalein, another herbal monomer isolated from the root of Scutellaria baicalensis, possesses many pharmacological effects including anti-inflammatory activity (Dinda et al., 2017) as shown by its repressing of caerulein-induced pancreatic injury and macrophage infiltration through inhibiting the phosphorylation of NF-\u03baB/p65, JAK2, STAT3, p38 and ERK1/2 (Jin et al., 2019).", [["root", "ANATOMY", 52, 56], ["pancreatic", "ANATOMY", 230, 240], ["macrophage", "ANATOMY", 252, 262], ["Baicalein", "CHEMICAL", 0, 9], ["the root of Scutellaria baicalensis", "CHEMICAL", 48, 83], ["caerulein", "CHEMICAL", 212, 221], ["pancreatic injury", "DISEASE", 230, 247], ["Baicalein", "CHEMICAL", 0, 9], ["caerulein", "CHEMICAL", 212, 221], ["Baicalein", "SIMPLE_CHEMICAL", 0, 9], ["root", "ORGANISM_SUBDIVISION", 52, 56], ["Scutellaria baicalensis", "ORGANISM", 60, 83], ["caerulein", "SIMPLE_CHEMICAL", 212, 221], ["pancreatic", "ORGAN", 230, 240], ["macrophage", "CELL", 252, 262], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 318, 323], ["p65", "GENE_OR_GENE_PRODUCT", 324, 327], ["JAK2", "GENE_OR_GENE_PRODUCT", 329, 333], ["STAT3", "GENE_OR_GENE_PRODUCT", 335, 340], ["p38", "GENE_OR_GENE_PRODUCT", 342, 345], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 350, 356], ["NF-\u03baB", "PROTEIN", 318, 323], ["p65", "PROTEIN", 324, 327], ["JAK2", "PROTEIN", 329, 333], ["STAT3", "PROTEIN", 335, 340], ["p38", "PROTEIN", 342, 345], ["ERK1", "PROTEIN", 350, 354], ["Scutellaria baicalensis", "SPECIES", 60, 83], ["Scutellaria baicalensis", "SPECIES", 60, 83], ["Baicalein", "TREATMENT", 0, 9], ["Scutellaria baicalensis", "TREATMENT", 60, 83], ["caerulein", "PROBLEM", 212, 221], ["pancreatic injury", "PROBLEM", 230, 247], ["macrophage infiltration", "PROBLEM", 252, 275], ["the phosphorylation", "TEST", 295, 314], ["NF", "TEST", 318, 320], ["JAK2", "TEST", 329, 333], ["STAT3", "TEST", 335, 340], ["p38", "TEST", 342, 345], ["ERK1", "TEST", 350, 354], ["root", "ANATOMY", 52, 56], ["Scutellaria baicalensis", "ANATOMY", 60, 83], ["pancreatic", "ANATOMY", 230, 240], ["injury", "OBSERVATION", 241, 247], ["macrophage infiltration", "OBSERVATION", 252, 275]]], ["Moreover, baicalein was able to suppress the over-production of inflammatory cytokines, including NO, PGE2, TNF-\u03b1, and IL-6, in an intervertebral disc degeneration model (Jin et al., 2019).", [["intervertebral disc", "ANATOMY", 131, 150], ["baicalein", "CHEMICAL", 10, 19], ["NO", "CHEMICAL", 98, 100], ["PGE2", "CHEMICAL", 102, 106], ["intervertebral disc degeneration", "DISEASE", 131, 163], ["baicalein", "CHEMICAL", 10, 19], ["NO", "CHEMICAL", 98, 100], ["PGE2", "CHEMICAL", 102, 106], ["baicalein", "SIMPLE_CHEMICAL", 10, 19], ["NO", "SIMPLE_CHEMICAL", 98, 100], ["PGE2", "SIMPLE_CHEMICAL", 102, 106], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["intervertebral disc", "MULTI-TISSUE_STRUCTURE", 131, 150], ["inflammatory cytokines", "PROTEIN", 64, 86], ["TNF", "PROTEIN", 108, 111], ["IL-6", "PROTEIN", 119, 123], ["baicalein", "TREATMENT", 10, 19], ["inflammatory cytokines", "PROBLEM", 64, 86], ["PGE2", "TEST", 102, 106], ["TNF", "TEST", 108, 111], ["IL", "TEST", 119, 121], ["an intervertebral disc degeneration model", "PROBLEM", 128, 169], ["inflammatory cytokines", "OBSERVATION", 64, 86], ["NO", "UNCERTAINTY", 98, 100], ["intervertebral disc", "ANATOMY", 131, 150]]], ["In addition, ginsenoside Rf, one of the active saponins found in ginseng, significantly decreased the level of IL-1\u03b2, IL-6 and TNF-\u03b1 in an incisional pain model (Kim et al., 2018).", [["ginsenoside Rf", "CHEMICAL", 13, 27], ["incisional pain", "DISEASE", 139, 154], ["ginsenoside Rf", "CHEMICAL", 13, 27], ["saponins", "CHEMICAL", 47, 55], ["ginsenoside Rf", "SIMPLE_CHEMICAL", 13, 27], ["saponins", "SIMPLE_CHEMICAL", 47, 55], ["ginseng", "ORGANISM", 65, 72], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 118, 122], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["IL-1\u03b2", "PROTEIN", 111, 116], ["IL-6", "PROTEIN", 118, 122], ["TNF-\u03b1", "PROTEIN", 127, 132], ["ginsenoside Rf", "TREATMENT", 13, 27], ["the active saponins", "PROBLEM", 36, 55], ["IL", "TEST", 111, 113], ["IL", "TEST", 118, 120], ["TNF", "TEST", 127, 130], ["an incisional pain model", "PROBLEM", 136, 160], ["incisional", "ANATOMY", 139, 149]]], ["Furthermore, tanshinone IIA (Tan IIA), a well-known flavonoid ingredient of Salvia miltiorrhiza, elicited an important therapeutic effect by inhibiting inflammatory response (Zheng et al., 2014).", [["tanshinone IIA", "CHEMICAL", 13, 27], ["Tan IIA", "CHEMICAL", 29, 36], ["Salvia miltiorrhiza", "CHEMICAL", 76, 95], ["tanshinone IIA", "CHEMICAL", 13, 27], ["Tan IIA", "CHEMICAL", 29, 36], ["flavonoid", "CHEMICAL", 52, 61], ["tanshinone IIA", "SIMPLE_CHEMICAL", 13, 27], ["Tan IIA", "SIMPLE_CHEMICAL", 29, 36], ["Salvia miltiorrhiza", "ORGANISM", 76, 95], ["Salvia miltiorrhiza", "SPECIES", 76, 95], ["Salvia miltiorrhiza", "SPECIES", 76, 95], ["tanshinone IIA (Tan IIA)", "PROBLEM", 13, 37], ["Salvia miltiorrhiza", "PROBLEM", 76, 95], ["inhibiting inflammatory response", "PROBLEM", 141, 173], ["tanshinone IIA", "OBSERVATION_MODIFIER", 13, 27], ["flavonoid ingredient", "OBSERVATION", 52, 72], ["Salvia miltiorrhiza", "OBSERVATION", 76, 95], ["inflammatory", "OBSERVATION_MODIFIER", 152, 164]]], ["An early study indicated that Tan IIA exerted anti-inflammatory effect by deactivating TLR4-MyD88-NF-\u03baB signaling pathway and regulating production of series of cytokines such as TNF-\u03b1, IL-1\u03b2 and COX-2 in LPS-induced RAW264.7 cells (Fan et al., 2016).Antioxidant effect of TCM ::: Mechanisms of TCM function in treating COVID-19The balance between oxidation and antioxidation plays an important role in the regulation of signal transduction, cell proliferation and apoptosis (Forrester et al., 2018).", [["RAW264.7 cells", "ANATOMY", 217, 231], ["cell", "ANATOMY", 442, 446], ["Tan IIA", "CHEMICAL", 30, 37], ["LPS", "CHEMICAL", 205, 208], ["COVID-19", "CHEMICAL", 320, 328], ["COVID-19", "CHEMICAL", 320, 328], ["Tan IIA", "GENE_OR_GENE_PRODUCT", 30, 37], ["TLR4", "GENE_OR_GENE_PRODUCT", 87, 91], ["MyD88", "GENE_OR_GENE_PRODUCT", 92, 97], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 98, 103], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 179, 184], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 186, 191], ["COX-2", "GENE_OR_GENE_PRODUCT", 196, 201], ["LPS", "SIMPLE_CHEMICAL", 205, 208], ["RAW264.7 cells", "CELL", 217, 231], ["cell", "CELL", 442, 446], ["TLR4", "PROTEIN", 87, 91], ["MyD88", "PROTEIN", 92, 97], ["NF-\u03baB", "PROTEIN", 98, 103], ["cytokines", "PROTEIN", 161, 170], ["TNF", "PROTEIN", 179, 182], ["IL-1\u03b2", "PROTEIN", 186, 191], ["COX-2", "PROTEIN", 196, 201], ["RAW264.7 cells", "CELL_LINE", 217, 231], ["An early study", "TEST", 0, 14], ["Tan IIA", "PROBLEM", 30, 37], ["B signaling pathway", "TREATMENT", 102, 121], ["cytokines", "TEST", 161, 170], ["TNF", "TEST", 179, 182], ["IL", "TEST", 186, 188], ["COX", "TEST", 196, 199], ["LPS", "TEST", 205, 208], ["TCM function", "PROBLEM", 295, 307], ["COVID", "TEST", 320, 325], ["antioxidation", "TREATMENT", 362, 375], ["signal transduction", "TREATMENT", 421, 440], ["anti-inflammatory effect", "OBSERVATION", 46, 70], ["RAW264.7 cells", "OBSERVATION", 217, 231], ["TCM function", "OBSERVATION", 295, 307], ["balance", "OBSERVATION", 332, 339]]], ["When the balance is destroyed by stress, virus or other factors, oxidative stress response will be stimulated (Forrester et al., 2018).", [["stress", "PROBLEM", 33, 39], ["virus", "PROBLEM", 41, 46], ["oxidative stress response", "PROBLEM", 65, 90]]], ["The excessive immune response associated with COVID-19 might largely promote the production of free radicals, consequently the over-accumulation of oxidative free radicals, leading to tissue injury and organ damage.", [["tissue", "ANATOMY", 184, 190], ["organ", "ANATOMY", 202, 207], ["COVID-19", "CHEMICAL", 46, 54], ["organ damage", "DISEASE", 202, 214], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "GENE_OR_GENE_PRODUCT", 46, 54], ["tissue", "TISSUE", 184, 190], ["organ", "ORGAN", 202, 207], ["The excessive immune response", "PROBLEM", 0, 29], ["COVID", "TEST", 46, 51], ["free radicals", "PROBLEM", 95, 108], ["oxidative free radicals", "PROBLEM", 148, 171], ["tissue injury", "PROBLEM", 184, 197], ["organ damage", "PROBLEM", 202, 214], ["excessive", "OBSERVATION_MODIFIER", 4, 13], ["immune response", "OBSERVATION", 14, 29], ["free radicals", "OBSERVATION", 95, 108], ["free radicals", "OBSERVATION", 158, 171], ["tissue", "ANATOMY", 184, 190], ["injury", "OBSERVATION", 191, 197], ["organ", "ANATOMY", 202, 207], ["damage", "OBSERVATION", 208, 214]]], ["The Protocol recommends the application of kinds of traditional Chinese herbs to inhibit oxidative stress stimulated by SARS-CoV-2 as many herbs such as Codonopsis pilosula, Glycyrrhiza glabra roots, Astragalus membranaceus, Lonicera japonica Thunb, and Forsythiae Fructus contain naturally-occurring bioactive components that exert anti-oxidative effects (National Health Commission of the People's Republic of China, 2020).Antioxidant effect of TCM ::: Mechanisms of TCM function in treating COVID-19Astragaloside IV (AS-IV), an active compound from Astragalus membranaceus, pharmacologically displays anti-oxidative stress effects (Qiu et al., 2010).", [["roots", "ANATOMY", 193, 198], ["Codonopsis pilosula, Glycyrrhiza glabra", "CHEMICAL", 153, 192], ["TCM", "CHEMICAL", 447, 450], ["COVID-19Astragaloside IV", "CHEMICAL", 494, 518], ["AS-IV", "CHEMICAL", 520, 525], ["COVID-19Astragaloside IV", "CHEMICAL", 494, 518], ["AS-IV", "CHEMICAL", 520, 525], ["SARS-CoV-2", "ORGANISM", 120, 130], ["Codonopsis pilosula", "ORGANISM", 153, 172], ["Glycyrrhiza glabra", "ORGANISM", 174, 192], ["roots", "ORGANISM", 193, 198], ["Astragalus membranaceus", "ORGANISM", 200, 223], ["Lonicera japonica", "ORGANISM", 225, 242], ["Thunb", "ORGANISM", 243, 248], ["Forsythiae Fructus", "ORGANISM", 254, 272], ["COVID-19Astragaloside IV", "SIMPLE_CHEMICAL", 494, 518], ["AS-IV", "SIMPLE_CHEMICAL", 520, 525], ["Astragalus membranaceus", "ORGANISM", 552, 575], ["Codonopsis pilosula", "SPECIES", 153, 172], ["Glycyrrhiza glabra", "SPECIES", 174, 192], ["Astragalus membranaceus", "SPECIES", 200, 223], ["Lonicera japonica", "SPECIES", 225, 242], ["Forsythiae", "SPECIES", 254, 264], ["People", "SPECIES", 391, 397], ["Astragalus membranaceus", "SPECIES", 552, 575], ["SARS-CoV", "SPECIES", 120, 128], ["Codonopsis pilosula", "SPECIES", 153, 172], ["Glycyrrhiza glabra", "SPECIES", 174, 192], ["Astragalus membranaceus", "SPECIES", 200, 223], ["Lonicera japonica", "SPECIES", 225, 242], ["Astragalus membranaceus", "SPECIES", 552, 575], ["The Protocol", "TREATMENT", 0, 12], ["traditional Chinese herbs", "TREATMENT", 52, 77], ["oxidative stress stimulated", "TREATMENT", 89, 116], ["many herbs", "TREATMENT", 134, 144], ["Codonopsis pilosula", "TREATMENT", 153, 172], ["Glycyrrhiza glabra roots", "TREATMENT", 174, 198], ["Astragalus membranaceus", "TREATMENT", 200, 223], ["Lonicera japonica Thunb", "TREATMENT", 225, 248], ["Forsythiae Fructus", "TREATMENT", 254, 272], ["TCM function", "PROBLEM", 469, 481], ["COVID", "TEST", 494, 499], ["19Astragaloside IV", "TREATMENT", 500, 518], ["an active compound", "PROBLEM", 528, 546], ["Astragalus membranaceus", "TREATMENT", 552, 575], ["anti-oxidative stress effects", "PROBLEM", 604, 633], ["Glycyrrhiza", "OBSERVATION", 174, 185], ["glabra roots", "ANATOMY", 186, 198], ["Astragalus membranaceus", "ANATOMY", 200, 223], ["active", "OBSERVATION_MODIFIER", 531, 537], ["Astragalus membranaceus", "OBSERVATION", 552, 575]]], ["A research study found that AS-IV (20 mg/kg) effectively attenuated the expression of 8-hydroxy-2\u2019-deoxyguanosine (8-OHdG) (a maker of oxidative damage in intact DNA) in both glomeruli and tubules, decreased the malondialdehyde (MDA) level and enhanced the superoxide dismutase (SOD) activity associated with indoxyl sulfate-induced tubulointerstitial injury (Ji et al., 2018), as well as displayed therapeutic potential in prevention of dementia caused by cerebral hypoperfusion, suggesting that the ameliorating effect of AS-IV on learning and memory deficits might be attributed to its suppressive effect on neuronal apoptosis and oxidative damage in the hippocampus (Kim et al., 2015).", [["glomeruli", "ANATOMY", 175, 184], ["tubules", "ANATOMY", 189, 196], ["tubulointerstitial", "ANATOMY", 333, 351], ["cerebral", "ANATOMY", 457, 465], ["neuronal", "ANATOMY", 611, 619], ["hippocampus", "ANATOMY", 658, 669], ["AS-IV", "CHEMICAL", 28, 33], ["8-hydroxy-2\u2019-deoxyguanosine", "CHEMICAL", 86, 113], ["8-OHdG", "CHEMICAL", 115, 121], ["malondialdehyde", "CHEMICAL", 212, 227], ["MDA", "CHEMICAL", 229, 232], ["superoxide", "CHEMICAL", 257, 267], ["indoxyl sulfate", "CHEMICAL", 309, 324], ["tubulointerstitial injury", "DISEASE", 333, 358], ["dementia", "DISEASE", 438, 446], ["cerebral hypoperfusion", "DISEASE", 457, 479], ["AS-IV", "CHEMICAL", 524, 529], ["learning and memory deficits", "DISEASE", 533, 561], ["8-hydroxy-2\u2019-deoxyguanosine", "CHEMICAL", 86, 113], ["8-OHdG", "CHEMICAL", 115, 121], ["malondialdehyde", "CHEMICAL", 212, 227], ["MDA", "CHEMICAL", 229, 232], ["superoxide", "CHEMICAL", 257, 267], ["indoxyl sulfate", "CHEMICAL", 309, 324], ["AS-IV", "SIMPLE_CHEMICAL", 28, 33], ["8-hydroxy-2\u2019-deoxyguanosine", "SIMPLE_CHEMICAL", 86, 113], ["8-OHdG", "SIMPLE_CHEMICAL", 115, 121], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 175, 184], ["tubules", "TISSUE", 189, 196], ["malondialdehyde", "SIMPLE_CHEMICAL", 212, 227], ["MDA", "SIMPLE_CHEMICAL", 229, 232], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 257, 277], ["SOD", "SIMPLE_CHEMICAL", 279, 282], ["indoxyl sulfate", "SIMPLE_CHEMICAL", 309, 324], ["tubulointerstitial", "MULTI-TISSUE_STRUCTURE", 333, 351], ["cerebral", "ORGAN", 457, 465], ["AS-IV", "GENE_OR_GENE_PRODUCT", 524, 529], ["neuronal", "CELL", 611, 619], ["hippocampus", "ORGAN", 658, 669], ["superoxide dismutase", "PROTEIN", 257, 277], ["SOD", "PROTEIN", 279, 282], ["A research study", "TEST", 0, 16], ["the expression", "TEST", 68, 82], ["hydroxy", "TEST", 88, 95], ["deoxyguanosine", "TREATMENT", 99, 113], ["oxidative damage", "PROBLEM", 135, 151], ["the malondialdehyde (MDA) level", "TEST", 208, 239], ["enhanced the superoxide dismutase (SOD) activity", "PROBLEM", 244, 292], ["indoxyl sulfate", "TREATMENT", 309, 324], ["tubulointerstitial injury", "PROBLEM", 333, 358], ["dementia", "PROBLEM", 438, 446], ["cerebral hypoperfusion", "PROBLEM", 457, 479], ["AS-IV on learning", "TREATMENT", 524, 541], ["memory deficits", "PROBLEM", 546, 561], ["neuronal apoptosis", "PROBLEM", 611, 629], ["oxidative damage in the hippocampus", "PROBLEM", 634, 669], ["both", "ANATOMY_MODIFIER", 170, 174], ["glomeruli", "ANATOMY", 175, 184], ["tubules", "ANATOMY_MODIFIER", 189, 196], ["decreased", "OBSERVATION_MODIFIER", 198, 207], ["superoxide dismutase", "OBSERVATION", 257, 277], ["tubulointerstitial", "ANATOMY", 333, 351], ["injury", "OBSERVATION", 352, 358], ["dementia", "OBSERVATION", 438, 446], ["cerebral", "ANATOMY", 457, 465], ["hypoperfusion", "OBSERVATION", 466, 479], ["neuronal apoptosis", "OBSERVATION", 611, 629], ["oxidative damage", "OBSERVATION", 634, 650], ["hippocampus", "ANATOMY", 658, 669]]], ["Moreover, AS-IV possessed antioxidant properties, including increasing SOD activity and reducing reactive oxygen species (ROS) generation and lipid peroxidation, consequentially protecting against ischemic brain injury (Li et al., 2012; Qu et al., 2009).", [["brain", "ANATOMY", 206, 211], ["AS-IV", "CHEMICAL", 10, 15], ["oxygen", "CHEMICAL", 106, 112], ["ROS", "CHEMICAL", 122, 125], ["ischemic brain injury", "DISEASE", 197, 218], ["oxygen", "CHEMICAL", 106, 112], ["AS-IV", "GENE_OR_GENE_PRODUCT", 10, 15], ["SOD", "SIMPLE_CHEMICAL", 71, 74], ["reactive oxygen species", "SIMPLE_CHEMICAL", 97, 120], ["ROS", "SIMPLE_CHEMICAL", 122, 125], ["lipid", "SIMPLE_CHEMICAL", 142, 147], ["brain", "ORGAN", 206, 211], ["SOD", "PROTEIN", 71, 74], ["IV possessed antioxidant properties", "TREATMENT", 13, 48], ["increasing SOD activity", "TREATMENT", 60, 83], ["reducing reactive oxygen species", "TREATMENT", 88, 120], ["lipid peroxidation", "PROBLEM", 142, 160], ["ischemic brain injury", "PROBLEM", 197, 218], ["reactive", "OBSERVATION_MODIFIER", 97, 105], ["oxygen species", "OBSERVATION", 106, 120], ["lipid peroxidation", "OBSERVATION", 142, 160], ["brain", "ANATOMY", 206, 211]]], ["Codonopsis pilosula polysaccharide (CP), a bioactive component in Codonopsis pilosula, enhanced the content of SOD and glutathione peroxidase (GSH-Px) in the liver and reduced the level of TNF-\u03b1 in serum of mice with hepatic injury induced by bacille-calmette-guerin/LPS (Liu et al., 2015).", [["liver", "ANATOMY", 158, 163], ["serum", "ANATOMY", 198, 203], ["hepatic", "ANATOMY", 217, 224], ["Codonopsis pilosula polysaccharide", "CHEMICAL", 0, 34], ["CP", "CHEMICAL", 36, 38], ["glutathione", "CHEMICAL", 119, 130], ["GSH", "CHEMICAL", 143, 146], ["hepatic injury", "DISEASE", 217, 231], ["bacille-calmette-guerin", "CHEMICAL", 243, 266], ["LPS", "CHEMICAL", 267, 270], ["glutathione", "CHEMICAL", 119, 130], ["GSH", "CHEMICAL", 143, 146], ["Codonopsis pilosula polysaccharide", "SIMPLE_CHEMICAL", 0, 34], ["CP", "SIMPLE_CHEMICAL", 36, 38], ["Codonopsis pilosula", "ORGANISM", 66, 85], ["SOD", "SIMPLE_CHEMICAL", 111, 114], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 119, 141], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 143, 149], ["liver", "ORGAN", 158, 163], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["mice", "ORGANISM", 207, 211], ["hepatic", "ORGAN", 217, 224], ["bacille-calmette-guerin", "SIMPLE_CHEMICAL", 243, 266], ["LPS", "SIMPLE_CHEMICAL", 267, 270], ["SOD", "PROTEIN", 111, 114], ["glutathione peroxidase", "PROTEIN", 119, 141], ["TNF-\u03b1", "PROTEIN", 189, 194], ["Codonopsis pilosula", "SPECIES", 0, 19], ["Codonopsis pilosula", "SPECIES", 66, 85], ["mice", "SPECIES", 207, 211], ["Codonopsis pilosula", "SPECIES", 0, 19], ["Codonopsis pilosula", "SPECIES", 66, 85], ["mice", "SPECIES", 207, 211], ["Codonopsis pilosula polysaccharide (CP", "PROBLEM", 0, 38], ["a bioactive component in Codonopsis pilosula", "TREATMENT", 41, 85], ["SOD", "PROBLEM", 111, 114], ["glutathione peroxidase", "TREATMENT", 119, 141], ["TNF", "TEST", 189, 192], ["hepatic injury", "PROBLEM", 217, 231], ["liver", "ANATOMY", 158, 163], ["hepatic", "ANATOMY", 217, 224], ["injury", "OBSERVATION", 225, 231]]], ["In addition, the effective chemicals in Salvia miltiorrhiza (Wang et al., 2016) and Lonicera japonica Thunb (LJT) (Guo et al., 2018) could increase activities of SOD, catalase (CAT) and GSH-Px in serum, and decrease the generation of ROS in doxorubicin (DOX)-induced acute cardiotoxicity animals and hyperlipidemia rats.", [["serum", "ANATOMY", 196, 201], ["Salvia miltiorrhiza", "CHEMICAL", 40, 59], ["GSH", "CHEMICAL", 186, 189], ["ROS", "CHEMICAL", 234, 237], ["doxorubicin", "CHEMICAL", 241, 252], ["DOX", "CHEMICAL", 254, 257], ["cardiotoxicity", "DISEASE", 273, 287], ["hyperlipidemia", "DISEASE", 300, 314], ["GSH", "CHEMICAL", 186, 189], ["doxorubicin", "CHEMICAL", 241, 252], ["DOX", "CHEMICAL", 254, 257], ["Salvia miltiorrhiza", "ORGANISM", 40, 59], ["Lonicera japonica", "ORGANISM", 84, 101], ["Thunb", "ORGANISM", 102, 107], ["SOD", "SIMPLE_CHEMICAL", 162, 165], ["catalase", "GENE_OR_GENE_PRODUCT", 167, 175], ["CAT", "GENE_OR_GENE_PRODUCT", 177, 180], ["GSH-Px", "GENE_OR_GENE_PRODUCT", 186, 192], ["serum", "ORGANISM_SUBSTANCE", 196, 201], ["ROS", "SIMPLE_CHEMICAL", 234, 237], ["doxorubicin", "SIMPLE_CHEMICAL", 241, 252], ["DOX", "SIMPLE_CHEMICAL", 254, 257], ["rats", "ORGANISM", 315, 319], ["SOD", "PROTEIN", 162, 165], ["catalase", "PROTEIN", 167, 175], ["CAT", "PROTEIN", 177, 180], ["Salvia miltiorrhiza", "SPECIES", 40, 59], ["Lonicera japonica", "SPECIES", 84, 101], ["rats", "SPECIES", 315, 319], ["Salvia miltiorrhiza", "SPECIES", 40, 59], ["Lonicera japonica", "SPECIES", 84, 101], ["Lonicera japonica Thunb", "TREATMENT", 84, 107], ["GSH", "TEST", 186, 189], ["Px in serum", "TEST", 190, 201], ["doxorubicin (DOX)", "TREATMENT", 241, 258], ["acute cardiotoxicity animals", "PROBLEM", 267, 295], ["hyperlipidemia rats", "PROBLEM", 300, 319], ["effective", "OBSERVATION_MODIFIER", 17, 26], ["Salvia miltiorrhiza", "ANATOMY", 40, 59], ["acute", "OBSERVATION_MODIFIER", 267, 272], ["cardiotoxicity", "OBSERVATION", 273, 287], ["hyperlipidemia", "OBSERVATION", 300, 314]]], ["In brief, TCM may improve organ injury by activating the activity of antioxidant enzymes and inhibiting oxidative stress caused by various inducers.Antioxidant effect of TCM ::: Mechanisms of TCM function in treating COVID-19Furthermore, pretreatment with Tan IIA induced the nuclear accumulation of Nrf2 and triggered the expression of its downstream gene heme oxygenase-1 (HO-1) and NADPH dehydrogenase quinone-1 (NQO-1) in both mice cardiac tissue and H9c2 cells (Guo et al., 2018).", [["organ", "ANATOMY", 26, 31], ["nuclear", "ANATOMY", 276, 283], ["cardiac tissue", "ANATOMY", 436, 450], ["H9c2 cells", "ANATOMY", 455, 465], ["TCM", "CHEMICAL", 10, 13], ["organ injury", "DISEASE", 26, 38], ["COVID-19Furthermore", "CHEMICAL", 217, 236], ["Tan IIA", "CHEMICAL", 256, 263], ["COVID-19Furthermore", "CHEMICAL", 217, 236], ["NADPH", "CHEMICAL", 385, 390], ["quinone", "CHEMICAL", 405, 412], ["NQO-1", "CHEMICAL", 416, 421], ["organ", "ORGAN", 26, 31], ["COVID-19Furthermore", "SIMPLE_CHEMICAL", 217, 236], ["Tan IIA", "GENE_OR_GENE_PRODUCT", 256, 263], ["nuclear", "CELLULAR_COMPONENT", 276, 283], ["Nrf2", "GENE_OR_GENE_PRODUCT", 300, 304], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 357, 373], ["HO-1", "GENE_OR_GENE_PRODUCT", 375, 379], ["NADPH dehydrogenase quinone-1", "GENE_OR_GENE_PRODUCT", 385, 414], ["NQO-1", "GENE_OR_GENE_PRODUCT", 416, 421], ["mice", "ORGANISM", 431, 435], ["cardiac tissue", "CELL", 436, 450], ["H9c2 cells", "CELL", 455, 465], ["antioxidant enzymes", "PROTEIN", 69, 88], ["Tan IIA", "PROTEIN", 256, 263], ["Nrf2", "PROTEIN", 300, 304], ["heme oxygenase-1 (HO-1", "PROTEIN", 357, 379], ["NADPH dehydrogenase quinone-1 (NQO-1", "PROTEIN", 385, 421], ["H9c2 cells", "CELL_LINE", 455, 465], ["mice", "SPECIES", 431, 435], ["mice", "SPECIES", 431, 435], ["organ injury", "PROBLEM", 26, 38], ["antioxidant enzymes", "TEST", 69, 88], ["inhibiting oxidative stress", "PROBLEM", 93, 120], ["TCM function", "PROBLEM", 192, 204], ["COVID", "TEST", 217, 222], ["Tan IIA", "TREATMENT", 256, 263], ["the nuclear accumulation of Nrf2", "PROBLEM", 272, 304], ["heme oxygenase", "TEST", 357, 371], ["HO", "TEST", 375, 377], ["NADPH dehydrogenase quinone", "TEST", 385, 412], ["injury", "OBSERVATION", 32, 38], ["TCM function", "OBSERVATION", 192, 204], ["cardiac tissue", "ANATOMY", 436, 450], ["H9c2 cells", "ANATOMY", 455, 465]]], ["Nrf2/HO-1 signaling was also affected by the water extract of Forsythiae Fructus which suppressed inflammation and disrupted inflammatory signaling cascade (Lee et al., 2018).", [["Forsythiae Fructus", "CHEMICAL", 62, 80], ["inflammation", "DISEASE", 98, 110], ["Nrf2", "GENE_OR_GENE_PRODUCT", 0, 4], ["HO-1", "GENE_OR_GENE_PRODUCT", 5, 9], ["Forsythiae Fructus", "ORGANISM", 62, 80], ["Nrf2", "PROTEIN", 0, 4], ["HO", "PROTEIN", 5, 7], ["Nrf2/HO", "TEST", 0, 7], ["Forsythiae Fructus", "PROBLEM", 62, 80], ["inflammation", "PROBLEM", 98, 110], ["disrupted inflammatory signaling cascade", "PROBLEM", 115, 155], ["inflammation", "OBSERVATION", 98, 110], ["inflammatory", "OBSERVATION_MODIFIER", 125, 137]]], ["Baicalin protected against LPS-induced severe lung injury by activating an antioxidant system and reducing both the number of inflammatory cells and expression of mediators via the Nrf2/HO-1 signaling pathway (Meng et al., 2019).", [["lung", "ANATOMY", 46, 50], ["inflammatory cells", "ANATOMY", 126, 144], ["Baicalin", "CHEMICAL", 0, 8], ["LPS", "CHEMICAL", 27, 30], ["lung injury", "DISEASE", 46, 57], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["LPS", "SIMPLE_CHEMICAL", 27, 30], ["lung", "ORGAN", 46, 50], ["inflammatory cells", "CELL", 126, 144], ["Nrf2", "GENE_OR_GENE_PRODUCT", 181, 185], ["HO-1", "GENE_OR_GENE_PRODUCT", 186, 190], ["inflammatory cells", "CELL_TYPE", 126, 144], ["Nrf2", "PROTEIN", 181, 185], ["HO", "PROTEIN", 186, 188], ["Baicalin", "TREATMENT", 0, 8], ["LPS", "TREATMENT", 27, 30], ["severe lung injury", "PROBLEM", 39, 57], ["an antioxidant system", "TREATMENT", 72, 93], ["inflammatory cells", "PROBLEM", 126, 144], ["against LPS", "OBSERVATION_MODIFIER", 19, 30], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["lung", "ANATOMY", 46, 50], ["injury", "OBSERVATION", 51, 57], ["inflammatory cells", "OBSERVATION", 126, 144]]], ["Moreover, it exerted beneficial effect on lung function as shown by anti-airway remodeling through regulating the release of proinflammatory cytokine in long-term cigarette smoke-induced chronic obstructive pulmonary disease model (Wang et al., 2018).", [["lung", "ANATOMY", 42, 46], ["pulmonary", "ANATOMY", 207, 216], ["smoke", "CHEMICAL", 173, 178], ["chronic obstructive pulmonary disease", "DISEASE", 187, 224], ["lung", "ORGAN", 42, 46], ["cigarette", "ORGANISM", 163, 172], ["pulmonary", "ORGAN", 207, 216], ["proinflammatory cytokine", "PROTEIN", 125, 149], ["lung function", "TEST", 42, 55], ["anti-airway remodeling", "PROBLEM", 68, 90], ["proinflammatory cytokine", "PROBLEM", 125, 149], ["chronic obstructive pulmonary disease model", "PROBLEM", 187, 230], ["beneficial", "OBSERVATION_MODIFIER", 21, 31], ["lung", "ANATOMY", 42, 46], ["proinflammatory cytokine", "OBSERVATION", 125, 149], ["long-term", "OBSERVATION_MODIFIER", 153, 162], ["chronic", "OBSERVATION_MODIFIER", 187, 194], ["obstructive", "OBSERVATION_MODIFIER", 195, 206], ["pulmonary", "ANATOMY", 207, 216], ["disease", "OBSERVATION", 217, 224]]], ["Neochlorogenic acid isolated from LJT, an activator of AMPK/Nrf2 signaling, prevented excessive macrophage-mediated responses associated with acute and chronic inflammatory disorders (Park et al., 2018).", [["macrophage", "ANATOMY", 96, 106], ["Neochlorogenic acid", "CHEMICAL", 0, 19], ["LJT", "CHEMICAL", 34, 37], ["Neochlorogenic acid", "CHEMICAL", 0, 19], ["Neochlorogenic acid", "SIMPLE_CHEMICAL", 0, 19], ["LJT", "SIMPLE_CHEMICAL", 34, 37], ["AMPK", "GENE_OR_GENE_PRODUCT", 55, 59], ["Nrf2", "GENE_OR_GENE_PRODUCT", 60, 64], ["macrophage", "CELL", 96, 106], ["AMPK", "PROTEIN", 55, 59], ["Nrf2", "PROTEIN", 60, 64], ["Neochlorogenic acid", "TEST", 0, 19], ["Nrf2 signaling", "PROBLEM", 60, 74], ["excessive macrophage", "PROBLEM", 86, 106], ["acute and chronic inflammatory disorders", "PROBLEM", 142, 182], ["Nrf2 signaling", "OBSERVATION", 60, 74], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["chronic", "OBSERVATION_MODIFIER", 152, 159], ["inflammatory", "OBSERVATION", 160, 172]]], ["Thus, previous studies revealed that the Nrf2-mediated HO-1 signaling pathway might be a crucial antioxidant target.", [["Nrf2", "GENE_OR_GENE_PRODUCT", 41, 45], ["HO-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["Nrf2", "PROTEIN", 41, 45], ["HO", "PROTEIN", 55, 57], ["previous studies", "TEST", 6, 22], ["the Nrf2", "TEST", 37, 45]]], ["Collectively, activation of the antioxidant enzymes activity and Nrf2/HO-1 signaling pathway is potentially recognized as one of the anti-oxidant mechanisms involved in the treatment of COVID-19 using TCM.Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19A study on clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan (China) indicated that among the 710 patients with COVID-19, most patients had organ function damages, including 35 with acute respiratory distress syndrome (ARDS), 15 with acute kidney injury, 12 with cardiac injury, and 15 with liver dysfunction (Yang et al., 2020b).", [["organ", "ANATOMY", 466, 471], ["respiratory", "ANATOMY", 514, 525], ["kidney", "ANATOMY", 566, 572], ["cardiac", "ANATOMY", 589, 596], ["liver", "ANATOMY", 617, 622], ["COVID-19", "CHEMICAL", 186, 194], ["COVID-19A", "CHEMICAL", 277, 286], ["critically ill", "DISEASE", 328, 342], ["SARS", "DISEASE", 357, 361], ["pneumonia", "DISEASE", 368, 377], ["organ function damages", "DISEASE", 466, 488], ["acute respiratory distress syndrome", "DISEASE", 508, 543], ["ARDS", "DISEASE", 545, 549], ["acute kidney injury", "DISEASE", 560, 579], ["cardiac injury", "DISEASE", 589, 603], ["liver dysfunction", "DISEASE", 617, 634], ["COVID-19", "CHEMICAL", 186, 194], ["Nrf2", "GENE_OR_GENE_PRODUCT", 65, 69], ["HO-1", "GENE_OR_GENE_PRODUCT", 70, 74], ["patients", "ORGANISM", 343, 351], ["SARS-CoV-2", "ORGANISM", 357, 367], ["patients", "ORGANISM", 424, 432], ["patients", "ORGANISM", 453, 461], ["organ", "ORGAN", 466, 471], ["kidney", "ORGAN", 566, 572], ["cardiac", "ORGAN", 589, 596], ["liver", "ORGAN", 617, 622], ["antioxidant enzymes", "PROTEIN", 32, 51], ["Nrf2", "PROTEIN", 65, 69], ["HO", "PROTEIN", 70, 72], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 424, 432], ["patients", "SPECIES", 453, 461], ["the antioxidant enzymes activity", "TEST", 28, 60], ["Nrf2/HO", "TEST", 65, 72], ["the anti-oxidant mechanisms", "TREATMENT", 129, 156], ["COVID", "TEST", 186, 191], ["TCM function", "PROBLEM", 252, 264], ["COVID", "TEST", 277, 282], ["19A study", "TEST", 283, 292], ["critically ill", "PROBLEM", 328, 342], ["SARS", "PROBLEM", 357, 361], ["CoV", "PROBLEM", 362, 365], ["pneumonia", "PROBLEM", 368, 377], ["COVID", "TEST", 438, 443], ["organ function damages", "PROBLEM", 466, 488], ["acute respiratory distress syndrome", "PROBLEM", 508, 543], ["ARDS)", "PROBLEM", 545, 550], ["acute kidney injury", "PROBLEM", 560, 579], ["cardiac injury", "PROBLEM", 589, 603], ["liver dysfunction", "PROBLEM", 617, 634], ["pneumonia", "OBSERVATION", 368, 377], ["acute", "OBSERVATION_MODIFIER", 508, 513], ["respiratory", "ANATOMY", 514, 525], ["distress", "OBSERVATION", 526, 534], ["acute", "OBSERVATION_MODIFIER", 560, 565], ["kidney", "ANATOMY", 566, 572], ["injury", "OBSERVATION", 573, 579], ["cardiac", "ANATOMY", 589, 596], ["injury", "OBSERVATION", 597, 603], ["liver", "ANATOMY", 617, 622], ["dysfunction", "OBSERVATION", 623, 634]]], ["Recently multiple lines of evidences pointed to the idea that renal impairment was common in COVID-19 patients, a condition that might lead to multi-organ failure and death eventually (Li et al., 2019b).", [["renal", "ANATOMY", 62, 67], ["multi-organ", "ANATOMY", 143, 154], ["renal impairment", "DISEASE", 62, 78], ["multi-organ failure", "DISEASE", 143, 162], ["death", "DISEASE", 167, 172], ["renal", "ORGAN", 62, 67], ["patients", "ORGANISM", 102, 110], ["multi-organ", "ORGAN", 143, 154], ["patients", "SPECIES", 102, 110], ["renal impairment", "PROBLEM", 62, 78], ["multi-organ failure", "PROBLEM", 143, 162], ["death", "PROBLEM", 167, 172], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["lines", "OBSERVATION", 18, 23], ["renal", "ANATOMY", 62, 67], ["impairment", "OBSERVATION", 68, 78], ["multi-organ", "ANATOMY", 143, 154], ["failure", "OBSERVATION", 155, 162]]], ["Studies have shown that the progression of various diseases such as ARDS, heart failure, chronic kidney disease and liver injury are closely related to apoptosis.Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19The apoptosis of pulmonary capillary endothelial cells and alveolar epithelial cells worsened the structural integrity and function of the alveolar-capillary barrier, and eventually resulted in pneumonia and ARDS (Hu, 2018).", [["heart", "ANATOMY", 74, 79], ["kidney", "ANATOMY", 97, 103], ["liver", "ANATOMY", 116, 121], ["pulmonary capillary endothelial cells", "ANATOMY", 259, 296], ["alveolar epithelial cells", "ANATOMY", 301, 326], ["alveolar-capillary barrier", "ANATOMY", 381, 407], ["ARDS", "DISEASE", 68, 72], ["heart failure", "DISEASE", 74, 87], ["chronic kidney disease", "DISEASE", 89, 111], ["liver injury", "DISEASE", 116, 128], ["pneumonia", "DISEASE", 436, 445], ["ARDS", "DISEASE", 450, 454], ["heart", "ORGAN", 74, 79], ["kidney", "ORGAN", 97, 103], ["liver", "ORGAN", 116, 121], ["pulmonary capillary endothelial cells", "CELL", 259, 296], ["alveolar epithelial cells", "CELL", 301, 326], ["alveolar-capillary barrier", "TISSUE", 381, 407], ["pulmonary capillary endothelial cells", "CELL_TYPE", 259, 296], ["alveolar epithelial cells", "CELL_TYPE", 301, 326], ["Studies", "TEST", 0, 7], ["various diseases", "PROBLEM", 43, 59], ["ARDS", "PROBLEM", 68, 72], ["heart failure", "PROBLEM", 74, 87], ["chronic kidney disease", "PROBLEM", 89, 111], ["liver injury", "PROBLEM", 116, 128], ["apoptosis", "PROBLEM", 152, 161], ["TCM function", "PROBLEM", 209, 221], ["COVID", "TEST", 234, 239], ["pulmonary capillary endothelial cells", "TEST", 259, 296], ["alveolar epithelial cells", "PROBLEM", 301, 326], ["pneumonia", "PROBLEM", 436, 445], ["ARDS", "PROBLEM", 450, 454], ["progression", "OBSERVATION_MODIFIER", 28, 39], ["various", "OBSERVATION_MODIFIER", 43, 50], ["diseases", "OBSERVATION", 51, 59], ["ARDS", "OBSERVATION", 68, 72], ["heart", "ANATOMY", 74, 79], ["failure", "OBSERVATION", 80, 87], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["kidney", "ANATOMY", 97, 103], ["disease", "OBSERVATION", 104, 111], ["liver", "ANATOMY", 116, 121], ["injury", "OBSERVATION", 122, 128], ["TCM function", "OBSERVATION", 209, 221], ["pulmonary capillary", "ANATOMY", 259, 278], ["endothelial cells", "OBSERVATION", 279, 296], ["alveolar", "ANATOMY_MODIFIER", 301, 309], ["epithelial cells", "OBSERVATION", 310, 326], ["structural", "OBSERVATION_MODIFIER", 340, 350], ["integrity", "OBSERVATION_MODIFIER", 351, 360], ["alveolar", "ANATOMY_MODIFIER", 381, 389], ["capillary barrier", "OBSERVATION", 390, 407], ["pneumonia", "OBSERVATION", 436, 445], ["ARDS", "OBSERVATION", 450, 454]]], ["Apoptosis was also in the pathogenesis of heart failure (Sabbah and Sharov, 1998).", [["heart", "ANATOMY", 42, 47], ["heart failure", "DISEASE", 42, 55], ["heart", "ORGAN", 42, 47], ["Apoptosis", "PROBLEM", 0, 9], ["heart failure", "PROBLEM", 42, 55], ["heart", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55]]], ["Apoptosis of podocytes could lead to proteinuria and the development and progression of glomerulosclerosis and renal fibrosis (Cao et al., 2016; Chuang et al., 2011).", [["podocytes", "ANATOMY", 13, 22], ["renal", "ANATOMY", 111, 116], ["proteinuria", "DISEASE", 37, 48], ["glomerulosclerosis", "DISEASE", 88, 106], ["renal fibrosis", "DISEASE", 111, 125], ["podocytes", "CELL", 13, 22], ["glomerulosclerosis", "PATHOLOGICAL_FORMATION", 88, 106], ["renal", "ORGAN", 111, 116], ["podocytes", "CELL_TYPE", 13, 22], ["Apoptosis of podocytes", "PROBLEM", 0, 22], ["proteinuria", "PROBLEM", 37, 48], ["glomerulosclerosis", "PROBLEM", 88, 106], ["renal fibrosis", "PROBLEM", 111, 125], ["podocytes", "ANATOMY", 13, 22], ["could lead to", "UNCERTAINTY", 23, 36], ["proteinuria", "OBSERVATION", 37, 48], ["progression", "OBSERVATION_MODIFIER", 73, 84], ["glomerulosclerosis", "OBSERVATION", 88, 106], ["renal", "ANATOMY", 111, 116], ["fibrosis", "OBSERVATION", 117, 125]]], ["Liver injury was also associated with dysregulation of hepatocyte apoptosis (Wang, 2015).", [["Liver", "ANATOMY", 0, 5], ["hepatocyte", "ANATOMY", 55, 65], ["Liver injury", "DISEASE", 0, 12], ["Liver", "ORGAN", 0, 5], ["hepatocyte", "CELL", 55, 65], ["Liver injury", "PROBLEM", 0, 12], ["dysregulation of hepatocyte apoptosis", "PROBLEM", 38, 75], ["injury", "OBSERVATION", 6, 12], ["hepatocyte", "ANATOMY", 55, 65], ["apoptosis", "OBSERVATION", 66, 75]]], ["Current research studies have found that 3 signaling pathways (Fig. 1) are involved in apoptosis, they are the exogenous apoptosis pathway induced by death receptors, endogenous apoptosis pathway mediated by mitochondria, and endoplasmic reticulum stress (Marriott et al., 2006; Zhao et al., 2013).Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19Among the various intervention guidelines on the use of TCM issued in different Chinese regions after the spread of COVID-19, Astragalus membranaceus is recommended in 13 prevention programs with the aim to reinforce vital Qi.", [["mitochondria", "ANATOMY", 208, 220], ["endoplasmic reticulum", "ANATOMY", 226, 247], ["death", "DISEASE", 150, 155], ["COVID-19", "CHEMICAL", 494, 502], ["Astragalus membranaceus", "DISEASE", 504, 527], ["3", "GENE_OR_GENE_PRODUCT", 41, 42], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 63, 69], ["mitochondria", "CELLULAR_COMPONENT", 208, 220], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 226, 247], ["Astragalus membranaceus", "ORGANISM", 504, 527], ["death receptors", "PROTEIN", 150, 165], ["Astragalus membranaceus", "SPECIES", 504, 527], ["Astragalus membranaceus", "SPECIES", 504, 527], ["Current research studies", "TEST", 0, 24], ["apoptosis", "PROBLEM", 87, 96], ["endogenous apoptosis pathway", "PROBLEM", 167, 195], ["TCM function", "PROBLEM", 345, 357], ["COVID", "TEST", 370, 375], ["TCM", "TREATMENT", 434, 437], ["COVID", "TEST", 494, 499], ["Astragalus membranaceus", "TREATMENT", 504, 527], ["exogenous apoptosis", "OBSERVATION", 111, 130], ["endogenous apoptosis", "OBSERVATION", 167, 187], ["TCM function", "OBSERVATION", 345, 357]]], ["Scutellaria baicalensis, Magnolia officinalis, Pseudo-ginseng, and Rhodiola crenulata are also usually used in different prescriptions (Xu et al., 2020).Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19It was found that Astragalus membranaceus and its active component (Astragalus polysaccharide, AP) and compound (AS-IV) could protect against multiple-organ damages induced by apoptosis.", [["organ", "ANATOMY", 384, 389], ["Scutellaria baicalensis", "CHEMICAL", 0, 23], ["COVID-19It", "CHEMICAL", 225, 235], ["AS-IV", "CHEMICAL", 346, 351], ["multiple-organ damages", "DISEASE", 375, 397], ["COVID-19It", "CHEMICAL", 225, 235], ["Scutellaria baicalensis", "ORGANISM", 0, 23], ["Magnolia officinalis", "ORGANISM", 25, 45], ["Pseudo-ginseng", "ORGANISM", 47, 61], ["Rhodiola crenulata", "ORGANISM", 67, 85], ["COVID-19It", "SIMPLE_CHEMICAL", 225, 235], ["Astragalus membranaceus", "ORGANISM", 251, 274], ["Astragalus polysaccharide", "SIMPLE_CHEMICAL", 301, 326], ["AP", "SIMPLE_CHEMICAL", 328, 330], ["AS-IV", "GENE_OR_GENE_PRODUCT", 346, 351], ["organ", "ORGAN", 384, 389], ["Scutellaria baicalensis", "SPECIES", 0, 23], ["Magnolia officinalis", "SPECIES", 25, 45], ["Pseudo-ginseng", "SPECIES", 47, 61], ["Rhodiola crenulata", "SPECIES", 67, 85], ["Astragalus membranaceus", "SPECIES", 251, 274], ["Scutellaria baicalensis", "SPECIES", 0, 23], ["Magnolia officinalis", "SPECIES", 25, 45], ["Pseudo-ginseng", "SPECIES", 47, 61], ["Rhodiola crenulata", "SPECIES", 67, 85], ["Astragalus membranaceus", "SPECIES", 251, 274], ["Scutellaria baicalensis", "TREATMENT", 0, 23], ["Magnolia officinalis", "TREATMENT", 25, 45], ["Rhodiola crenulata", "TREATMENT", 67, 85], ["TCM function", "PROBLEM", 200, 212], ["COVID", "TEST", 225, 230], ["Astragalus membranaceus", "PROBLEM", 251, 274], ["its active component", "PROBLEM", 279, 299], ["Astragalus polysaccharide", "PROBLEM", 301, 326], ["compound (AS-IV)", "TREATMENT", 336, 352], ["multiple-organ damages", "PROBLEM", 375, 397], ["apoptosis", "PROBLEM", 409, 418], ["baicalensis", "OBSERVATION_MODIFIER", 12, 23], ["Magnolia officinalis", "OBSERVATION", 25, 45], ["TCM function", "OBSERVATION", 200, 212], ["Astragalus membranaceus", "OBSERVATION", 251, 274], ["active", "OBSERVATION_MODIFIER", 283, 289], ["component", "OBSERVATION_MODIFIER", 290, 299], ["organ", "ANATOMY", 384, 389], ["damages", "OBSERVATION", 390, 397], ["apoptosis", "OBSERVATION", 409, 418]]], ["AP could inhibit mitochondrial-mediated apoptosis and reduce cell damage by mediating the PI3K/Akt/FoxO3a signaling pathway (Lu and Yang, 2017); it could also decrease hepatocytes apoptosis caused by oxidative stress (Liu, 2018b).", [["mitochondrial", "ANATOMY", 17, 30], ["cell", "ANATOMY", 61, 65], ["hepatocytes", "ANATOMY", 168, 179], ["AP", "CHEMICAL", 0, 2], ["AP", "SIMPLE_CHEMICAL", 0, 2], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["cell", "CELL", 61, 65], ["PI3K", "GENE_OR_GENE_PRODUCT", 90, 94], ["Akt", "GENE_OR_GENE_PRODUCT", 95, 98], ["FoxO3a", "GENE_OR_GENE_PRODUCT", 99, 105], ["hepatocytes", "CELL", 168, 179], ["PI3K", "PROTEIN", 90, 94], ["Akt", "PROTEIN", 95, 98], ["FoxO3a", "PROTEIN", 99, 105], ["mitochondrial-mediated apoptosis", "PROBLEM", 17, 49], ["reduce cell damage", "PROBLEM", 54, 72], ["the PI3K", "TEST", 86, 94], ["hepatocytes apoptosis", "PROBLEM", 168, 189], ["apoptosis", "OBSERVATION", 40, 49], ["reduce cell damage", "OBSERVATION", 54, 72], ["decrease", "OBSERVATION_MODIFIER", 159, 167], ["hepatocytes apoptosis", "OBSERVATION", 168, 189]]], ["AS-IV dose-dependently inhibited the rise in apoptosis induced by oxidative stress in renal podocytes (Xiao et al., 2013), and prevented human umbilical vein endothelial cell (HUVEC) apoptosis by inhibiting Nox4 expression through the Nox4/Smad2 pathway (H2O2-induced cell apoptosis) (Ma et al., 2015; Zhang et al., 2020b).", [["renal podocytes", "ANATOMY", 86, 101], ["human umbilical vein endothelial cell", "ANATOMY", 137, 174], ["HUVEC", "ANATOMY", 176, 181], ["cell", "ANATOMY", 268, 272], ["AS-IV", "CHEMICAL", 0, 5], ["H2O2", "CHEMICAL", 255, 259], ["H2O2", "CHEMICAL", 255, 259], ["AS-IV", "SIMPLE_CHEMICAL", 0, 5], ["renal podocytes", "CELL", 86, 101], ["human umbilical vein endothelial cell", "CELL", 137, 174], ["HUVEC", "CELL", 176, 181], ["Nox4", "GENE_OR_GENE_PRODUCT", 207, 211], ["Nox4", "GENE_OR_GENE_PRODUCT", 235, 239], ["Smad2", "GENE_OR_GENE_PRODUCT", 240, 245], ["H2O2", "SIMPLE_CHEMICAL", 255, 259], ["cell", "CELL", 268, 272], ["renal podocytes", "CELL_TYPE", 86, 101], ["human umbilical vein endothelial cell", "CELL_TYPE", 137, 174], ["HUVEC", "CELL_LINE", 176, 181], ["Nox4", "PROTEIN", 207, 211], ["Nox4", "PROTEIN", 235, 239], ["Smad2", "PROTEIN", 240, 245], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["apoptosis", "PROBLEM", 45, 54], ["oxidative stress in renal podocytes", "PROBLEM", 66, 101], ["human umbilical vein endothelial cell (HUVEC) apoptosis", "TREATMENT", 137, 192], ["the Nox4/Smad2 pathway", "TREATMENT", 231, 253], ["H2O2-induced cell apoptosis", "TREATMENT", 255, 282], ["apoptosis", "OBSERVATION", 45, 54], ["oxidative stress", "OBSERVATION", 66, 82], ["renal podocytes", "ANATOMY", 86, 101], ["umbilical vein", "ANATOMY", 143, 157], ["endothelial cell", "OBSERVATION", 158, 174], ["cell apoptosis", "OBSERVATION", 268, 282]]], ["Baicalein protected cardiomyocytes by decreasing oxidative stress, myocardial inflammatory responses and apoptosis associated with LPS-induced sepsis (Lee et al., 2011).", [["cardiomyocytes", "ANATOMY", 20, 34], ["myocardial", "ANATOMY", 67, 77], ["Baicalein", "CHEMICAL", 0, 9], ["LPS", "CHEMICAL", 131, 134], ["sepsis", "DISEASE", 143, 149], ["Baicalein", "CHEMICAL", 0, 9], ["Baicalein", "SIMPLE_CHEMICAL", 0, 9], ["cardiomyocytes", "CELL", 20, 34], ["myocardial", "MULTI-TISSUE_STRUCTURE", 67, 77], ["LPS", "SIMPLE_CHEMICAL", 131, 134], ["cardiomyocytes", "CELL_TYPE", 20, 34], ["Baicalein protected cardiomyocytes", "PROBLEM", 0, 34], ["decreasing oxidative stress", "PROBLEM", 38, 65], ["myocardial inflammatory responses", "PROBLEM", 67, 100], ["apoptosis", "PROBLEM", 105, 114], ["LPS", "PROBLEM", 131, 134], ["sepsis", "PROBLEM", 143, 149], ["cardiomyocytes", "ANATOMY", 20, 34], ["decreasing", "OBSERVATION_MODIFIER", 38, 48], ["oxidative stress", "OBSERVATION", 49, 65], ["myocardial", "ANATOMY", 67, 77], ["inflammatory", "OBSERVATION", 78, 90], ["sepsis", "OBSERVATION", 143, 149]]], ["It could also stabilize MARCH5 expression by upregulating expression of KLF4, and in a sequence promote mitochondrial fusion, stabilize mitophagy and reduce apoptosis, suggesting that baicalein could significantly attenuate apoptosis induced by oxidative damage (Li et al., 2020a).", [["mitochondrial", "ANATOMY", 104, 117], ["baicalein", "CHEMICAL", 184, 193], ["baicalein", "CHEMICAL", 184, 193], ["MARCH5", "GENE_OR_GENE_PRODUCT", 24, 30], ["KLF4", "GENE_OR_GENE_PRODUCT", 72, 76], ["mitochondrial", "CELLULAR_COMPONENT", 104, 117], ["baicalein", "SIMPLE_CHEMICAL", 184, 193], ["MARCH5", "PROTEIN", 24, 30], ["KLF4", "PROTEIN", 72, 76], ["KLF4", "TREATMENT", 72, 76], ["mitochondrial fusion", "TREATMENT", 104, 124], ["mitophagy", "PROBLEM", 136, 145], ["apoptosis", "PROBLEM", 157, 166], ["oxidative damage", "PROBLEM", 245, 261], ["mitochondrial fusion", "OBSERVATION", 104, 124]]], ["Additionally, studies showed that triptriolide exerted its protective effect via inhibiting apoptosis and restoring of survivor, on podocytes with exposure to puromycin aminonucleoside, which could induce apoptosis by increasing protein expression of caspase-3 and Bax (Yang et al., 2019).", [["podocytes", "ANATOMY", 132, 141], ["triptriolide", "CHEMICAL", 34, 46], ["puromycin aminonucleoside", "CHEMICAL", 159, 184], ["triptriolide", "CHEMICAL", 34, 46], ["puromycin aminonucleoside", "CHEMICAL", 159, 184], ["triptriolide", "SIMPLE_CHEMICAL", 34, 46], ["podocytes", "CELL", 132, 141], ["puromycin aminonucleoside", "SIMPLE_CHEMICAL", 159, 184], ["caspase-3", "GENE_OR_GENE_PRODUCT", 251, 260], ["Bax", "GENE_OR_GENE_PRODUCT", 265, 268], ["podocytes", "CELL_TYPE", 132, 141], ["caspase-3", "PROTEIN", 251, 260], ["Bax", "PROTEIN", 265, 268], ["studies", "TEST", 14, 21], ["triptriolide", "TREATMENT", 34, 46], ["inhibiting apoptosis", "PROBLEM", 81, 101], ["puromycin aminonucleoside", "TREATMENT", 159, 184], ["apoptosis", "PROBLEM", 205, 214], ["caspase", "TEST", 251, 258]]], ["Magnolol, a purified single compound from Magnolia officinalis, showed anti-apoptotic effect by protecting the liver from warm ischemia-reperfusion injury through upregulation of mRNA expression of the anti-apoptotic factor Bcl-XL and suppression of gene expression of Bcl-Xs (Jawan et al., 2003).", [["liver", "ANATOMY", 111, 116], ["Magnolol", "CHEMICAL", 0, 8], ["Magnolol", "CHEMICAL", 0, 8], ["Magnolol", "SIMPLE_CHEMICAL", 0, 8], ["Magnolia officinalis", "ORGANISM", 42, 62], ["liver", "ORGAN", 111, 116], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 224, 230], ["Bcl-Xs", "GENE_OR_GENE_PRODUCT", 269, 275], ["anti-apoptotic factor", "PROTEIN", 202, 223], ["Bcl", "PROTEIN", 224, 227], ["Bcl", "PROTEIN", 269, 272], ["Magnolia officinalis", "SPECIES", 42, 62], ["Magnolia officinalis", "SPECIES", 42, 62], ["Magnolol", "TREATMENT", 0, 8], ["a purified single compound from Magnolia officinalis", "PROBLEM", 10, 62], ["anti-apoptotic effect", "PROBLEM", 71, 92], ["warm ischemia-reperfusion injury", "PROBLEM", 122, 154], ["the anti-apoptotic factor Bcl", "TREATMENT", 198, 227], ["Bcl", "TEST", 269, 272], ["Magnolia officinalis", "OBSERVATION", 42, 62], ["anti-apoptotic effect", "OBSERVATION", 71, 92], ["liver", "ANATOMY", 111, 116], ["warm ischemia-reperfusion injury", "OBSERVATION", 122, 154]]], ["Taken together, the active ingredients from TCM recommended in the Protocol could inhibit mitochondrial pathway-involved apoptosis.Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19AS-IV could suppress apoptotic and inflammatory responses in HUVECs upon to the stimulation with high glucose by inhibiting the JNK signaling pathway (You et al., 2019).", [["mitochondrial", "ANATOMY", 90, 103], ["HUVECs", "ANATOMY", 272, 278], ["TCM", "CHEMICAL", 44, 47], ["COVID-19AS-IV", "CHEMICAL", 203, 216], ["glucose", "CHEMICAL", 313, 320], ["glucose", "CHEMICAL", 313, 320], ["mitochondrial", "CELLULAR_COMPONENT", 90, 103], ["COVID-19AS-IV", "SIMPLE_CHEMICAL", 203, 216], ["HUVECs", "CELL", 272, 278], ["glucose", "SIMPLE_CHEMICAL", 313, 320], ["JNK", "GENE_OR_GENE_PRODUCT", 339, 342], ["HUVECs", "CELL_LINE", 272, 278], ["JNK", "PROTEIN", 339, 342], ["the Protocol", "TREATMENT", 63, 75], ["mitochondrial pathway", "PROBLEM", 90, 111], ["apoptosis", "PROBLEM", 121, 130], ["TCM function", "PROBLEM", 178, 190], ["COVID", "TEST", 203, 208], ["IV", "TREATMENT", 214, 216], ["apoptotic", "PROBLEM", 232, 241], ["inflammatory responses", "PROBLEM", 246, 268], ["high glucose", "PROBLEM", 308, 320], ["active", "OBSERVATION_MODIFIER", 20, 26], ["TCM function", "OBSERVATION", 178, 190], ["inflammatory", "OBSERVATION", 246, 258]]], ["Xuesaitong (XST), a TCM pharmaceutic preparation consisting of total saponins from the root of Pseudo-ginseng, could effectively treat patients with cerebrovascular diseases by inhibiting the overload of Ca2+ in brain cells, stabilizing cell membrane and protecting the brain from ischemia/reperfusion damage (Zhong et al., 2005).", [["root", "ANATOMY", 87, 91], ["cerebrovascular", "ANATOMY", 149, 164], ["brain cells", "ANATOMY", 212, 223], ["cell membrane", "ANATOMY", 237, 250], ["brain", "ANATOMY", 270, 275], ["Xuesaitong", "CHEMICAL", 0, 10], ["XST", "CHEMICAL", 12, 15], ["Pseudo-ginseng", "CHEMICAL", 95, 109], ["cerebrovascular diseases", "DISEASE", 149, 173], ["Ca2", "CHEMICAL", 204, 207], ["ischemia", "DISEASE", 281, 289], ["saponins", "CHEMICAL", 69, 77], ["Ca2+", "CHEMICAL", 204, 208], ["Xuesaitong", "SIMPLE_CHEMICAL", 0, 10], ["saponins", "SIMPLE_CHEMICAL", 69, 77], ["root", "ORGANISM_SUBDIVISION", 87, 91], ["Pseudo-ginseng", "ORGANISM", 95, 109], ["patients", "ORGANISM", 135, 143], ["cerebrovascular", "ANATOMICAL_SYSTEM", 149, 164], ["Ca2+", "SIMPLE_CHEMICAL", 204, 208], ["brain cells", "CELL", 212, 223], ["cell membrane", "CELLULAR_COMPONENT", 237, 250], ["brain", "ORGAN", 270, 275], ["Ca2", "PROTEIN", 204, 207], ["brain cells", "CELL_TYPE", 212, 223], ["Pseudo-ginseng", "SPECIES", 95, 109], ["patients", "SPECIES", 135, 143], ["Pseudo-ginseng", "SPECIES", 95, 109], ["a TCM pharmaceutic preparation", "TREATMENT", 18, 48], ["total saponins", "TREATMENT", 63, 77], ["cerebrovascular diseases", "PROBLEM", 149, 173], ["the overload", "PROBLEM", 188, 200], ["Ca2+ in brain cells", "PROBLEM", 204, 223], ["stabilizing cell membrane", "PROBLEM", 225, 250], ["ischemia", "PROBLEM", 281, 289], ["reperfusion damage", "PROBLEM", 290, 308], ["cerebrovascular", "ANATOMY", 149, 164], ["diseases", "OBSERVATION", 165, 173], ["overload", "OBSERVATION", 192, 200], ["brain cells", "ANATOMY", 212, 223], ["stabilizing cell membrane", "OBSERVATION", 225, 250], ["brain", "ANATOMY", 270, 275], ["ischemia", "OBSERVATION", 281, 289], ["reperfusion damage", "OBSERVATION", 290, 308]]], ["XST attenuated ischemic stroke in mice through regulating microglial phenotypes and decreasing apoptosis of neuronal cells (Li et al., 2019a).", [["microglial", "ANATOMY", 58, 68], ["neuronal cells", "ANATOMY", 108, 122], ["XST", "CHEMICAL", 0, 3], ["ischemic stroke", "DISEASE", 15, 30], ["XST", "SIMPLE_CHEMICAL", 0, 3], ["mice", "ORGANISM", 34, 38], ["microglial", "CELL", 58, 68], ["neuronal cells", "CELL", 108, 122], ["neuronal cells", "CELL_TYPE", 108, 122], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["XST attenuated ischemic stroke", "PROBLEM", 0, 30], ["microglial phenotypes", "PROBLEM", 58, 79], ["decreasing apoptosis of neuronal cells", "PROBLEM", 84, 122], ["attenuated", "OBSERVATION_MODIFIER", 4, 14], ["ischemic", "OBSERVATION_MODIFIER", 15, 23], ["stroke", "OBSERVATION", 24, 30], ["microglial phenotypes", "OBSERVATION", 58, 79], ["decreasing", "OBSERVATION_MODIFIER", 84, 94], ["apoptosis", "OBSERVATION_MODIFIER", 95, 104], ["neuronal cells", "OBSERVATION", 108, 122]]], ["Moreover, treatment with XST ameliorated podocyte apoptosis in diabetic rats partly through modulation of PTEN-PDK1-Akt-mTOR pathway and Nox4 expression, which might point to a novel natural therapeutic way to cure diabetic nephropathy (Xue et al., 2020).", [["podocyte", "ANATOMY", 41, 49], ["XST", "CHEMICAL", 25, 28], ["diabetic", "DISEASE", 63, 71], ["diabetic nephropathy", "DISEASE", 215, 235], ["XST", "CHEMICAL", 25, 28], ["XST", "SIMPLE_CHEMICAL", 25, 28], ["podocyte", "CELL", 41, 49], ["rats", "ORGANISM", 72, 76], ["PTEN", "GENE_OR_GENE_PRODUCT", 106, 110], ["PDK1", "GENE_OR_GENE_PRODUCT", 111, 115], ["Akt", "GENE_OR_GENE_PRODUCT", 116, 119], ["mTOR", "GENE_OR_GENE_PRODUCT", 120, 124], ["Nox4", "GENE_OR_GENE_PRODUCT", 137, 141], ["PTEN", "PROTEIN", 106, 110], ["PDK1", "PROTEIN", 111, 115], ["Akt", "PROTEIN", 116, 119], ["mTOR", "PROTEIN", 120, 124], ["Nox4", "PROTEIN", 137, 141], ["rats", "SPECIES", 72, 76], ["treatment", "TREATMENT", 10, 19], ["XST ameliorated podocyte apoptosis in diabetic rats", "TREATMENT", 25, 76], ["PTEN", "TEST", 106, 110], ["PDK1", "TEST", 111, 115], ["Nox4 expression", "PROBLEM", 137, 152], ["diabetic nephropathy", "PROBLEM", 215, 235], ["podocyte apoptosis", "OBSERVATION", 41, 59], ["nephropathy", "OBSERVATION", 224, 235]]], ["Thus, inhibition of endoplasmic reticulum stress is one of the mechanisms by which TCM exerts its anti-apoptosis actions.Anti-apoptotic effect of TCM ::: Mechanisms of TCM function in treating COVID-19Study indicated that aging induced by D-galactose could trigger marked neuronal apoptosis through activation of extrinsic-dependent apoptotic pathways.", [["endoplasmic reticulum", "ANATOMY", 20, 41], ["neuronal", "ANATOMY", 272, 280], ["TCM", "CHEMICAL", 83, 86], ["COVID-19Study", "CHEMICAL", 193, 206], ["D-galactose", "CHEMICAL", 239, 250], ["COVID-19Study", "CHEMICAL", 193, 206], ["D-galactose", "CHEMICAL", 239, 250], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 20, 41], ["D-galactose", "SIMPLE_CHEMICAL", 239, 250], ["neuronal", "CELL", 272, 280], ["endoplasmic reticulum stress", "PROBLEM", 20, 48], ["TCM function", "PROBLEM", 168, 180], ["COVID", "TEST", 193, 198], ["marked neuronal apoptosis", "PROBLEM", 265, 290], ["endoplasmic reticulum stress", "OBSERVATION", 20, 48], ["TCM function", "OBSERVATION", 168, 180], ["marked", "OBSERVATION_MODIFIER", 265, 271], ["neuronal apoptosis", "OBSERVATION", 272, 290], ["dependent", "OBSERVATION_MODIFIER", 323, 332], ["apoptotic pathways", "OBSERVATION", 333, 351]]], ["Intriguingly, Rhodiola crenulata protected against neurotoxicities which could stimulate the apoptotic pathways in aging brain (Chen et al., 2020a).", [["brain", "ANATOMY", 121, 126], ["Rhodiola", "CHEMICAL", 14, 22], ["Rhodiola crenulata", "ORGANISM", 14, 32], ["brain", "ORGAN", 121, 126], ["Rhodiola crenulata", "SPECIES", 14, 32], ["Rhodiola crenulata", "SPECIES", 14, 32], ["neurotoxicities", "PROBLEM", 51, 66], ["brain", "ANATOMY", 121, 126]]], ["Furthermore, Rhodiola polysaccharide could reduce the apoptosis of bone marrow cells and promote the recovery of its hemopoietic function by affecting Fas/FasL-caspase-3 apoptosis signal pathway (Li et al., 2008a), which was also involved in apoptosis associated with jaundice hepatitis.", [["bone marrow cells", "ANATOMY", 67, 84], ["hemopoietic", "ANATOMY", 117, 128], ["Rhodiola polysaccharide", "CHEMICAL", 13, 36], ["jaundice hepatitis", "DISEASE", 268, 286], ["Rhodiola polysaccharide", "SIMPLE_CHEMICAL", 13, 36], ["bone marrow cells", "CELL", 67, 84], ["hemopoietic", "CELL", 117, 128], ["Fas", "GENE_OR_GENE_PRODUCT", 151, 154], ["FasL", "GENE_OR_GENE_PRODUCT", 155, 159], ["caspase-3", "GENE_OR_GENE_PRODUCT", 160, 169], ["bone marrow cells", "CELL_TYPE", 67, 84], ["Fas", "PROTEIN", 151, 154], ["FasL", "PROTEIN", 155, 159], ["caspase-3", "PROTEIN", 160, 169], ["Rhodiola polysaccharide", "TREATMENT", 13, 36], ["the apoptosis of bone marrow cells", "PROBLEM", 50, 84], ["Fas", "TEST", 151, 154], ["FasL-caspase", "TREATMENT", 155, 167], ["apoptosis", "PROBLEM", 242, 251], ["jaundice hepatitis", "PROBLEM", 268, 286], ["bone", "ANATOMY", 67, 71], ["marrow cells", "OBSERVATION", 72, 84], ["hemopoietic function", "OBSERVATION", 117, 137], ["jaundice", "OBSERVATION", 268, 276]]], ["Rhubarb exerted its therapeutic efficacy in patients with jaundice hepatitis by regulating the Fas/FasL system (Huang et al., 2008).", [["Rhubarb", "CHEMICAL", 0, 7], ["jaundice hepatitis", "DISEASE", 58, 76], ["Rhubarb", "CHEMICAL", 0, 7], ["Rhubarb", "SIMPLE_CHEMICAL", 0, 7], ["patients", "ORGANISM", 44, 52], ["Fas", "GENE_OR_GENE_PRODUCT", 95, 98], ["FasL", "GENE_OR_GENE_PRODUCT", 99, 103], ["Fas", "PROTEIN", 95, 98], ["FasL", "PROTEIN", 99, 103], ["patients", "SPECIES", 44, 52], ["Rhubarb", "TREATMENT", 0, 7], ["jaundice hepatitis", "PROBLEM", 58, 76], ["therapeutic", "OBSERVATION_MODIFIER", 20, 31], ["jaundice", "OBSERVATION", 58, 66]]], ["Ligustrazine could repress Fas/FasL axis to inhibit hepatocyte apoptosis, consequently improving CCl4-induced liver fibrosis in rats (Li et al., 2008b).", [["hepatocyte", "ANATOMY", 52, 62], ["liver", "ANATOMY", 110, 115], ["Ligustrazine", "CHEMICAL", 0, 12], ["CCl4", "CHEMICAL", 97, 101], ["liver fibrosis", "DISEASE", 110, 124], ["Ligustrazine", "CHEMICAL", 0, 12], ["CCl4", "CHEMICAL", 97, 101], ["Ligustrazine", "SIMPLE_CHEMICAL", 0, 12], ["Fas", "GENE_OR_GENE_PRODUCT", 27, 30], ["FasL", "GENE_OR_GENE_PRODUCT", 31, 35], ["hepatocyte", "CELL", 52, 62], ["CCl4", "SIMPLE_CHEMICAL", 97, 101], ["liver", "ORGAN", 110, 115], ["rats", "ORGANISM", 128, 132], ["Fas", "PROTEIN", 27, 30], ["FasL", "PROTEIN", 31, 35], ["rats", "SPECIES", 128, 132], ["Ligustrazine", "TREATMENT", 0, 12], ["FasL axis", "PROBLEM", 31, 40], ["hepatocyte apoptosis", "PROBLEM", 52, 72], ["CCl4", "TEST", 97, 101], ["liver fibrosis", "PROBLEM", 110, 124], ["FasL axis", "OBSERVATION", 31, 40], ["hepatocyte", "ANATOMY", 52, 62], ["apoptosis", "OBSERVATION", 63, 72], ["improving", "OBSERVATION_MODIFIER", 87, 96], ["CCl4", "OBSERVATION", 97, 101], ["liver", "ANATOMY", 110, 115], ["fibrosis", "OBSERVATION", 116, 124]]], ["Additionally, polysaccharide from lycium barbarum modulated the apoptosis of brain cells by inhibiting the expression of Fas; it also played a role in improving brain functional memory (Cai et al., 2005).", [["brain cells", "ANATOMY", 77, 88], ["brain", "ANATOMY", 161, 166], ["polysaccharide", "SIMPLE_CHEMICAL", 14, 28], ["lycium barbarum", "ORGANISM", 34, 49], ["brain cells", "CELL", 77, 88], ["Fas", "GENE_OR_GENE_PRODUCT", 121, 124], ["brain", "ORGAN", 161, 166], ["brain cells", "CELL_TYPE", 77, 88], ["Fas", "PROTEIN", 121, 124], ["lycium barbarum", "SPECIES", 34, 49], ["lycium barbarum", "SPECIES", 34, 49], ["polysaccharide", "TREATMENT", 14, 28], ["lycium barbarum", "TREATMENT", 34, 49], ["the apoptosis of brain cells", "PROBLEM", 60, 88], ["brain cells", "OBSERVATION", 77, 88]]], ["Therefore, traditional Chinese herbs and active components recommended in the Protocol could suppress apoptosis through mediating the death receptor pathway.OutlookSince 2003, TCM has played a significant role in combating viruses such as SARS-CoV, MERS-CoV and Ebola virus (Chen and Nakamura, 2004).", [["death", "DISEASE", 134, 139], ["TCM", "CHEMICAL", 176, 179], ["SARS-CoV", "DISEASE", 239, 247], ["Ebola virus", "DISEASE", 262, 273], ["SARS-CoV", "ORGANISM", 239, 247], ["MERS-CoV", "ORGANISM", 249, 257], ["Ebola virus", "ORGANISM", 262, 273], ["death receptor", "PROTEIN", 134, 148], ["Ebola virus", "SPECIES", 262, 273], ["SARS-CoV", "SPECIES", 239, 247], ["MERS-CoV", "SPECIES", 249, 257], ["Ebola virus", "SPECIES", 262, 273], ["traditional Chinese herbs", "TREATMENT", 11, 36], ["active components", "TREATMENT", 41, 58], ["the Protocol", "TREATMENT", 74, 86], ["apoptosis", "PROBLEM", 102, 111], ["combating viruses", "PROBLEM", 213, 230], ["SARS", "PROBLEM", 239, 243], ["Ebola virus", "PROBLEM", 262, 273]]], ["TCM has received much attention due to its multi-component, multi-target properties, and multi-pharmacological effects.", [["TCM", "CHEMICAL", 0, 3]]], ["Various herbal formulas and active components of TCM have certain potential in treating COVID-19 via differential pharmacological mechanisms (Fig. 2).", [["TCM", "CHEMICAL", 49, 52], ["COVID-19", "CHEMICAL", 88, 96], ["COVID-19", "CHEMICAL", 88, 96], ["TCM", "CELL", 49, 52], ["Various herbal formulas", "TREATMENT", 0, 23], ["active components of TCM", "TREATMENT", 28, 52], ["COVID", "TEST", 88, 93], ["herbal formulas", "OBSERVATION", 8, 23], ["active", "OBSERVATION_MODIFIER", 28, 34]]], ["Amount of evidences supported the therapeutic efficacy of TCM in improving the clinical symptoms of COVID-19, while, the underlying mechanisms behind the antiviral effects, especially in models infected with SARS-CoV-2, the immunomodulatory response in host cells, and the inhibitory effects on cytokine inflammatory storm, etc., remain elusive.", [["cells", "ANATOMY", 258, 263], ["TCM", "CHEMICAL", 58, 61], ["COVID-19", "CHEMICAL", 100, 108], ["SARS", "DISEASE", 208, 212], ["COVID-19", "CHEMICAL", 100, 108], ["COVID-19", "CELL", 100, 108], ["SARS-CoV-2", "ORGANISM", 208, 218], ["host cells", "CELL", 253, 263], ["host cells", "CELL_TYPE", 253, 263], ["cytokine", "PROTEIN", 295, 303], ["SARS-CoV", "SPECIES", 208, 216], ["TCM", "TREATMENT", 58, 61], ["the clinical symptoms", "PROBLEM", 75, 96], ["COVID", "TEST", 100, 105], ["the antiviral effects", "PROBLEM", 150, 171], ["SARS", "PROBLEM", 208, 212], ["CoV", "TEST", 213, 216], ["host cells", "PROBLEM", 253, 263], ["cytokine inflammatory storm", "PROBLEM", 295, 322], ["therapeutic", "OBSERVATION_MODIFIER", 34, 45], ["antiviral effects", "OBSERVATION", 154, 171], ["infected", "OBSERVATION_MODIFIER", 194, 202], ["host cells", "OBSERVATION", 253, 263], ["inflammatory storm", "OBSERVATION", 304, 322]]], ["Moreover, the screening for candidate naturally-occurring component from TCM should be further carried out and the novel compatibility with active components will be further developed based on the exploration of substance basis and the clarification of pharmacological mechanism.", [["the screening", "TEST", 10, 23], ["TCM", "TREATMENT", 73, 76], ["the exploration", "TEST", 193, 208], ["substance basis", "TREATMENT", 212, 227]]], ["Importantly, multicenter studies with rigorous randomized controlled trials need to be performed to provide more clinical evidences of the clinical effectiveness of TCM.Author contributions", [["multicenter studies", "TEST", 13, 32], ["rigorous randomized controlled trials", "TREATMENT", 38, 75]]]], "43b340eb1776b4c487c7893797fd744fc3fdb04e": [["IntroductionNowadays, a large majority of businesses are supported or carried out online.", [["large", "OBSERVATION_MODIFIER", 24, 29]]], ["Afterward, being aware about the necessity to orient their marketing actions to the right target, online stores opted for a near-real time analysis of visitors' information.", [["right", "ANATOMY_MODIFIER", 84, 89]]], ["The latest study suggesting such a strategy in e-commerce websites could be found in [1] where authors proposed a system with two modules which predicts the purchasing intent of the visitor by using some session and user information along with aggregated pageview data kept track during the visit.", [["The latest study", "TEST", 0, 16]]], ["Though the fact that the system proposed in [1] is appealing in terms of efficiency and scalability, the risk of abandon it implies stands for a problem which is not to be neglected.IntroductionIn this paper, we do not aim to propose a new model that substitutes systems like the one of Sakar et al. [1] .", [["a new model that substitutes systems", "TREATMENT", 234, 270]]], ["5 concludes the paper and suggests some directions for future research.Literature ReviewLiterature encompasses many studies which are turned towards categorization of online visits in e-commerce websites.Literature ReviewA first study of Mobasher et al. [2] assessed two different clustering techniques based on user transactions and pageviews in order to find out useful aggregate profiles that can be used by recommendation systems to achieve effective personalization at early stages of user's visits in an online store.Literature ReviewLater, the study of Moe [3] prepared the ground for a system which can take customized actions according to the category of a visit.", [["many studies", "TEST", 111, 123], ["the study", "TEST", 547, 556]]], ["The proposed system rests on observed in-store navigational patterns (including the general content of the pages viewed) and a k-means algorithm for clustering.Literature ReviewIn [4] , Poggi et al. proposed a system which handles the loss of throughput in Web servers due to overloading, by assigning priorities to sessions on an ecommerce website according to the revenue that will generate.", [["a k-means algorithm", "TEST", 125, 144], ["overloading", "PROBLEM", 276, 287], ["loss", "OBSERVATION_MODIFIER", 235, 239], ["overloading", "OBSERVATION", 276, 287]]], ["Data were formed of clickstream and session information and Markov chains, logistic linear regression, decision trees and na\u00efve Bayes were investigated in order to measure the probability of users' purchasing intention [4] .Literature ReviewIn [5] and [6] , authors designed the prediction of purchasing intention problem as a supervised learning problem and historical data collected from an online bookstore were used to categorize the user sessions as browsing and buyer sessions.", [["historical data", "TEST", 359, 374]]], ["In this scope, Support vector machines (SVMs) with different kernel types and k-Nearest Neighbor (k-NN) were respectively investigated in [5] and [6] to carry out classification.Literature ReviewIn a more recent study [7] , Suchacka and Chodak constructed a new approach to analyze historical data obtained from a real online bookstore.", [["Support vector machines", "TREATMENT", 15, 38], ["Suchacka", "TREATMENT", 224, 232]]], ["To build such a system, a data set based on the Google Analytics tracking code [9] has been created.", [["a data", "TEST", 24, 30]]], ["Moreover, na\u00efve Bayes and multilayer perceptron classifiers have been explored for classification.Literature ReviewIn [1] , authors set up a real-time user behavior analysis system for virtual shopping environment which is made up of two modules.", [["multilayer perceptron classifiers", "TREATMENT", 26, 59]]], ["Further, oversampling and feature selection preprocessing algorithms were applied to improve the effectiveness and the scalability of a set of supervised machine learning techniques.", [["feature selection preprocessing algorithms", "TREATMENT", 26, 68], ["supervised machine learning techniques", "TREATMENT", 143, 181]]], ["The highest accuracy of 87.24% and F1 Score of 0.86 were obtained with a Multilayer Perceptron Network (MLP).", [["The highest accuracy", "TEST", 0, 20], ["F1 Score", "TEST", 35, 43], ["a Multilayer Perceptron Network (MLP)", "TREATMENT", 71, 108]]], ["In the second module, authors used a Long Short-Term Memory-based Recurrent Neural Network (LSTM-RNN) based on sequential clickstream data to produce the probability estimate of visitor's intention to leave the site without completing the transaction.", [["RNN", "DNA", 97, 100], ["a Long Short-Term Memory", "TREATMENT", 35, 59]]], ["Next, we depict the dataset used for validation as well as the machine learning techniques which have been explored for classification.Functional DescriptionBased on previous studies, we can notice that no work has addressed the purchasing intention of online visitors immediately after they connect to the website.", [["validation", "TREATMENT", 37, 47], ["the machine learning techniques", "TREATMENT", 59, 90], ["previous studies", "TEST", 166, 182]]], ["By contrast to these studies, our system aims to detect users with high purchasing intention as soon as they connect to the e-commerce website and to offer content only to those who intend to complete a transaction.", [["these studies", "TEST", 15, 28]]], ["That risk should not be neglected since it naturally impacts the effectiveness of any system with a business objective (for instance each of the systems introduced respectively in [1,5,6] and [7] ).Functional DescriptionAs mentioned earlier, through our proposed system, we do not aspire to replace the previous systems that have tackled the same problem by using clickstream data.", [["should not be", "UNCERTAINTY", 10, 23]]], ["Moreover, among the 12330 sessions in the dataset, 84.5% (10422) were negative class samples that did not finalize a transaction and the rest (1908) were positive class samples ending with purchasing [1] .Data DescriptionBased in Table 1 , we can notice that, except the \"Day\" feature, all the rest of features are categorical.", [["the dataset", "TEST", 38, 49]]], ["In order to homogenize the features types, we used a binning process in which the \"Day\" variable is discretized to 5 discrete levels [10] .PredictionTechnically, a challenging issue for the proposed system consists in finding out the most suitable machine learning technique for the prediction problem.", [["a binning process", "TREATMENT", 51, 68], ["the prediction problem", "PROBLEM", 279, 301]]], ["In this context, specifications of input data are among main criteria which could be used to elect such a technique [11, 12] .", [["input data", "TEST", 35, 45]]], ["In our case, since features are categorical [13] , three appropriate techniques for this type of features are selected, namely: na\u00efve Bayes classifier, C4.5 classifier and random forest.", [["C4.5 classifier", "CELL_LINE", 152, 167]]], ["It assumes the independence of the input features.", [["independence", "OBSERVATION_MODIFIER", 15, 27]]], ["Despite its simplicity, NBC can often outperform more sophisticated classification methods [16] . \u2022 C4.5 classifier C4.5 is an extension of the earlier ID3 algorithm and stands for an algorithm used to generate a decision tree [17] which can be used for classification.", [["ID3", "DNA", 152, 155], ["NBC", "PROBLEM", 24, 27], ["an algorithm", "TEST", 181, 193]]], ["At each node of the tree, C4.5 selects the attribute of the data that most effectively splits its set of samples into subsets enriched in one class or the other.", [["node", "ANATOMY", 8, 12], ["samples", "ANATOMY", 105, 112], ["C4.5", "DNA", 26, 30], ["node", "OBSERVATION", 8, 12], ["tree", "ANATOMY_MODIFIER", 20, 24]]], ["The splitting criterion is the normalized information gain (difference in entropy).", [["The splitting criterion", "PROBLEM", 0, 23]]], ["The C4.5 algorithm then recurses on the partitioned sublists.\u2022 Random forest classifierRandom Forest (RF) [18] is a well-known decision tree ensemble that is commonly used in classification.", [["Random forest classifierRandom Forest (RF)", "TREATMENT", 63, 105]]], ["In many cases, RF showed a good performance that outstrips that of many other classification algorithms [19] .", [["RF", "PROTEIN", 15, 17]]], ["As a decision tree ensemble, RF needs to construct several different decision trees.", [["RF", "PROTEIN", 29, 31]]], ["In order to accomplish that, each tree is set up considering a bootstrap sample set of the original training data.", [["the original training data", "TEST", 87, 113]]], ["That consists in creating a new set sampling with replacement instances from the original set until getting the size of that original training data.", [["replacement instances", "TREATMENT", 50, 71], ["new", "OBSERVATION_MODIFIER", 28, 31], ["size", "OBSERVATION_MODIFIER", 112, 116]]], ["Using one of the bootstrap sample sets of the training data, a random tree is obtained.", [["the training data", "TEST", 42, 59], ["a random tree", "TEST", 61, 74]]], ["In order to favor the diversity of the ensemble, each random tree follows a traditional top-down induction procedure with several modifications.", [["a traditional top-down induction procedure", "TREATMENT", 74, 116], ["several modifications", "TREATMENT", 122, 143]]], ["At each step, when the best attribute is chosen, only a small subset of attributes from the dataset is considered.\u2022 Random forest classifierConsidering only the subset of attributes chosen, we then compute the best attribute as in Classification And Regression Trees (CART) [20] .", [["Random forest classifier", "TREATMENT", 116, 140], ["small", "OBSERVATION_MODIFIER", 56, 61]]], ["Each tree is built to its maximum depth and no pruning procedure is applied after the tree has been fully built.", [["pruning procedure", "TREATMENT", 47, 64], ["tree", "OBSERVATION_MODIFIER", 5, 9], ["maximum", "OBSERVATION_MODIFIER", 26, 33], ["depth", "OBSERVATION_MODIFIER", 34, 39], ["no", "UNCERTAINTY", 44, 46], ["pruning procedure", "OBSERVATION", 47, 64], ["tree", "ANATOMY_MODIFIER", 86, 90]]], ["3.2 are fed to na\u00efve Bayes, C4.5 decision tree and random forest classifiers using 70% of dataset for training and the rest for validation [21, 22] .", [["training", "TREATMENT", 102, 110]]], ["Moreover, to ensure statistical significance, this procedure is repeated 100 times with random training/validation partitions.", [["this procedure", "TREATMENT", 46, 60], ["random training/validation partitions", "TREATMENT", 88, 125]]], ["Table 2 presents the average accuracy, sensitivity (true positive rate), specificity (true negative rate) and F1 Score for each classifier.Experiments and ResultsThe results show that na\u00efve Bayes classifier yields the highest accuracy rate on test data.", [["specificity", "TEST", 73, 84], ["test data", "TEST", 243, 252]]], ["However, a class imbalance problem emerges [23] since, for each classifier, the sensitivity is much lower than specificity (sensitivity is even null for na\u00efve Bayes classifier).", [["a class imbalance problem", "PROBLEM", 9, 34], ["the sensitivity", "TEST", 76, 91]]], ["Indeed, it is clear that each classification technique tends to label the test samples as the majority class (negative class).", [["samples", "ANATOMY", 79, 86], ["the test samples", "TEST", 70, 86], ["clear", "OBSERVATION", 14, 19]]], ["This class imbalance problem is a natural situation for the addressed problem since most of the online visits do not end with purchasing [24] .", [["This class imbalance problem", "PROBLEM", 0, 28]]], ["However, this issue should be properly handled since correctly identifying directed buying visits which are represented with positive class in the dataset is as crucial as identifying negative class samples.Experiments and ResultsTo deal with class imbalance problem, we considered the use of the widely used technique to balance the training set before the learning phase, namely the \"Synthetic Minority Oversampling Technique\" (SMOTE) methodology [25] .", [["class imbalance problem", "PROBLEM", 243, 266], ["the training", "TREATMENT", 330, 342]]], ["To do that, 30% of the data set consisting of 12330 samples is first excluded for testing and the oversampling SMOTE method is applied to the remaining 70% of the samples.Experiments and ResultsThe results obtained on the balanced dataset are reported in Table 3 .", [["samples", "ANATOMY", 52, 59], ["samples", "ANATOMY", 163, 170], ["samples", "CANCER", 52, 59], ["testing", "TEST", 82, 89], ["the oversampling SMOTE method", "TREATMENT", 94, 123]]], ["As it is seen, the highest accuracy of 86.78% and F1 Score of 0.60 is obtained with the random forest classifier.Conclusion and ProspectsThe appeal of the proposed work is related to the need to set up a model that forecasts the visitor's shopping intent as soon as the e-commerce website is visited.", [["the highest accuracy", "TEST", 15, 35], ["F1 Score", "TEST", 50, 58], ["highest", "OBSERVATION_MODIFIER", 19, 26]]], ["Three classification techniques have been investigated to resolve the addressed problem, namely na\u00efve Bayes, C4.5 and random forest.", [["C4.5", "CELL_LINE", 109, 113]]], ["However, to confirm the effectiveness of a such global system, its exploration in online retailers in real-world and real-time settings should be achieved and its performance should be compared to that of competitive models.", [["a such global system", "PROBLEM", 41, 61], ["its exploration", "TEST", 63, 78]]]]}